https://semaglutides.org/news/2026/09/rule-702-general-causation-hearing-opens-mdl-3094-2026/2026-09-15T01:35:26Zweekly https://semaglutides.org/news/2026/09/status-check-two-unreconciled-medicare-semaglutide-prices-2027-2026/2026-09-15T03:04:33Zweekly https://semaglutides.org/news/2026/09/status-check-no-glp-1-injury-settlement-no-2026/2026-09-15T03:04:58Zweekly https://semaglutides.org/news/2026/09/tga-counterfeit-retatrutide-eightfold-semaglutide-dose-2026/2026-09-15T03:32:11Zweekly https://semaglutides.org/news/2026/09/mdl-3094-daubert-hearing-2026/2026-09-15T03:32:22Zweekly https://semaglutides.org/news/2026/09/easd-2026-milan-sets-up-competitor-data-2026/2026-09-15T03:32:27Zweekly https://semaglutides.org/news/2026/09/generic-liraglutide-cash-prices-run-three-eleven-times-2026/2026-09-15T03:32:49Zweekly https://semaglutides.org/news/2026/09/label-check-what-current-zepbound-prescribing-information-actually-2026/2026-09-15T03:32:37Zweekly https://semaglutides.org/news/2026/09/novo-38-percent-us-obesity-share-cmd-week-2026/2026-09-15T03:32:38Zweekly https://semaglutides.org/news/2026/09/novo-nordisk-rebrands-novo-introduces-novo-way-2026/2026-09-15T03:32:36Zweekly https://semaglutides.org/news/2026/09/roche-pharma-day-three-obesity-mechanisms-2026/2026-09-15T03:33:00Zweekly https://semaglutides.org/news/2026/09/semaglutide-cash-prices-settle-149-499-band-while-2026/2026-09-15T03:32:57Zweekly https://semaglutides.org/news/2026/09/sixteen-challenger-programs-phase-3-none-before-2027-2026/2026-09-15T03:33:17Zweekly https://semaglutides.org/news/2026/09/status-check-balance-window-closes-january-one-committed-state-2026/2026-09-15T03:33:23Zweekly https://semaglutides.org/news/2026/09/status-check-bridge-copays-excluded-from-part-d-affordability-mechanisms-2026/2026-09-15T03:33:13Zweekly https://semaglutides.org/news/2026/09/status-check-no-balance-state-no-post-2027-medicare-answer-2026/2026-09-15T03:33:18Zweekly https://semaglutides.org/news/2026/09/status-check-novo-675-list-price-above-every-negotiated-price-2026/2026-09-15T03:33:33Zweekly https://semaglutides.org/news/2026/09/status-check-zepbound-caremark-class-action-live-as-restoration-nears-2026/2026-09-15T03:33:32Zweekly https://semaglutides.org/news/2026/09/lean-mass-race-dozen-programs-one-approved-drug-2026/2026-09-15T03:33:50Zweekly https://semaglutides.org/news/2026/09/tirzepatide-evidence-base-what-has-what-has-not-2026/2026-09-15T03:33:58Zweekly https://semaglutides.org/news/2026/09/state-of-play-september-2026/2026-09-15T03:33:59Zweekly https://semaglutides.org/news/2026/09/aetna-posts-zepbound-formulary-addition-effective-october-2026/2026-09-15T04:24:18Zweekly https://semaglutides.org/news/2026/09/amgen-maritide-readouts-outside-2026-window-2026/2026-09-15T04:24:31Zweekly https://semaglutides.org/news/2026/09/astrazeneca-obesity-case-two-fall-readouts-2026/2026-09-15T04:24:52Zweekly https://semaglutides.org/news/2026/09/baseline-keyword-serp-landscape-captured-semaglutides-org-2026/2026-09-15T04:24:34Zweekly https://semaglutides.org/news/2026/09/branded-tirzepatide-self-pay-prices-sit-far-below-2026/2026-09-15T04:24:41Zweekly https://semaglutides.org/news/2026/09/china-semaglutide-generics-stuck-data-exclusivity-2026/2026-09-15T04:25:00Zweekly https://semaglutides.org/news/2026/09/chinese-licensing-sets-price-of-entry-obesity-2026/2026-09-15T04:25:17Zweekly https://semaglutides.org/news/2026/09/cms-2027-medicare-landscape-still-pending-before-open-enrollment-2026/2026-09-15T04:25:06Zweekly https://semaglutides.org/news/2026/09/corbus-canyon-1-topline-crb-913-2026/2026-09-15T04:24:53Zweekly https://semaglutides.org/news/2026/09/india-generic-semaglutide-price-war-six-months-on-2026/2026-09-15T04:25:22Zweekly https://semaglutides.org/news/2026/09/mazdutide-us-path-theoretical-lilly-phase-2-published-2026/2026-09-15T07:59:01Zweekly https://semaglutides.org/news/2026/09/pfizer-obesity-case-rests-on-monthly-injectable-2026/2026-09-15T04:25:31Zweekly https://semaglutides.org/news/2026/09/status-check-globe-guard-drug-pricing-model-rules-unfinalized-2026/2026-09-15T04:25:39Zweekly https://semaglutides.org/news/2026/09/status-check-marketplace-weakest-glp-1-coverage-channel-2027-2026/2026-09-15T04:25:33Zweekly https://semaglutides.org/news/2026/09/status-check-pbm-delinking-does-not-bite-until-2028-2026/2026-09-15T04:25:25Zweekly https://semaglutides.org/news/2026/09/survodutide-heads-to-easd-without-filing-date-2026/2026-09-15T04:25:47Zweekly https://semaglutides.org/news/2026/09/compounding-fight-state-of-play-september-2026/2026-09-15T04:26:13Zweekly https://semaglutides.org/news/2026/09/viking-vk2735-maintenance-data-outstanding-readout-2026/2026-09-15T04:26:15Zweekly https://semaglutides.org/news/2026/09/science-times-ai-reddit-analysis-overlooked-side-effects-2026/2026-09-15T05:14:45Zweekly https://semaglutides.org/news/2026/09/retatrutide-30-billion-forecast-q1-2027-filing-2026/2026-09-15T05:15:02Zweekly https://semaglutides.org/news/2026/09/citi-raises-lilly-price-target-1600-2026/2026-09-15T05:15:03Zweekly https://semaglutides.org/news/2026/09/doustdar-not-winner-takes-all-obesity-2026/2026-09-15T05:15:05Zweekly https://semaglutides.org/news/2026/09/eloralintide-phase-3-tirzepatide-combination-2026/2026-09-15T05:15:08Zweekly https://semaglutides.org/news/2026/09/kailera-trades-below-ipo-price-data-slips-2026/2026-09-15T05:15:26Zweekly https://semaglutides.org/news/2026/09/obesityweek-2026-late-breakers-surface-2026/2026-09-15T05:15:41Zweekly https://semaglutides.org/news/2026/09/r-zepbound-passes-233-000-members-r-mounjaro-2026/2026-09-15T05:15:33Zweekly https://semaglutides.org/news/2026/09/telehealth-platforms-compounded-pathway-narrows-september-2026/2026-09-15T05:15:55Zweekly https://semaglutides.org/news/2026/09/lilly-morgan-stanley-healthcare-conference-2026/2026-09-15T05:34:49Zweekly https://semaglutides.org/news/2026/09/canadian-grocers-generic-semaglutide-pharmacy-volumes-2026/2026-09-15T04:25:49Zweekly https://semaglutides.org/news/2026/09/glp1-bipolar-hospitalization-2026/2026-09-15T04:25:53Zweekly https://semaglutides.org/news/2026/09/novo-aligns-ozempic-price-with-canadian-generics-2026/2026-09-15T04:25:57Zweekly https://semaglutides.org/news/2026/09/wegovy-pill-four-to-one-lead-over-foundayo-2026/2026-09-15T04:26:29Zweekly https://semaglutides.org/news/2026/09/ukraine-charges-27-falsified-tirzepatide-ring-2026/2026-09-15T04:26:08Zweekly https://semaglutides.org/news/2026/09/largest-musculoskeletal-synthesis-date-no-bone-joint-effect-2026/2026-09-15T03:33:52Zweekly https://semaglutides.org/news/2026/09/musculoskeletal-meta-analysis-1-25-million-people-finds-2026/2026-09-15T03:34:01Zweekly https://semaglutides.org/news/2026/09/meta-analysis-links-glp-1-drugs-lean-mass-2026/2026-09-15T04:26:09Zweekly https://semaglutides.org/news/2026/09/penn-researchers-publish-ai-study-400-000-glp-2026/2026-09-15T04:26:15Zweekly https://semaglutides.org/news/2026/09/fda-warning-letter-tally-32-glp-1-peptides-2026/2026-09-15T04:26:31Zweekly https://semaglutides.org/news/2026/09/hims-margin-reset-one-year-2027-test-2026/2026-09-15T05:15:33Zweekly https://semaglutides.org/news/2026/09/review-consolidates-case-glp-1-drugs-psoriasis-2026/2026-09-15T05:15:41Zweekly https://semaglutides.org/news/2026/09/fda-approves-scholar-rock-apitegromab-isembyld-2026/2026-09-15T03:34:00Zweekly https://semaglutides.org/news/2026/09/lillys-tirzepatide-reaches-57-glp-1-market-2026/2026-09-15T03:34:17Zweekly https://semaglutides.org/news/2026/09/wernicke-encephalopathy-signal-semaglutide-tirzepatide-2026/2026-09-15T03:34:23Zweekly https://semaglutides.org/news/2026/09/review-finds-mfn-drugmakers-hold-section-232-tariff-relief-until-2029-2026/2026-09-15T03:34:33Zweekly https://semaglutides.org/news/2026/09/aarp-briefs-members-bridge-savings-ahead-of-open-enrollment-2026/2026-09-15T04:26:46Zweekly https://semaglutides.org/news/2026/09/semaglutide-patent-cliff-analysis-2026/2026-09-15T04:26:40Zweekly https://semaglutides.org/news/2026/09/fda-approves-isembyld-apitegromab-first-myostatin-inhibitor-2026/2026-09-15T04:26:54Zweekly https://semaglutides.org/news/2026/09/jp-morgan-resumes-hims-coverage-neutral-2026/2026-09-15T04:26:35Zweekly https://semaglutides.org/news/2026/09/lilly-shares-close-1-115-70-market-value-2026/2026-09-15T04:26:55Zweekly https://semaglutides.org/news/2026/09/mfn-deal-state-pushback-medwatch-2026/2026-09-15T07:59:09Zweekly https://semaglutides.org/news/2026/09/oral-glp1-tracker-september-2026/2026-09-15T04:26:51Zweekly https://semaglutides.org/news/2026/09/wegovy-pill-foundayo-both-hit-record-weekly-prescriptions-2026/2026-09-15T04:26:58Zweekly https://semaglutides.org/news/2026/09/danone-yogurt-sales-surge-among-us-glp-1-users-2026/2026-09-15T05:18:21Zweekly https://semaglutides.org/news/2026/09/health-canada-counterfeit-glp1-advisory-2026/2026-09-15T05:15:51Zweekly https://semaglutides.org/news/2026/09/lilly-begins-selling-foundayo-israel-2026/2026-09-15T05:15:55Zweekly https://semaglutides.org/news/2026/09/lilly-completes-ataibeckley-2026/2026-09-15T05:16:06Zweekly https://semaglutides.org/news/2026/09/lilly-tirzepatide-ckd-phase-2-completes-2026/2026-09-15T05:16:08Zweekly https://semaglutides.org/news/2026/09/novo-town-hall-september-2026/2026-09-15T05:16:07Zweekly https://semaglutides.org/news/2026/09/virginia-approves-power-project-lilly-goochland-2026/2026-09-15T05:16:45Zweekly https://semaglutides.org/news/2026/09/china-approves-wegovy-mash-2026/2026-09-15T03:34:33Zweekly https://semaglutides.org/news/2026/09/seventh-circuit-retatrutide-argument-preview-september-2026/2026-09-15T03:34:30Zweekly https://semaglutides.org/news/2026/09/weight-regain-model-2026/2026-09-15T08:00:26Zweekly https://semaglutides.org/news/2026/09/lilly-glp1-windfall-womens-health-push-2026/2026-09-15T04:27:17Zweekly https://semaglutides.org/news/2026/09/cell-reports-asprosin-obesity-memory-explains-regain-2026/2026-09-15T04:27:08Zweekly https://semaglutides.org/news/2026/09/current-obesity-names-engagement-unsolved-problem-digital-obesity-2026/2026-09-15T04:27:19Zweekly https://semaglutides.org/news/2026/09/foundayo-prescriber-base-8000-to-36000-2026/2026-09-15T04:27:26Zweekly https://semaglutides.org/news/2026/09/lilly-china-93-percent-growth-international-share-2026/2026-09-15T04:27:16Zweekly https://semaglutides.org/news/2026/09/lilly-refers-200-entities-regulators-law-enforcement-2026/2026-09-15T04:27:23Zweekly https://semaglutides.org/news/2026/09/frontiers-review-divergent-ocular-safety-across-glp-1-drugs-2026/2026-09-15T04:27:26Zweekly https://semaglutides.org/news/2026/09/umbrella-review-quantifies-glp-1-drugs-insulin-adjuncts-2026/2026-09-15T04:27:49Zweekly https://semaglutides.org/news/2026/09/ql-biopharm-registers-semaglutide-zovaglutide-switch-trial-2026/2026-09-15T05:16:39Zweekly https://semaglutides.org/news/2026/09/huntsville-tif-district-lilly-alabama-plant-2026/2026-09-15T05:16:33Zweekly https://semaglutides.org/news/2026/09/novo-research-head-2026/2026-09-15T05:16:42Zweekly https://semaglutides.org/news/2026/09/cagrisema-diabetic-neuropathy-trial-2026/2026-09-15T05:16:35Zweekly https://semaglutides.org/news/2026/09/review-raises-untested-question-tirzepatide-oral-progestogens-2026/2026-09-15T05:16:54Zweekly https://semaglutides.org/news/2026/09/weekly-basal-insulin-plus-semaglutide-combination-t2d-2026/2026-09-15T05:16:58Zweekly https://semaglutides.org/news/2026/09/nmpa-accepts-hengrui-ribupatide-filing-t2d-2026/2026-09-15T03:34:37Zweekly https://semaglutides.org/news/2026/09/endocrine-society-obesity-scientific-statement-center-on-obesity-2026/2026-09-15T03:34:45Zweekly https://semaglutides.org/news/2026/09/analysis-puts-tirzepatide-nearly-two-thirds-lillys-quarterly-2026/2026-09-15T04:27:39Zweekly https://semaglutides.org/news/2026/09/medscape-tirzepatide-beats-semaglutide-weight-not-safety-2026/2026-09-15T04:27:50Zweekly https://semaglutides.org/news/2026/09/forbes-says-administration-left-pbms-largely-untouched-2026/2026-09-15T04:27:42Zweekly https://semaglutides.org/news/2026/09/clark-hill-guidance-fifth-circuit-tirzepatide-compounding-2026/2026-09-15T04:27:48Zweekly https://semaglutides.org/news/2026/09/morgan-stanley-downgrade-2026/2026-09-15T04:29:57Zweekly https://semaglutides.org/news/2026/09/novo-q3-ziltivekimab-impairment-view-2026/2026-09-15T04:28:05Zweekly https://semaglutides.org/news/2026/09/mounjaro-cv-nod-physician-views-2026/2026-09-15T04:28:01Zweekly https://semaglutides.org/news/2026/09/foodnavigator-glp-1-messaging-consumers-more-selective-2026/2026-09-15T04:28:07Zweekly https://semaglutides.org/news/2026/09/zealand-zupreme-2-marked-completed-2026/2026-09-15T04:28:30Zweekly https://semaglutides.org/news/2026/09/tiktok-fake-glp-1-market-targets-women-2026/2026-09-15T05:16:56Zweekly https://semaglutides.org/news/2026/09/counsel-guidance-patient-specific-justification-after-fifth-circuit-2026/2026-09-15T05:17:01Zweekly https://semaglutides.org/news/2026/09/mannkind-licenses-inhaled-glp1-rose-pharma-2026/2026-09-15T05:17:03Zweekly https://semaglutides.org/news/2026/09/novo-opens-pediatric-cagrisema-t2d-trial-2026/2026-09-15T05:17:14Zweekly https://semaglutides.org/news/2026/09/weightwatchers-appoints-stephen-bye-ceo-2026/2026-09-15T05:17:38Zweekly https://semaglutides.org/news/2026/09/weightwatchers-dear-media-glp-1-podcast-2026/2026-09-15T05:34:28Zweekly https://semaglutides.org/news/2026/09/truveta-19-percent-jump-glp-1-prescribing-seniors-after-bridge-2026/2026-09-15T01:36:17Zweekly https://semaglutides.org/news/2026/09/aleniglipron-open-label-extension-16-2-weight-loss-2026/2026-09-15T03:34:56Zweekly https://semaglutides.org/news/2026/09/cms-bridge-prior-authorization-under-12-hours-no-formal-appeal-2026/2026-09-15T03:34:59Zweekly https://semaglutides.org/news/2026/09/ers-2026-semaglutide-tied-40-percent-fewer-asthma/2026-09-15T03:35:01Zweekly https://semaglutides.org/news/2026/09/lilly-mochi-conspiracy-claims-trimmed-september-2026/2026-09-15T03:35:05Zweekly https://semaglutides.org/news/2026/09/novo-shuts-two-more-ziltivekimab-heart-trials-2026/2026-09-15T03:35:06Zweekly https://semaglutides.org/news/2026/09/amycretin-late-stage-2026/2026-09-15T03:35:18Zweekly https://semaglutides.org/news/2026/09/sandoz-canada-generic-semaglutide-launch-excludes-glp1-targets-2026/2026-09-15T03:35:25Zweekly https://semaglutides.org/news/2026/09/novo-capital-markets-day-preview-analysts-2026/2026-09-15T04:28:34Zweekly https://semaglutides.org/news/2026/09/obesity-market-forecast-2026/2026-09-15T04:28:29Zweekly https://semaglutides.org/news/2026/09/cms-limited-bridge-outreach-manufacturers-advertise-program-2026/2026-09-15T04:28:57Zweekly https://semaglutides.org/news/2026/09/eight-generic-semaglutide-files-health-canada-2026/2026-09-15T04:29:08Zweekly https://semaglutides.org/news/2026/09/gallup-revises-2026-glp-1-obesity-estimates/2026-09-15T04:28:51Zweekly https://semaglutides.org/news/2026/09/emarketer-glp-1-use-reshapes-whole-household-habits-2026/2026-09-15T04:28:56Zweekly https://semaglutides.org/news/2026/09/moonwalk-raises-70m-adipose-rnai-obesity-2026/2026-09-15T04:28:48Zweekly https://semaglutides.org/news/2026/09/novo-shares-ziltivekimab-halt-outweighs-step-young-2026/2026-09-15T04:28:54Zweekly https://semaglutides.org/news/2026/09/novo-share-performance-sept-2026/2026-09-15T04:29:04Zweekly https://semaglutides.org/news/2026/09/zepbound-cost-offset-published-numbers-dom-2026/2026-09-15T04:29:27Zweekly https://semaglutides.org/news/2026/09/peerj-meta-analysis-confirms-regain-withdrawal-improvement-side-2026/2026-09-15T04:29:13Zweekly https://semaglutides.org/news/2026/09/structure-therapeutics-clinical-data-oral-small-molecule-amylin-2026/2026-09-15T04:29:19Zweekly https://semaglutides.org/news/2026/09/three-guided-q3-obesity-milestones-still-open-2026/2026-09-15T04:29:30Zweekly https://semaglutides.org/news/2026/09/amgen-shares-slide-after-rival-lp-a-failure-2026/2026-09-15T05:17:22Zweekly https://semaglutides.org/news/2026/09/step-young-obesityweek-2026/2026-09-15T01:36:03Zweekly https://semaglutides.org/news/2026/09/lilly-us-manufacturing-passes-50-billion-2026/2026-09-15T04:29:26Zweekly https://semaglutides.org/news/2026/09/mounjaro-india-top-selling-drug-tirzepatide-share-2026/2026-09-15T04:29:38Zweekly https://semaglutides.org/news/2026/09/semaglutide-tirzepatide-equivalent-weight-loss-type-2-diabetes-2026/2026-09-15T04:29:35Zweekly https://semaglutides.org/news/2026/09/no-final-503b-bulks-determination-september-2026/2026-09-15T04:29:35Zweekly https://semaglutides.org/news/2026/09/north-carolina-confirms-no-restoration-state-employee-glp-2026/2026-09-15T04:29:45Zweekly https://semaglutides.org/news/2026/09/case-report-four-semaglutide-doses-at-once-pen-error-2026/2026-09-15T05:17:14Zweekly https://semaglutides.org/news/2026/09/glp-1-drugs-fewer-nerve-complications-than-dpp-4-inhibitors-2026/2026-09-15T05:17:27Zweekly https://semaglutides.org/news/2026/09/head-head-asthma-analysis-finds-no-advantage-tirzepatide-2026/2026-09-15T05:17:34Zweekly https://semaglutides.org/news/2026/09/lilly-international-growth-canada-generic-constraints-2026/2026-09-15T05:17:56Zweekly https://semaglutides.org/news/2026/09/novo-buyback-9-billion-dkk-september-2026/2026-09-15T05:17:42Zweekly https://semaglutides.org/news/2026/09/novo-stock-step-young-2026/2026-09-15T05:17:41Zweekly https://semaglutides.org/news/2026/09/medicare-second-negotiation-round-savings-2026/2026-09-15T04:29:45Zweekly https://semaglutides.org/news/2026/09/lilly-employee-pbm-rightway-caremark-context-2026/2026-09-15T05:17:50Zweekly https://semaglutides.org/news/2026/09/lilly-moves-against-imports-counterfeit-mounjaro-2026/2026-09-15T05:34:17Zweekly https://semaglutides.org/news/2026/09/medicaid-obesity-coverage-count-twelve-states-falling-october-2026/2026-09-15T03:35:38Zweekly https://semaglutides.org/news/2026/09/hims-waitlist-149-wegovy-ozempic-novo-partnership-2026/2026-09-15T04:30:07Zweekly https://semaglutides.org/news/2026/09/lillydirect-self-pay-ladder-refill-condition-confirmed-2026/2026-09-15T04:29:53Zweekly https://semaglutides.org/news/2026/09/weightwatchers-lillydirect-med-plus-nationwide-2026/2026-09-15T04:30:11Zweekly https://semaglutides.org/news/2026/09/zepbound-savings-card-2026-terms-tighter-caps-confirmed-2026/2026-09-15T04:30:05Zweekly https://semaglutides.org/news/2026/09/weightwatchers-chequp-uk-partnership-expanded-2026/2026-09-15T05:18:22Zweekly https://semaglutides.org/news/2026/09/novo-halts-hermes-athena-ziltivekimab-trials-2026/2026-09-15T03:05:01Zweekly https://semaglutides.org/news/2026/09/foundayo-reaches-44-000-weekly-scripts-oral-glp-2026/2026-09-15T03:35:38Zweekly https://semaglutides.org/news/2026/09/patient-injury-suits-mochi-supplier-network-pharmacies-2026/2026-09-15T03:35:33Zweekly https://semaglutides.org/news/2026/09/pediatric-glp1-prescribing-study-2026/2026-09-15T03:35:41Zweekly https://semaglutides.org/news/2026/09/retatrutide-30-3-average-weight-loss-triumph-1-2026/2026-09-15T03:35:45Zweekly https://semaglutides.org/news/2026/09/washington-shuts-aequita-pharmacy-mochi-supply-chain-2026/2026-09-15T03:36:01Zweekly https://semaglutides.org/news/2026/09/lilly-retatrutide-enforcement-scale-detail-2026/2026-09-15T05:39:37Zweekly https://semaglutides.org/news/2026/09/novo-begins-phase-3-two-cagrilintide-presentations-2026/2026-09-15T04:30:18Zweekly https://semaglutides.org/news/2026/09/lilly-registers-phase-1-gastric-emptying-study-tirzepatide-2026/2026-09-15T05:18:01Zweekly https://semaglutides.org/news/2026/09/medscape-not-an-easy-way-out-rethinking-glp-1-stigma-2026/2026-09-15T05:18:02Zweekly https://semaglutides.org/news/2026/09/novo-new-injectable-obesity-phase-3-september-2026/2026-09-15T05:18:17Zweekly https://semaglutides.org/news/2026/09/state-boards-retatrutide-2026/2026-09-15T05:18:06Zweekly https://semaglutides.org/news/2026/09/strive-pharmacy-presources-peptide-ingredients-503a-rule-2026/2026-09-15T05:18:26Zweekly https://semaglutides.org/news/2026/09/veru-enobosarm-glp1-muscle-study-closes-enrollment-2026/2026-09-15T05:19:08Zweekly https://semaglutides.org/news/2026/09/california-sb-1089-sent-governor-2026/2026-09-15T03:36:10Zweekly https://semaglutides.org/news/2026/09/novo-united-labs-ubt251-phase-2-19-7-percent-2026/2026-09-15T03:36:11Zweekly https://semaglutides.org/news/2026/09/nyu-genetic-study-links-glp1r-activity-male-pattern-hair-loss-2026/2026-09-15T03:36:10Zweekly https://semaglutides.org/news/2026/09/easo-position-statement-incretin-therapies-comprehensive-obesity-care-2026/2026-09-15T04:30:13Zweekly https://semaglutides.org/news/2026/09/fda-shortage-record-still-lists-liraglutide-shortage-while-2026/2026-09-15T04:30:15Zweekly https://semaglutides.org/news/2026/09/menarini-licenses-gan-lee-bofanglutide-europe-2026/2026-09-15T04:30:47Zweekly https://semaglutides.org/news/2026/09/novo-wins-copycat-pharmacy-false-ad-suit-2026/2026-09-15T04:30:33Zweekly https://semaglutides.org/news/2026/09/state-licensing-boards-warning-notices-ruo-peptides-2026/2026-09-15T04:30:38Zweekly https://semaglutides.org/news/2026/09/ildong-sets-september-29-topline-oral-glp1-2026/2026-09-15T05:18:26Zweekly https://semaglutides.org/news/2026/09/aspen-africa-mounjaro-forecast-2026/2026-09-15T05:18:42Zweekly https://semaglutides.org/news/2026/09/structural-blueprint-of-glp-1-signaling-brain-disease-2026/2026-09-15T05:18:45Zweekly https://semaglutides.org/news/2026/09/superluminal-raises-60m-mc4r-obesity-drug-2026/2026-09-15T05:18:40Zweekly https://semaglutides.org/news/2026/09/tirzepatide-help-post-bariatric-hypoglycemia-three-cases-2026/2026-09-15T05:18:42Zweekly https://semaglutides.org/news/2026/09/only-indiana-commits-balance-medicaid-model-29-states-decline-2026/2026-09-15T03:05:06Zweekly https://semaglutides.org/news/2026/09/modern-healthcare-documents-employer-glp-1-retreat-cigna-pwc-starbucks-2026/2026-09-15T03:36:15Zweekly https://semaglutides.org/news/2026/09/nature-late-life-semaglutide-extends-lifespan-female-mice-2026/2026-09-15T03:36:20Zweekly https://semaglutides.org/news/2026/09/starbucks-ends-glp-1-weight-loss-coverage-october-2026/2026-09-15T03:36:27Zweekly https://semaglutides.org/news/2026/09/medicare-bridge-blockbuster-revenue-lilly-analyst-2026/2026-09-15T04:30:39Zweekly https://semaglutides.org/news/2026/09/fda-screens-glp-1-ingredients-at-border-fake-pharmacy-labels-2026/2026-09-15T04:30:32Zweekly https://semaglutides.org/news/2026/09/oac-presses-pepsico-starbucks-to-keep-glp-1-coverage-2026/2026-09-15T04:30:41Zweekly https://semaglutides.org/news/2026/09/poison-control-surge-unapproved-glp-1-products-2026/2026-09-15T04:30:53Zweekly https://semaglutides.org/news/2026/09/september-pricing-snapshot-lillydirect-pens-vials-2026/2026-09-15T04:31:07Zweekly https://semaglutides.org/news/2026/09/upper-macungie-final-approval-lilly-fogelsville-2026/2026-09-15T04:31:10Zweekly https://semaglutides.org/news/2026/09/edo-finds-pharma-nfl-ads-twice-effective-prime-2026/2026-09-15T05:18:45Zweekly https://semaglutides.org/news/2026/09/updated-zepbound-mounjaro-labels-posted-2026/2026-09-15T05:18:59Zweekly https://semaglutides.org/news/2026/09/fda-updates-unapproved-glp-1-guidance-compounded-tirzepatide-2026/2026-09-15T03:04:54Zweekly https://semaglutides.org/news/2026/09/glp-1-injury-dockets-reach-4-022-216-2026/2026-09-15T03:05:03Zweekly https://semaglutides.org/news/2026/09/fda-green-list-import-alert-fraudulent-compounded-labels-2026/2026-09-15T03:36:35Zweekly https://semaglutides.org/news/2026/09/fda-posts-batch-warning-letters-online-peptide-sellers-2026/2026-09-15T03:36:44Zweekly https://semaglutides.org/news/2026/09/fifth-circuit-semaglutide-delisting-opinion-september-2026/2026-09-15T03:36:51Zweekly https://semaglutides.org/news/2026/09/glp1-litigation-september-2026/2026-09-15T03:36:49Zweekly https://semaglutides.org/news/2026/09/jpml-count-4-022-pending-mdl-3094-216-2026/2026-09-15T03:36:51Zweekly https://semaglutides.org/news/2026/09/kff-poll-one-third-aware-trumprx-most-doubt-price-policies-2026/2026-09-15T03:37:03Zweekly https://semaglutides.org/news/2026/09/lilly-cuts-foundayo-self-pay-prices-two-doses-2026/2026-09-15T03:37:05Zweekly https://semaglutides.org/news/2026/09/20-drugmakers-have-drug-pricing-agreements-2026/2026-09-15T03:37:17Zweekly https://semaglutides.org/news/2026/09/wegovy-pill-germany-launch-2026/2026-09-15T03:37:22Zweekly https://semaglutides.org/news/2026/09/hims-securities-class-action-velanki-filed-2026/2026-09-15T03:37:20Zweekly https://semaglutides.org/news/2026/09/unitedhealthcares-updated-weight-loss-prior-authorization-program-takes-2026/2026-09-15T03:37:22Zweekly https://semaglutides.org/news/2026/09/mounjaro-heart-label-payer-leverage-analysis-2026/2026-09-15T04:30:57Zweekly https://semaglutides.org/news/2026/09/bmj-canada-250-dollar-patent-fee-lapse-2026/2026-09-15T04:31:00Zweekly https://semaglutides.org/news/2026/09/esc-2026-tirzepatide-maintenance-2026/2026-09-15T04:31:10Zweekly https://semaglutides.org/news/2026/09/npj-higher-semaglutide-dose-fewer-neuropsychiatric-events-2026/2026-09-15T04:31:11Zweekly https://semaglutides.org/news/2026/09/mash-outcomes-master-protocol-including-tirzepatide-recruiting-2026/2026-09-15T04:31:20Zweekly https://semaglutides.org/news/2026/09/novo-haegebarth-global-research-petersen-external-innovation-2026/2026-09-15T04:31:22Zweekly https://semaglutides.org/news/2026/09/pfizer-starts-september-berobenatide-phase-3-trials-2026/2026-09-15T04:31:55Zweekly https://semaglutides.org/news/2026/09/reuters-company-by-company-reference-glp-1-pricing-deal-terms-2026/2026-09-15T04:31:30Zweekly https://semaglutides.org/news/2026/09/time-reports-mfn-medicaid-prices-not-lowest-for-consumers-2026/2026-09-15T04:31:28Zweekly https://semaglutides.org/news/2026/09/virtual-glp-1-program-strength-coaching-improves-both-2026/2026-09-15T04:31:32Zweekly https://semaglutides.org/news/2026/09/brazil-paraguay-anvisa-dinavisa-counterfeit-agreement-2026/2026-09-15T05:19:00Zweekly https://semaglutides.org/news/2026/09/cspc-registers-phase-2-syh2069-type-2-diabetes-2026/2026-09-15T05:19:30Zweekly https://semaglutides.org/news/2026/09/hims-shares-fall-fda-unapproved-glp-1-warning-2026/2026-09-15T05:19:07Zweekly https://semaglutides.org/news/2026/09/lancet-diabetes-endocrinology-editorial-soaring-glp-1-use-2026/2026-09-15T05:19:08Zweekly https://semaglutides.org/news/2026/09/regeneron-trevogrumab-readout-date-moves-2026/2026-09-15T05:19:22Zweekly https://semaglutides.org/news/2026/09/solera-adds-noom-weight-management-network-2026/2026-09-15T05:19:24Zweekly https://semaglutides.org/news/2026/09/nyt-doustdar-profile-second-act-2026/2026-09-15T05:19:28Zweekly https://semaglutides.org/news/2026/09/treasure-ckd-reaches-estimated-primary-completion-no-results-2026/2026-09-15T05:19:27Zweekly https://semaglutides.org/news/2026/09/rule-702-expert-hearing-tests-whether-glp-1-2026/2026-09-15T03:05:11Zweekly https://semaglutides.org/news/2026/09/five-semaglutide-presentations-now-market-once-2026/2026-09-15T03:37:34Zweekly https://semaglutides.org/news/2026/09/generic-liraglutide-undercuts-every-branded-glp-1-acquisition-2026/2026-09-15T03:37:39Zweekly https://semaglutides.org/news/2026/09/semaglutide-indication-map-2026/2026-09-15T03:37:45Zweekly https://semaglutides.org/news/2026/09/wegovy-self-pay-prices-2026/2026-09-15T03:37:47Zweekly https://semaglutides.org/news/2026/09/lilly-fda-retatrutide-appeal-2026/2026-09-15T04:31:44Zweekly https://semaglutides.org/news/2026/09/compounded-price-gap-2026/2026-09-15T07:05:51Zweekly https://semaglutides.org/news/2026/09/mdl-3094-4000-cases-2026/2026-09-15T04:31:49Zweekly https://semaglutides.org/news/2026/09/jama-pediatrics-biliary-events-youth-glp-1-2026/2026-09-15T04:31:53Zweekly https://semaglutides.org/news/2026/09/glp1-liability-estimates-2026/2026-09-15T04:31:55Zweekly https://semaglutides.org/news/2026/09/mash-semaglutide-only-2026/2026-09-15T04:32:07Zweekly https://semaglutides.org/news/2026/09/ajmc-glp-1-linked-lower-obesity-related-cancer-risk-2026/2026-09-15T04:32:17Zweekly https://semaglutides.org/news/2026/09/wegovy-hfpef-review-2026/2026-09-15T04:32:06Zweekly https://semaglutides.org/news/2026/09/zenagamtide-naming-2026/2026-09-15T04:32:25Zweekly https://semaglutides.org/news/2026/09/corbus-expects-topline-phase-1b-results-peripheral-cb1-2026/2026-09-15T05:19:44Zweekly https://semaglutides.org/news/2026/09/glp1-environmental-debate-2026/2026-09-15T05:19:57Zweekly https://semaglutides.org/news/2026/09/medicaid-cohort-glp-1-use-and-new-depression-diagnoses-2026/2026-09-15T05:19:41Zweekly https://semaglutides.org/news/2026/09/nice-orforglipron-appraisal-2026/2026-09-15T05:19:49Zweekly https://semaglutides.org/news/2026/09/optometry-guidance-glp-1-naion-what-to-tell-patients-2026/2026-09-15T05:21:54Zweekly https://semaglutides.org/news/2026/09/oral-glp1-market-size-2026/2026-09-15T05:19:49Zweekly https://semaglutides.org/news/2026/09/obesity-pillars-orforglipron-older-adults-post-hoc-2026/2026-09-15T05:20:02Zweekly https://semaglutides.org/news/2026/08/medicare-glp-1-bridge-enrollment-passes-half-million-2026/2026-09-15T03:05:28Zweekly https://semaglutides.org/news/2026/08/brazil-clears-two-more-semaglutide-pens-interchangeable-2026/2026-09-15T03:37:57Zweekly https://semaglutides.org/news/2026/08/guardian-gray-market-retatrutide-patients-2026/2026-09-15T03:37:57Zweekly https://semaglutides.org/news/2026/08/mfn-agreements-reach-26-manufacturers-89-percent-branded-market-2026/2026-09-15T03:38:01Zweekly https://semaglutides.org/news/2026/08/house-bill-10185-part-d-premium-credit-2027-2026/2026-09-15T04:32:13Zweekly https://semaglutides.org/news/2026/08/adjust-t1d-extension-shows-glycemic-gains-fade-stopping-2026/2026-09-15T04:32:12Zweekly https://semaglutides.org/news/2026/08/brazil-glp-1-smuggling-seizures-triple-2026/2026-09-15T04:32:25Zweekly https://semaglutides.org/news/2026/08/hims-hers-launches-branded-glp-1s-australia-2026/2026-09-15T04:32:23Zweekly https://semaglutides.org/news/2026/08/lilly-buys-merida-2026/2026-09-15T04:32:32Zweekly https://semaglutides.org/news/2026/08/lilly-foundayos-big-consumer-ad-campaign-fronted-martha-2026/2026-09-15T04:32:52Zweekly https://semaglutides.org/news/2026/08/lilly-registers-2001-patient-orforglipron-overweight-trial-2026/2026-09-15T04:32:35Zweekly https://semaglutides.org/news/2026/08/taltz-zepbound-one-year-2026/2026-09-15T04:32:38Zweekly https://semaglutides.org/news/2026/08/penn-glp1-male-pattern-hair-loss-study-2026/2026-09-15T04:32:56Zweekly https://semaglutides.org/news/2026/08/brazil-glp1-black-market-reuters-2026/2026-09-15T04:32:45Zweekly https://semaglutides.org/news/2026/08/glp1-low-starter-doses-effective-reuters-2026/2026-09-15T04:32:58Zweekly https://semaglutides.org/news/2026/08/sciwind-ecnoglutide-phase-3-knee-osteoarthritis-2026/2026-09-15T04:33:08Zweekly https://semaglutides.org/news/2026/08/sun-pharma-secures-section-232-tariff-relief-pricing-agreement-2026/2026-09-15T04:33:15Zweekly https://semaglutides.org/news/2026/08/zepbound-label-revision-keeps-dual-weight-sleep-apnea-2026/2026-09-15T04:33:02Zweekly https://semaglutides.org/news/2026/08/altimmune-performa-registers-1800-patient-phase-3-2026/2026-09-15T05:20:48Zweekly https://semaglutides.org/news/2026/08/boston-globe-ozempic-hypocrisy-shamed-either-way-2026/2026-09-15T07:57:59Zweekly https://semaglutides.org/news/2026/08/fda-telehealth-advertising-compliance-warning-2026/2026-09-15T05:20:07Zweekly https://semaglutides.org/news/2026/08/innovent-mazdutide-9mg-phase-3-record-unknown-2026/2026-09-15T05:20:28Zweekly https://semaglutides.org/news/2026/08/meta-analysis-newer-glp-1-agents-nondiabetic-adults-weight-loss-2026/2026-09-15T05:20:33Zweekly https://semaglutides.org/news/2026/08/penn-hair-loss-findings-reach-mainstream-coverage-2026/2026-09-15T05:20:24Zweekly https://semaglutides.org/news/2026/08/semaglutide-analysis-6239-adults-beyond-weight-2026/2026-09-15T05:20:24Zweekly https://semaglutides.org/news/2026/08/wegovy-pill-4-mg-introductory-price-expires-2026/2026-09-15T05:20:50Zweekly https://semaglutides.org/news/2026/08/white-house-favored-nation-deals-nine-manufacturers-2026/2026-09-15T05:20:51Zweekly https://semaglutides.org/news/2026/08/ascletis-doses-first-patient-global-phase-3-asc30-2026/2026-09-15T03:38:08Zweekly https://semaglutides.org/news/2026/08/weight-drugs-trigger-cultural-body-trauma-for-women-2026/2026-09-15T05:20:52Zweekly https://semaglutides.org/news/2026/08/esc-2026-heart-failure-guideline-backs-semaglutide-tirzepatide-hfpef-2026/2026-09-15T03:38:12Zweekly https://semaglutides.org/news/2026/08/large-cohort-compares-glp-1-drugs-spironolactone-resistant-2026/2026-09-15T04:33:14Zweekly https://semaglutides.org/news/2026/08/novo-esc-2026-oral-semaglutide-organ-protection/2026-09-15T04:33:21Zweekly https://semaglutides.org/news/2026/08/lilly-cardiovascular-indication-dual-gip-glp-1-agonist-2026/2026-09-15T03:05:27Zweekly https://semaglutides.org/news/2026/08/lilly-mounjaro-heart-indication-built-head-head-trial-2026/2026-09-15T03:05:44Zweekly https://semaglutides.org/news/2026/08/mounjaro-cv-filing-2026/2026-09-15T03:05:34Zweekly https://semaglutides.org/news/2026/08/foundayo-passes-40-000-weekly-prescriptions-2026/2026-09-15T04:33:15Zweekly https://semaglutides.org/news/2026/08/google-updates-site-reputation-abuse-guidance-editorially-overseen-2026/2026-09-15T04:33:28Zweekly https://semaglutides.org/news/2026/08/india-generics-struggle-2026/2026-09-15T04:33:35Zweekly https://semaglutides.org/news/2026/08/pcpa-tiered-generic-semaglutide-pricing-2026/2026-09-15T05:20:57Zweekly https://semaglutides.org/news/2026/08/hadassah-what-happens-to-jewish-food-culture-age-of-ozempic-2026/2026-09-15T05:20:52Zweekly https://semaglutides.org/news/2026/08/fda-approves-mounjaro-cardiovascular-indication-2026/2026-09-15T03:05:40Zweekly https://semaglutides.org/news/2026/08/fifth-circuit-upholds-fdas-glp-1-shortage-delistings-2026/2026-09-15T03:05:39Zweekly https://semaglutides.org/news/2026/08/novo-confirms-2027-us-list-price-cut-2026/2026-09-15T03:38:14Zweekly https://semaglutides.org/news/2026/08/researchers-propose-adaptive-maintenance-framework-beyond-continue-stop-2026/2026-09-15T03:38:30Zweekly https://semaglutides.org/news/2026/08/william-blair-maps-rest-of-2026-obesity-catalysts-2026/2026-09-15T03:38:28Zweekly https://semaglutides.org/news/2026/08/china-nmpa-accepts-wegovy-pill-filing-2026/2026-09-15T07:58:13Zweekly https://semaglutides.org/news/2026/08/eudravigilance-analysis-compares-suicide-self-injury-glp-1-2026/2026-09-15T04:33:36Zweekly https://semaglutides.org/news/2026/08/fifth-circuit-record-lilly-23-billion-capacity-2026/2026-09-15T04:33:32Zweekly https://semaglutides.org/news/2026/08/arla-foods-ingredients-revenue-up-19-percent-glp-1-whey-2026/2026-09-15T05:21:05Zweekly https://semaglutides.org/news/2026/08/deutsche-bank-downgrades-novo-2026/2026-09-15T05:21:33Zweekly https://semaglutides.org/news/2026/08/lilly-registers-china-phase-3-orforglipron-2026/2026-09-15T05:21:45Zweekly https://semaglutides.org/news/2026/08/cagrisema-korea-phase-3-start-2026/2026-09-15T05:21:20Zweekly https://semaglutides.org/news/2026/08/both-tirzepatide-labels-updated-basis-surpass-cvot-2026/2026-09-15T03:38:35Zweekly https://semaglutides.org/news/2026/08/court-lets-zepbound-formulary-lawsuit-against-cvs-caremark-2026/2026-09-15T03:38:39Zweekly https://semaglutides.org/news/2026/08/cvs-walgreens-each-fill-100000-medicare-bridge-prescriptions-2026/2026-09-15T03:38:41Zweekly https://semaglutides.org/news/2026/08/kff-estimates-medicare-bridge-cost-1-3-to-10-billion-2026/2026-09-15T03:38:48Zweekly https://semaglutides.org/news/2026/08/real-world-analysis-finds-gray-market-retatrutide-underperforms-2026/2026-09-15T03:39:02Zweekly https://semaglutides.org/news/2026/08/abbvie-phase-2-amylin-analog-abbv-295-2026/2026-09-15T04:33:40Zweekly https://semaglutides.org/news/2026/08/glp-1-medicines-force-rethink-obesity-eating-disorder-care-2026/2026-09-15T04:33:46Zweekly https://semaglutides.org/news/2026/08/glp1-construction-wave-lilly-site-detail-2026/2026-09-15T04:33:53Zweekly https://semaglutides.org/news/2026/08/digital-engagement-linked-persistence-persistence-results-2026/2026-09-15T04:33:57Zweekly https://semaglutides.org/news/2026/08/ftc-complaint-names-fifteen-ad-platforms-hims-tracking-2026/2026-09-15T04:34:05Zweekly https://semaglutides.org/news/2026/08/jama-psychiatry-glp-1-mortality-serious-mental-illness-2026/2026-09-15T04:34:01Zweekly https://semaglutides.org/news/2026/08/zepbound-healthcare-costs-study-2026/2026-09-15T04:33:57Zweekly https://semaglutides.org/news/2026/08/meta-analysis-pools-real-world-incretin-results-bariatric-2026/2026-09-15T04:34:12Zweekly https://semaglutides.org/news/2026/08/obesity-action-coalition-assesses-bridge-opening-weeks-troa-cosponsors-2026/2026-09-15T04:34:10Zweekly https://semaglutides.org/news/2026/08/walgreens-says-half-of-bridge-patients-new-to-glp-1s-2026/2026-09-15T04:34:20Zweekly https://semaglutides.org/news/2026/08/white-house-prepares-medicaid-mfn-deals-midsize-biotechs-2026/2026-09-15T04:34:18Zweekly https://semaglutides.org/news/2026/08/pfizer-files-japan-phase-3-monthly-berobenatide-2026/2026-09-15T05:21:14Zweekly https://semaglutides.org/news/2026/08/fda-records-novo-nordisk-notice-saxenda-will-discontinued-2026/2026-09-15T03:05:59Zweekly https://semaglutides.org/news/2026/08/kff-documents-medicare-bridge-excludes-5-9-million-sicker-patients-2026/2026-09-15T03:05:51Zweekly https://semaglutides.org/news/2026/08/business-group-health-14-percent-employers-dropping-glp-1-2027-2026/2026-09-15T03:38:55Zweekly https://semaglutides.org/news/2026/08/chipotle-shake-shack-smoothie-king-run-glp-1-2026/2026-09-15T03:38:59Zweekly https://semaglutides.org/news/2026/08/four-glp1-decisions-2026/2026-09-15T03:39:09Zweekly https://semaglutides.org/news/2026/08/large-employer-glp-1-coverage-falls-60-72-2026/2026-09-15T03:39:12Zweekly https://semaglutides.org/news/2026/08/pepsico-drops-employee-weight-loss-drug-coverage-october-2026/2026-09-15T03:39:12Zweekly https://semaglutides.org/news/2026/08/va-dod-guideline-discourages-stopping-effective-obesity-medication-2026/2026-09-15T03:39:27Zweekly https://semaglutides.org/news/2026/08/genentech-hanmi-deal-2026/2026-09-15T04:34:36Zweekly https://semaglutides.org/news/2026/08/foundayo-type-2-diabetes-decision-q4-2026-window/2026-09-15T04:34:22Zweekly https://semaglutides.org/news/2026/08/veteran-analysis-glp-1-fewer-overdoses-drug-related-deaths-2026/2026-09-15T04:34:27Zweekly https://semaglutides.org/news/2026/08/novo-failed-acquisitions-tally-2026/2026-09-15T05:21:26Zweekly https://semaglutides.org/news/2026/08/surpass-peds-commentary-tirzepatide-youth-type-2-diabetes-2026/2026-09-15T05:21:21Zweekly https://semaglutides.org/news/2026/08/nutraingredients-glp-1-companion-nutrition-race-heats-up-2026/2026-09-15T05:21:34Zweekly https://semaglutides.org/news/2026/08/guardian-asks-how-to-talk-about-changing-bodies-ozempic-age-2026/2026-09-15T05:40:13Zweekly https://semaglutides.org/news/2026/08/fda-issues-batch-peptide-warning-letters-naming-tirzepatide-2026/2026-09-15T03:39:29Zweekly https://semaglutides.org/news/2026/08/fda-tallies-1-700-adverse-event-naming-compounded-2026/2026-09-15T03:39:29Zweekly https://semaglutides.org/news/2026/08/lilly-novo-nad-challenges-glp-1-copycat-ads-2026/2026-09-15T03:39:33Zweekly https://semaglutides.org/news/2026/08/novo-nordisk-opens-zenagamtide-phase-3-trial-2026/2026-09-15T03:39:44Zweekly https://semaglutides.org/news/2026/08/amgen-maritime-2-extension-opens-enrollment-2026/2026-09-15T07:57:13Zweekly https://semaglutides.org/news/2026/08/fda-warns-research-use-only-peptide-sellers-2026/2026-09-15T04:34:35Zweekly https://semaglutides.org/news/2026/08/foundayo-uk-launch-2026/2026-09-15T04:34:39Zweekly https://semaglutides.org/news/2026/08/lilly-novo-national-advertising-division-copycats-2026/2026-09-15T04:34:42Zweekly https://semaglutides.org/news/2026/08/lilly-novo-lanham-act-503b-compliance-claims-2026/2026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/08/nad-noom-willow-health-drop-compounded-glp-1-claims-2026/2026-09-15T04:35:03Zweekly https://semaglutides.org/news/2026/08/nice-requests-more-information-foundayo-appraisal-2026/2026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/08/zenagamtide-head-to-head-semaglutide-korea-2026/2026-09-15T04:35:24Zweekly https://semaglutides.org/news/2026/08/china-obesity-drug-advertising-workarounds-2026/2026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/08/english-high-court-dynamic-blocking-order-counterfeits-2026/2026-09-15T05:21:46Zweekly https://semaglutides.org/news/2026/08/orforglipron-older-adults-post-hoc-attain-2026/2026-09-15T05:21:59Zweekly https://semaglutides.org/news/2026/08/real-world-tirzepatide-one-year-mace-infections-2026/2026-09-15T05:22:05Zweekly https://semaglutides.org/news/2026/08/pharma-weight-loss-advertising-china-feature-2026/2026-09-15T07:05:48Zweekly https://semaglutides.org/news/2026/08/wdbj-parents-hiding-glp-1-use-from-children-2026/2026-09-15T05:34:24Zweekly https://semaglutides.org/news/2026/08/ledisa-glp-1-patch-false-advertising-class-action-2026/2026-09-15T05:22:04Zweekly https://semaglutides.org/news/2026/08/states-reject-medicaid-glp1-price-deal-2026/2026-09-15T03:39:39Zweekly https://semaglutides.org/news/2026/08/bmj-fact-check-uk-glp-1-death-reports-yellow-card-2026/2026-09-15T04:35:20Zweekly https://semaglutides.org/news/2026/08/tirzepatide-linked-lower-stroke-risk-glp-1-drugs-2026/2026-09-15T04:35:22Zweekly https://semaglutides.org/news/2026/08/medicare-274-negotiated-semaglutide-price-explained-2026/2026-09-15T04:35:36Zweekly https://semaglutides.org/news/2026/08/lilly-breaks-ground-houston-generation-park-2026/2026-09-15T04:35:25Zweekly https://semaglutides.org/news/2026/08/regeneron-olatorepatide-phase-2-obesity-registry-2026/2026-09-15T04:35:32Zweekly https://semaglutides.org/news/2026/08/scholar-rock-apitegromab-regulatory-update-august-2026/2026-09-15T04:36:19Zweekly https://semaglutides.org/news/2026/08/scholar-rock-embraze-lean-mass-data-and-regulatory-update-2026/2026-09-15T04:35:49Zweekly https://semaglutides.org/news/2026/08/structure-accomplish-phase-3-trials-recruiting-2026/2026-09-15T04:35:56Zweekly https://semaglutides.org/news/2026/08/unitedhealthcare-publishes-updated-glp-1-quantity-limits-september-2026/2026-09-15T04:35:54Zweekly https://semaglutides.org/news/2026/08/biopharma-dive-cost-and-perception-reshape-glp-1-market-2026/2026-09-15T05:22:03Zweekly https://semaglutides.org/news/2026/08/delhi-high-court-sun-pharma-semaglutide-tablets-2026/2026-09-15T05:22:14Zweekly https://semaglutides.org/news/2026/08/rexall-novo-canada-home-delivery-2026/2026-09-15T05:22:24Zweekly https://semaglutides.org/news/2026/08/aon-projects-employer-healthcare-costs-rise-9-5-percent-2027-2026/2026-09-15T03:39:55Zweekly https://semaglutides.org/news/2026/08/pbms-commit-display-trumprx-cash-prices-real-time-benefit-tools-2026/2026-09-15T03:39:56Zweekly https://semaglutides.org/news/2026/08/guardian-documents-brands-scrapping-plus-sizes-glp-1-2026/2026-09-15T03:40:02Zweekly https://semaglutides.org/news/2026/08/glp1-changing-us-healthcare-2026/2026-09-15T04:35:58Zweekly https://semaglutides.org/news/2026/08/gubra-h1-2026-three-partnered-obesity-programs-2026/2026-09-15T04:36:00Zweekly https://semaglutides.org/news/2026/08/meta-analysis-13-243-patients-links-glp-1-2026/2026-09-15T04:36:08Zweekly https://semaglutides.org/news/2026/08/novo-phase-3-lowest-effective-wegovy-pill-dose-2026/2026-09-15T04:36:17Zweekly https://semaglutides.org/news/2026/08/brazilian-web-survey-documents-glp-1-self-medication-2026/2026-09-15T05:22:22Zweekly https://semaglutides.org/news/2026/08/lilly-kenosha-site-expansion-opening-2026/2026-09-15T05:22:27Zweekly https://semaglutides.org/news/2026/08/upper-macungie-planners-endorse-lilly-campus-2026/2026-09-15T05:22:20Zweekly https://semaglutides.org/news/2026/08/astrazeneca-three-selene-phase-3-trials-amylin-analog-2026/2026-09-15T03:40:07Zweekly https://semaglutides.org/news/2026/08/mississippi-boards-jointly-bar-providers-research-grade-peptides-2026/2026-09-15T03:40:12Zweekly https://semaglutides.org/news/2026/08/novo-presses-fda-semaglutide-ddc-list-2026/2026-09-15T03:40:15Zweekly https://semaglutides.org/news/2026/08/oral-wegovy-outsells-foundayo-first-shared-quarter-2026/2026-09-15T03:40:28Zweekly https://semaglutides.org/news/2026/08/pcos-does-not-blunt-tirzepatide-weight-loss-54-2026/2026-09-15T03:40:25Zweekly https://semaglutides.org/news/2026/08/pharmacy-acquisition-cost-generic-liraglutide-falls-third-six-2026/2026-09-15T03:40:35Zweekly https://semaglutides.org/news/2026/08/va-launches-622-veteran-semaglutide-alcohol-use-disorder-trial-2026/2026-09-15T03:40:33Zweekly https://semaglutides.org/news/2026/08/achieve-5-orforglipron-basal-insulin-results-2026/2026-09-15T07:56:38Zweekly https://semaglutides.org/news/2026/08/amylin-design-debate-lilly-eloralintide-readout-2026/2026-09-15T07:57:27Zweekly https://semaglutides.org/news/2026/08/ftc-first-tracking-pixel-health-data-case-hims-2026/2026-09-15T04:36:23Zweekly https://semaglutides.org/news/2026/08/foundayo-q2-2026-sales/2026-09-15T04:36:26Zweekly https://semaglutides.org/news/2026/08/nature-reviews-endocrinology-calls-gip-direction-question-seeming-2026/2026-09-15T04:36:35Zweekly https://semaglutides.org/news/2026/08/foodnavigator-new-consumer-data-challenges-glp-1-food-forecasts-2026/2026-09-15T04:36:53Zweekly https://semaglutides.org/news/2026/08/overton-nominated-fda-commissioner-compounding-dockets-2026/2026-09-15T04:36:49Zweekly https://semaglutides.org/news/2026/08/northeastern-asks-whether-ozempic-is-reviving-eating-disorders-2026/2026-09-15T04:36:39Zweekly https://semaglutides.org/news/2026/08/retatrutide-demand-physician-patient-tension-2026/2026-09-15T05:22:29Zweekly https://semaglutides.org/news/2026/08/remodel-findings-suggest-kidney-protection-not-diabetes-specific-2026/2026-09-15T05:22:32Zweekly https://semaglutides.org/news/2026/08/resilience-lilly-750-million-biomanufacturing-2026/2026-09-15T05:22:42Zweekly https://semaglutides.org/news/2026/08/koreas-regulator-finds-no-confirmed-causal-link-mounjaro-pancreatitis-2026/2026-09-15T05:22:39Zweekly https://semaglutides.org/news/2026/08/novo-takes-first-round-oral-obesity-duel-2026/2026-09-15T05:23:01Zweekly https://semaglutides.org/news/2026/08/circulation-analysis-select-37-8-drop-inflammation-semaglutide-2026/2026-09-15T03:40:40Zweekly https://semaglutides.org/news/2026/08/canada-warns-illegal-retatrutide-cbp-seizures-jump-2026/2026-09-15T04:37:06Zweekly https://semaglutides.org/news/2026/08/enveda-completes-phase-1-env-308-2026/2026-09-15T04:37:07Zweekly https://semaglutides.org/news/2026/08/fact-checkers-kff-question-drug-price-drop-attribution-2026/2026-09-15T04:36:55Zweekly https://semaglutides.org/news/2026/08/no-lawful-503a-pathway-retatrutide-analysis-2026/2026-09-15T05:40:22Zweekly https://semaglutides.org/news/2026/08/lilly-retatrutide-lawsuits-new-enforcement-playbook-2026/2026-09-15T04:37:02Zweekly https://semaglutides.org/news/2026/08/orforglipron-maintenance-after-injectable-switch-2026/2026-09-15T04:37:25Zweekly https://semaglutides.org/news/2026/08/glp-1-receptor-activation-suppresses-defensive-aggression-dmpag-2026/2026-09-15T05:22:44Zweekly https://semaglutides.org/news/2026/08/hims-ceo-cnbc-ftc-headline-stock-recovers-2026/2026-09-15T05:22:57Zweekly https://semaglutides.org/news/2026/08/white-house-claims-largest-drug-price-drop-trumprx-700-million-2026/2026-09-15T03:40:40Zweekly https://semaglutides.org/news/2026/08/axios-analysis-glp-1-competition-behind-drug-price-decline-2026/2026-09-15T04:37:10Zweekly https://semaglutides.org/news/2026/08/novo-132-knockoff-lawsuits-tally-2026/2026-09-15T04:37:27Zweekly https://semaglutides.org/news/2026/08/researchers-name-glp-1-treatment-stigma-distinct-phenomenon-2026/2026-09-15T04:37:37Zweekly https://semaglutides.org/news/2026/08/nestle-plans-products-for-ozempic-face-and-side-effects-2026/2026-09-15T04:37:24Zweekly https://semaglutides.org/news/2026/08/lawsuit-claims-link-between-glp-1-drugs-and-blindness-2026/2026-09-15T04:37:25Zweekly https://semaglutides.org/news/2026/08/novo-canada-ozempic-savings-card-2026/2026-09-15T04:37:37Zweekly https://semaglutides.org/news/2026/08/mexico-approves-wegovy-oral-tablet-2026/2026-09-15T05:22:50Zweekly https://semaglutides.org/news/2026/08/prolonged-glp-1-exposure-remodels-beta-cell-gene-expression-2026/2026-09-15T05:22:59Zweekly https://semaglutides.org/news/2026/08/experiment-documents-weight-loss-drug-users-judged-harshly-2026/2026-09-15T03:40:46Zweekly https://semaglutides.org/news/2026/08/one-year-after-semaglutide-shortage-compounding-compliance-review-2026/2026-09-15T05:23:09Zweekly https://semaglutides.org/news/2026/08/states-regulate-compounded-glp-1s-above-federal-floor-2026/2026-09-15T05:40:39Zweekly https://semaglutides.org/news/2026/08/foundayo-eighty-percent-glp1-naive-patients-2026/2026-09-15T04:37:41Zweekly https://semaglutides.org/news/2026/08/novo-moves-preliminary-injunction-lilly-glp-1-ads-2026/2026-09-15T03:41:03Zweekly https://semaglutides.org/news/2026/08/anti-obesity-fourth-class-2026/2026-09-15T04:37:43Zweekly https://semaglutides.org/news/2026/08/lilly-sues-makers-generic-style-mounjaro-zepbound-copies-2026/2026-09-15T04:37:47Zweekly https://semaglutides.org/news/2026/08/survey-1-226-patients-puts-numbers-skin-laxity-2026/2026-09-15T04:37:44Zweekly https://semaglutides.org/news/2026/08/brain-switch-two-opposite-routes-weight-loss-2026/2026-09-15T05:23:06Zweekly https://semaglutides.org/news/2026/08/foundayos-label-establishes-no-timing-rules-oral-glp-2026/2026-09-15T03:41:05Zweekly https://semaglutides.org/news/2026/08/kff-prior-authorization-metrics-show-12-18-percent-2026/2026-09-15T03:40:58Zweekly https://semaglutides.org/news/2026/08/retatrutide-black-market-crackdown-2026/2026-09-15T03:41:12Zweekly https://semaglutides.org/news/2026/08/zealand-h1-2026-petrelintide-phase-3-timing-2026/2026-09-15T03:41:09Zweekly https://semaglutides.org/news/2026/08/novo-ceo-claims-90-percent-oral-glp1-share-2026/2026-09-15T04:38:13Zweekly https://semaglutides.org/news/2026/08/lilly-files-lawsuits-retatrutide-gray-market-2026/2026-09-15T03:06:02Zweekly https://semaglutides.org/news/2026/08/anesthesiology-analysis-finds-no-increased-aspiration-risk-preoperative-2026/2026-09-15T03:41:16Zweekly https://semaglutides.org/news/2026/08/prescription-drug-cpi-falls-3-1-percent-steepest-since-1963-2026/2026-09-15T03:41:27Zweekly https://semaglutides.org/news/2026/08/u-s-news-2026-2027-glp-1-telehealth/2026-09-15T07:59:56Zweekly https://semaglutides.org/news/2026/08/kailera-q2-2026-oral-ribupatide-ind-active-2026/2026-09-15T04:38:27Zweekly https://semaglutides.org/news/2026/08/novos-ceo-defends-lawsuit-concedes-lillys-lead-2026/2026-09-15T04:38:03Zweekly https://semaglutides.org/news/2026/08/altimmune-q2-2026-cash-runway-pemvidutide-2026/2026-09-15T05:24:09Zweekly https://semaglutides.org/news/2026/08/foundayo-europe-approval-2026/2026-09-15T04:38:10Zweekly https://semaglutides.org/news/2026/08/lateral-septum-cravings-2026/2026-09-15T04:38:04Zweekly https://semaglutides.org/news/2026/08/chrissy-metz-discloses-glp-1-use-joins-ro-2026/2026-09-15T03:41:44Zweekly https://semaglutides.org/news/2026/08/hims-10q-discloses-60-million-ftc-legal-accrual-2026/2026-09-15T03:41:39Zweekly https://semaglutides.org/news/2026/08/mhra-orforglipron-2026/2026-09-15T03:41:35Zweekly https://semaglutides.org/news/2026/08/uk-becomes-country-europe-authorize-orforglipron-2026/2026-09-15T03:41:38Zweekly https://semaglutides.org/news/2026/08/case-series-muscle-grip-strength-gains-tirzepatide-testosterone-2026/2026-09-15T04:38:25Zweekly https://semaglutides.org/news/2026/08/hims-hers-q2-2026-revenue-753-million-gaap/2026-09-15T04:38:20Zweekly https://semaglutides.org/news/2026/08/systematic-review-finds-no-evidence-best-injection-2026/2026-09-15T04:38:21Zweekly https://semaglutides.org/news/2026/08/novo-aws-ai-partnership-2026/2026-09-15T05:23:17Zweekly https://semaglutides.org/news/2026/08/second-obesity-commentary-sets-safety-evidence-gaps-tirzepatide-2026/2026-09-15T04:39:10Zweekly https://semaglutides.org/news/2026/08/wegovy-total-scripts-slip-obesity-share-399-2026/2026-09-15T04:38:29Zweekly https://semaglutides.org/news/2026/08/uk-secures-lower-section-232-pharmaceutical-tariff-rate-2026/2026-09-15T04:38:54Zweekly https://semaglutides.org/news/2026/08/doustdar-wegovy-pill-must-win-2026/2026-09-15T05:23:46Zweekly https://semaglutides.org/news/2026/08/antitrust-suit-dismissed-2026/2026-09-15T03:06:04Zweekly https://semaglutides.org/news/2026/08/cms-extends-medicare-glp-1-bridge-through-december-2026/2026-09-15T03:06:11Zweekly https://semaglutides.org/news/2026/08/network-meta-analysis-ranks-liraglutide-last-three-obesity-2026/2026-09-15T04:38:50Zweekly https://semaglutides.org/news/2026/08/reuters-glp-1-antitrust-dismissal-2026/2026-09-15T04:38:41Zweekly https://semaglutides.org/news/2026/08/uk-yellow-card-figures-show-tirzepatide-largest-share-2026/2026-09-15T04:38:50Zweekly https://semaglutides.org/news/2026/08/health-canada-generic-semaglutide-backlog-august-2026/2026-09-15T05:23:26Zweekly https://semaglutides.org/news/2026/08/cms-bridge-plan-guidance-2026/2026-09-15T05:23:27Zweekly https://semaglutides.org/news/2026/08/eli-lilly-48-revenue-growth-raises-2026-guidance/2026-09-15T03:06:13Zweekly https://semaglutides.org/news/2026/08/lilly-q2-revenue-jumps-48-23-billion-while-2026/2026-09-15T03:06:21Zweekly https://semaglutides.org/news/2026/08/lilly-self-pay-now-zepbound-prescriptions-2026/2026-09-15T03:06:34Zweekly https://semaglutides.org/news/2026/08/mounjaro-zepbound-top-14-8-billion-single-quarter-2026/2026-09-15T03:06:32Zweekly https://semaglutides.org/news/2026/08/foundayo-posts-98-million-partial-quarter-below-expectations-2026/2026-09-15T03:42:01Zweekly https://semaglutides.org/news/2026/08/q2-2026-earnings-comparison/2026-09-15T03:42:05Zweekly https://semaglutides.org/news/2026/08/retatrutide-filing-plan-2026/2026-09-15T03:42:04Zweekly https://semaglutides.org/news/2026/08/lilly-tirzepatide-revenue-14-9-billion-one-quarter-2026/2026-09-15T03:42:12Zweekly https://semaglutides.org/news/2026/08/amgen-q2-nine-maritide-phase-3-trials-2026/2026-09-15T04:39:10Zweekly https://semaglutides.org/news/2026/08/lilly-fda-retatrutide-classification-2026/2026-09-15T04:38:59Zweekly https://semaglutides.org/news/2026/08/network-meta-analysis-compares-glp-1-therapy-testosterone-2026/2026-09-15T04:39:06Zweekly https://semaglutides.org/news/2026/08/lillys-public-pipeline-table-lists-brenipatide-macupatide-long-2026/2026-09-15T05:23:37Zweekly https://semaglutides.org/news/2026/08/novo-injunction-dutch-semaglutide-nasal-spray-2026/2026-09-15T05:23:39Zweekly https://semaglutides.org/news/2026/08/novo-q2-2026-raises-outlook/2026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/08/novo-q2-2026-brand-level-sales-split/2026-09-15T03:42:10Zweekly https://semaglutides.org/news/2026/08/reimagine-4-miss-2026/2026-09-15T03:42:15Zweekly https://semaglutides.org/news/2026/08/novo-q2-2026-pipeline-impairments/2026-09-15T04:39:07Zweekly https://semaglutides.org/news/2026/08/novo-shares-fall-despite-q2-guidance-raise-2026/2026-09-15T04:39:18Zweekly https://semaglutides.org/news/2026/08/pfizer-cuts-two-ex-metsera-obesity-programs-2026/2026-09-15T04:39:27Zweekly https://semaglutides.org/news/2026/08/pnas-agrp-hunger-neurons-required-semaglutide-fat-loss-2026/2026-09-15T04:39:24Zweekly https://semaglutides.org/news/2026/08/amgen-drops-amg513-2026/2026-09-15T05:23:52Zweekly https://semaglutides.org/news/2026/08/altimmune-starts-performa-phase-3-pemvidutide-mash-2026/2026-09-15T04:39:30Zweekly https://semaglutides.org/news/2026/08/danish-national-cohort-semaglutide-persistence-published-jama-network-2026/2026-09-15T04:39:39Zweekly https://semaglutides.org/news/2026/08/mdl-3094-august-2026-count/2026-09-15T04:39:41Zweekly https://semaglutides.org/news/2026/08/retatrutide-expanded-access-2026/2026-09-15T04:39:44Zweekly https://semaglutides.org/news/2026/08/canada-65-percent-semaglutide-price-trigger-2026/2026-09-15T05:23:54Zweekly https://semaglutides.org/news/2026/08/tirzepatide-help-partial-lipodystrophy-rare-fat-storage-disorder-2026/2026-09-15T05:23:54Zweekly https://semaglutides.org/news/2026/08/eli-lilly-holds-60-branded-obesity-market-2026/2026-09-15T03:42:35Zweekly https://semaglutides.org/news/2026/08/structure-therapeutics-doses-patients-phase-3-accomplish-program-2026/2026-09-15T03:42:35Zweekly https://semaglutides.org/news/2026/08/china-glp1-candidates-2026/2026-09-15T04:39:53Zweekly https://semaglutides.org/news/2026/08/cvs-oral-glp1-formulary-2026/2026-09-15T04:39:53Zweekly https://semaglutides.org/news/2026/08/lean-mass-glp1-2026/2026-09-15T04:40:11Zweekly https://semaglutides.org/news/2026/08/multi-dose-wegovy-flextouch-pen-rolling-2026/2026-09-15T04:40:06Zweekly https://semaglutides.org/news/2026/08/obesity-pipeline-broadens-2026/2026-09-15T04:40:08Zweekly https://semaglutides.org/news/2026/08/ozempic-25mg-tablet-filing-2026/2026-09-15T04:39:59Zweekly https://semaglutides.org/news/2026/08/pfizer-monthly-shot-2026/2026-09-15T04:40:18Zweekly https://semaglutides.org/news/2026/08/zepbound-label-revision-updates-diabetic-retinopathy-section-2026/2026-09-15T04:40:09Zweekly https://semaglutides.org/news/2026/07/ziltivekimab-fails-zeus-heart-trial-erasing-30-billion-2026/2026-09-15T03:06:43Zweekly https://semaglutides.org/news/2026/07/zeus-trial-fails-2026/2026-09-15T03:42:37Zweekly https://semaglutides.org/news/2026/07/section-232-pharmaceutical-tariffs-take-effect-17-named-2026/2026-09-15T03:42:51Zweekly https://semaglutides.org/news/2026/07/cleveland-clinic-advises-against-microdosing-glp-1-medications-2026/2026-09-15T04:40:22Zweekly https://semaglutides.org/news/2026/07/cms-ends-part-d-premium-stabilization-demonstration-2027-premiums-2026/2026-09-15T04:40:24Zweekly https://semaglutides.org/news/2026/07/deadline-state-medicaid-agencies-apply-balance-model-2026/2026-09-15T04:40:25Zweekly https://semaglutides.org/news/2026/07/503b-comment-closes-2026/2026-09-15T03:42:49Zweekly https://semaglutides.org/news/2026/07/sun-pharma-wins-brazilian-approval-semaglutide-injections-2026/2026-09-15T04:40:30Zweekly https://semaglutides.org/news/2026/07/lilly-resilience-750m-2026/2026-09-15T05:23:56Zweekly https://semaglutides.org/news/2026/07/treasure-ckd-completes-without-reporting-results-2026/2026-09-15T05:24:11Zweekly https://semaglutides.org/news/2026/07/health-canada-registry-approved-unmarketed-semaglutide-2026/2026-09-15T05:24:09Zweekly https://semaglutides.org/news/2026/07/ftc-utah-los-angeles-county-sue-hims-hers-2026/2026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/07/oral-semaglutide-reduces-heavy-drinking-treatment-seeking-trial-2026/2026-09-15T03:42:49Zweekly https://semaglutides.org/news/2026/07/imak-novo-canadian-patent-extension-lapse-2026/2026-09-15T04:40:44Zweekly https://semaglutides.org/news/2026/07/viking-confirms-oral-vk2735-phase-3-fourth-quarter-2026/2026-09-15T04:40:55Zweekly https://semaglutides.org/news/2026/07/japanese-cohort-finds-2-5-mg-5-mg-2026/2026-09-15T03:43:05Zweekly https://semaglutides.org/news/2026/07/altimmune-positive-phase-2-results-pemvidutide-alcohol-use-2026/2026-09-15T04:40:40Zweekly https://semaglutides.org/news/2026/07/gubra-opens-phase-1-2a-gub-ucn2-2026/2026-09-15T04:40:48Zweekly https://semaglutides.org/news/2026/07/cagrisema-securities-suit-survives-dismissal-2026/2026-09-15T04:40:58Zweekly https://semaglutides.org/news/2026/07/rest-trial-protocol-published-formalizing-taper-question-2026/2026-09-15T03:43:05Zweekly https://semaglutides.org/news/2026/07/novo-seeks-injunction-on-lilly-ads-2026/2026-09-15T03:43:03Zweekly https://semaglutides.org/news/2026/07/two-brain-regions-found-explain-gip-paradox-2026/2026-09-15T03:43:25Zweekly https://semaglutides.org/news/2026/07/triumph-2-3-results-2026/2026-09-15T03:06:54Zweekly https://semaglutides.org/news/2026/07/australia-adds-naion-all-glp-1-product-information-2026/2026-09-15T03:43:37Zweekly https://semaglutides.org/news/2026/07/fda-advisory-committee-recommends-six-peptides-503a-bulks-2026/2026-09-15T03:43:24Zweekly https://semaglutides.org/news/2026/07/lilly-retatrutide-ready-file-targeting-obesity-sleep-apnea-2026/2026-09-15T03:43:34Zweekly https://semaglutides.org/news/2026/07/systematic-review-finds-glp-1-drugs-raise-testosterone-2026/2026-09-15T04:40:50Zweekly https://semaglutides.org/news/2026/07/bmj-study-finds-glp-1-drugs-raise-risk-2026/2026-09-15T03:43:32Zweekly https://semaglutides.org/news/2026/07/novo-challenges-lilly-ads-2026/2026-09-15T03:07:04Zweekly https://semaglutides.org/news/2026/07/president-phased-tariffs-imported-generic-drugs-2026/2026-09-15T03:07:07Zweekly https://semaglutides.org/news/2026/07/review-maps-off-label-evidence-five-domains-finds-2026/2026-09-15T04:41:01Zweekly https://semaglutides.org/news/2026/07/hengrui-positive-phase-3-diabetes-readout-ribupatide-china-2026/2026-09-15T04:41:10Zweekly https://semaglutides.org/news/2026/07/rebel-wilson-becomes-nooms-chief-wellness-officer-2026/2026-09-15T04:41:11Zweekly https://semaglutides.org/news/2026/07/lilly-agrees-acquire-ataibeckley-2-8-billion-upfront-2026/2026-09-15T04:41:18Zweekly https://semaglutides.org/news/2026/07/boehringer-ingelheim-phase-2-trial-gubra-originated-triple-2026/2026-09-15T05:24:31Zweekly https://semaglutides.org/news/2026/07/ec-approves-wegovy-pill-2026/2026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/07/expert-consensus-sets-meal-pattern-targets-glp-based-2026/2026-09-15T04:41:16Zweekly https://semaglutides.org/news/2026/07/wegovy-pill-fifth-approval-2026/2026-09-15T04:41:16Zweekly https://semaglutides.org/news/2026/07/sams-club-bundles-weightwatchers-benefit-against-costcos-glp-2026/2026-09-15T04:41:18Zweekly https://semaglutides.org/news/2026/07/three-case-series-describes-flat-mood-lost-motivation-2026/2026-09-15T04:41:25Zweekly https://semaglutides.org/news/2026/07/goodrx-114-million-americans-no-commercial-coverage-zepbound-2026/2026-09-15T03:43:37Zweekly https://semaglutides.org/news/2026/07/largest-tirzepatide-faers-study-finds-medication-errors-top-2026/2026-09-15T03:43:57Zweekly https://semaglutides.org/news/2026/07/structure-therapeutics-accomplish-phase-3-program-aleniglipron-2026/2026-09-15T03:43:55Zweekly https://semaglutides.org/news/2026/07/cms-bridge-guidance-2026/2026-09-15T04:41:29Zweekly https://semaglutides.org/news/2026/07/meta-analysis-finds-no-clear-rise-birth-defects-2026/2026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/07/military-health-system-cohort-82-one-persistence-tirzepatide-2026/2026-09-15T04:41:44Zweekly https://semaglutides.org/news/2026/07/perceptions-survey-quantifies-workplace-side-obesity-treatment-2026/2026-09-15T04:41:33Zweekly https://semaglutides.org/news/2026/07/bmj-network-meta-analysis-biggest-fat-loss-biggest-2026/2026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/07/survey-finds-glp-1s-now-11-4-employer-2026/2026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/07/fda-accepts-second-generic-tirzepatide-application-amneal-adalvo-2026/2026-09-15T04:41:44Zweekly https://semaglutides.org/news/2026/07/novo-nordisk-publishes-full-step-body-composition-detail-2026/2026-09-15T04:41:34Zweekly https://semaglutides.org/news/2026/07/wegovy-pill-uk-patients-2026/2026-09-15T04:41:46Zweekly https://semaglutides.org/news/2026/07/gallup-11-adults-now-take-glp-1-weight-2026/2026-09-15T03:07:15Zweekly https://semaglutides.org/news/2026/07/surmount-osa-post-hoc-biggest-daytime-function-gains-2026/2026-09-15T04:41:53Zweekly https://semaglutides.org/news/2026/07/case-series-fewer-migraine-attacks-tirzepatide-large-caveat-2026/2026-09-15T05:34:34Zweekly https://semaglutides.org/news/2026/07/masshealth-stops-covering-glp-1s-prescribed-only-weight-2026/2026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/07/mhra-approves-wegovy-liver-disease-2026/2026-09-15T04:41:55Zweekly https://semaglutides.org/news/2026/07/audit-finds-compounded-glp-1-market-still-operating-2026/2026-09-15T03:44:08Zweekly https://semaglutides.org/news/2026/07/mdl-3163-authorizes-early-motion-practice-causation-preemption-2026/2026-09-15T04:41:58Zweekly https://semaglutides.org/news/2026/07/medicare-bridge-live-2026/2026-09-15T03:07:29Zweekly https://semaglutides.org/news/2026/07/medicare-glp-1-bridge-publishing-explicit-bmi-eligibility-2026/2026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/07/massachusetts-gic-ends-obesity-only-glp-1-coverage-2026/2026-09-15T03:44:26Zweekly https://semaglutides.org/news/2026/07/lilly-fda-precheck-2026/2026-09-15T05:24:18Zweekly https://semaglutides.org/news/2026/07/apollo-care-recalls-roughly-162-000-vials-compounded-2026/2026-09-15T03:44:24Zweekly https://semaglutides.org/news/2026/07/jama-health-forum-secret-shopper-study-finds-compounded-2026/2026-09-15T03:44:37Zweekly https://semaglutides.org/news/2026/07/summary-judgment-briefing-completes-mdl-3094-2026/2026-09-15T03:44:34Zweekly https://semaglutides.org/news/2026/07/nationwide-cohort-208-155-post-bariatric-patients-finds-2026/2026-09-15T03:44:32Zweekly https://semaglutides.org/news/2026/07/amazon-foundayo-2026/2026-09-15T04:42:16Zweekly https://semaglutides.org/news/2026/07/tga-glp1-eye-warnings-2026/2026-09-15T04:42:04Zweekly https://semaglutides.org/news/2026/07/surpass-cn-mono-published-completing-tirzepatides-china-registration-2026/2026-09-15T04:42:11Zweekly https://semaglutides.org/news/2026/07/foundayo-medication-guide-reissued-7-missed-dose-restart-2026/2026-09-15T05:24:19Zweekly https://semaglutides.org/news/2026/07/foundayo-prescribing-information-revised-2026/2026-09-15T05:24:50Zweekly https://semaglutides.org/news/2026/06/wegovy-label-consolidates-injection-tablet-one-prescribing-information-2026-2/2026-09-15T03:44:45Zweekly https://semaglutides.org/news/2026/06/fda-scientists-publicly-flag-evidence-gaps-compounded-peptides-2026/2026-09-15T04:42:13Zweekly https://semaglutides.org/news/2026/06/sandoz-files-revoke-novo-nordisk-semaglutide-patent-unified-2026/2026-09-15T04:42:29Zweekly https://semaglutides.org/news/2026/06/mfn-deal-loophole-2026/2026-09-15T04:42:28Zweekly https://semaglutides.org/news/2026/06/health-canada-approves-generic-semaglutide-weight-loss-2026/2026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/06/astrazeneca-opens-embold-phase-3-master-protocol-elecoglipron-2026/2026-09-15T03:44:54Zweekly https://semaglutides.org/news/2026/06/fda-accepts-sandoz-applications-generic-tirzepatide-2026/2026-09-15T03:44:54Zweekly https://semaglutides.org/news/2026/06/uk-lilly-obesity-partnership-2026/2026-09-15T04:42:38Zweekly https://semaglutides.org/news/2026/06/fda-503b-comment-extension-2026/2026-09-15T07:58:42Zweekly https://semaglutides.org/news/2026/06/chmp-recommends-adding-surpass-cvot-results-eu-mounjaro-2026/2026-09-15T03:45:08Zweekly https://semaglutides.org/news/2026/06/cms-data-shows-liraglutide-brand-spending-collapsed-generic-2026/2026-09-15T03:45:12Zweekly https://semaglutides.org/news/2026/06/lillydirect-uk-launch-2026/2026-09-15T05:24:29Zweekly https://semaglutides.org/news/2026/06/lilly-oura-wearable-2026/2026-09-15T05:24:29Zweekly https://semaglutides.org/news/2026/06/lilly-completes-centessa-acquisition-2026/2026-09-15T05:24:47Zweekly https://semaglutides.org/news/2026/06/hypothesis-paper-proposes-tirzepatide-refractory-endometriosis-no-human-2026/2026-09-15T05:34:43Zweekly https://semaglutides.org/news/2026/06/retatrutide-compassionate-use-2026/2026-09-15T04:42:38Zweekly https://semaglutides.org/news/2026/06/los-angeles-times-documents-how-far-microdosing-has-2026/2026-09-15T04:42:34Zweekly https://semaglutides.org/news/2026/06/nhs-england-expands-tirzepatide-eligibility-second-cohort-2026/2026-09-15T04:42:51Zweekly https://semaglutides.org/news/2026/06/pwc-finds-one-five-households-now-includes-glp-2026/2026-09-15T03:07:41Zweekly https://semaglutides.org/news/2026/06/lancet-issues-expression-concern-exenatide-parkinsons-trial-2026/2026-09-15T04:42:56Zweekly https://semaglutides.org/news/2026/06/wegovy-tablet-mash-filing-2026/2026-09-15T04:43:02Zweekly https://semaglutides.org/news/2026/06/wegovy-label-consolidates-injection-tablet-one-prescribing-information-2026/2026-09-15T04:42:50Zweekly https://semaglutides.org/news/2026/06/perceptions-survey-why-518-adults-tirzepatide-2026/2026-09-15T04:42:53Zweekly https://semaglutides.org/news/2026/06/college-physicians-issues-living-guideline-obesity-pharmacotherapy-2026/2026-09-15T03:45:15Zweekly https://semaglutides.org/news/2026/06/fda-sends-25-letters-telehealth-companies-compounded-weight-2026/2026-09-15T03:45:11Zweekly https://semaglutides.org/news/2026/06/pooled-analysis-finds-tirzepatide-works-same-adults-65-2026/2026-09-15T04:43:02Zweekly https://semaglutides.org/news/2026/06/fda-issues-25-warning-letters-telehealth-companies-compounded-2026/2026-09-15T03:45:18Zweekly https://semaglutides.org/news/2026/06/fda-publishes-list-unlawful-compounded-drug-marketing-claims-2026/2026-09-15T03:45:17Zweekly https://semaglutides.org/news/2026/06/fda-updates-guidance-page-telehealth-companies-promoting-compounded-2026/2026-09-15T03:45:30Zweekly https://semaglutides.org/news/2026/06/polish-cohort-shows-how-widely-incretin-drugs-already-2026/2026-09-15T04:43:13Zweekly https://semaglutides.org/news/2026/06/endo-2026-semaglutide-linked-15-percent-fewer-fractures/2026-09-15T04:43:07Zweekly https://semaglutides.org/news/2026/06/endo-2026-glp-1-drugs-do-not-harm/2026-09-15T04:43:14Zweekly https://semaglutides.org/news/2026/06/retatrutide-ada-medicare-2026/2026-09-15T04:43:31Zweekly https://semaglutides.org/news/2026/06/bcbs-federal-employee-program-approves-zepbound-policy-requiring-2026/2026-09-15T03:45:42Zweekly https://semaglutides.org/news/2026/06/mhra-approves-wegovy-tablet-european-2026/2026-09-15T03:45:37Zweekly https://semaglutides.org/news/2026/06/surveys-show-employers-pulling-back-glp-1-coverage-2026/2026-09-15T03:45:42Zweekly https://semaglutides.org/news/2026/06/mhra-wegovy-pill-approval-2026/2026-09-15T03:45:43Zweekly https://semaglutides.org/news/2026/06/novo-it-security-incident-2026/2026-09-15T04:43:27Zweekly https://semaglutides.org/news/2026/06/wegovy-pill-passes-3-million-prescriptions-doustdar-he-2026/2026-09-15T04:43:24Zweekly https://semaglutides.org/news/2026/06/shaquille-oneal-he-takes-zepbound-sleep-apnea-2026/2026-09-15T03:45:46Zweekly https://semaglutides.org/news/2026/06/pfizer-phase-3-trial-berobenatide-2026/2026-09-15T04:43:24Zweekly https://semaglutides.org/news/2026/06/wegovy-pill-new-patients-2026/2026-09-15T03:45:59Zweekly https://semaglutides.org/news/2026/06/goldman-sachs-raises-2030-obesity-market-forecast-114-2026/2026-09-15T04:43:37Zweekly https://semaglutides.org/news/2026/06/achieve-3-lillys-oral-pill-beats-oral-semaglutide-2026/2026-09-15T03:46:03Zweekly https://semaglutides.org/news/2026/06/astrazenecas-elecoglipron-moves-phase-3-11-8-weight-2026/2026-09-15T03:46:18Zweekly https://semaglutides.org/news/2026/06/retatrutide-black-market-cbs-2026/2026-09-15T03:46:12Zweekly https://semaglutides.org/news/2026/06/faers-comparison-puts-tirzepatides-optic-neuropathy-signal-far-2026/2026-09-15T03:46:14Zweekly https://semaglutides.org/news/2026/06/fda-issues-warning-letters-altru-telehealth-fitish-others-2026/2026-09-15T03:46:14Zweekly https://semaglutides.org/news/2026/06/ada-standards-of-care-2026/2026-09-15T04:43:33Zweekly https://semaglutides.org/news/2026/06/foundayo-t2d-trials-2026/2026-09-15T04:44:03Zweekly https://semaglutides.org/news/2026/06/wegovy-pill-3m-scripts-2026/2026-09-15T03:07:51Zweekly https://semaglutides.org/news/2026/06/annals-oncology-glp-1-use-tied-41-percent-2026/2026-09-15T03:46:29Zweekly https://semaglutides.org/news/2026/06/cagrisema-reimagine-ada-2026/2026-09-15T03:46:34Zweekly https://semaglutides.org/news/2026/06/novo-nordisk-presents-cagrisema-reimagine-zenagamtide-data-ada-2026/2026-09-15T03:46:45Zweekly https://semaglutides.org/news/2026/06/survodutide-phase-3-data-published-nejm-show-34-2026/2026-09-15T03:46:48Zweekly https://semaglutides.org/news/2026/06/foundayo-menopause-data-2026/2026-09-15T04:43:38Zweekly https://semaglutides.org/news/2026/06/synchronize-1-published-survodutide-dual-glp-1-glucagon-2026/2026-09-15T04:44:03Zweekly https://semaglutides.org/news/2026/06/ten-faers-review-finds-alopecia-reporting-signals-semaglutide-2026/2026-09-15T04:43:53Zweekly https://semaglutides.org/news/2026/06/pfizer-details-monthly-berobenatide-data-plans-10-phase-2026/2026-09-15T03:46:42Zweekly https://semaglutides.org/news/2026/06/retatrutide-cuts-sleep-apnea-severity-60-percent-triumph-2026/2026-09-15T03:46:45Zweekly https://semaglutides.org/news/2026/06/retatrutide-ada-full-data-2026/2026-09-15T03:47:00Zweekly https://semaglutides.org/news/2026/06/lilly-lays-five-molecule-obesity-strategy-ada-2026/2026-09-15T04:44:09Zweekly https://semaglutides.org/news/2026/06/novo-ada-2026-analyses/2026-09-15T04:44:05Zweekly https://semaglutides.org/news/2026/06/surmount-maintain-appears-print-lancet-2026/2026-09-15T04:44:04Zweekly https://semaglutides.org/news/2026/06/ada-2026-opens/2026-09-15T03:47:04Zweekly https://semaglutides.org/news/2026/06/consensus-issues-practical-guidelines-glp-1-use-type-2026/2026-09-15T03:47:08Zweekly https://semaglutides.org/news/2026/06/structure-therapeutics-publishes-aleniglipron-phase-2b-data-nature-2026/2026-09-15T04:44:15Zweekly https://semaglutides.org/news/2026/06/prospective-cohort-18-percent-weight-loss-tirzepatide-bariatric-2026/2026-09-15T05:24:38Zweekly https://semaglutides.org/news/2026/06/telehealth-survey-real-world-sleep-improvements-tirzepatide-2026/2026-09-15T05:34:39Zweekly https://semaglutides.org/news/2026/06/large-cohort-quantifies-motility-risk-glp-1-drugs-2026/2026-09-15T03:47:14Zweekly https://semaglutides.org/news/2026/06/bridge-program-limits-2026/2026-09-15T04:44:21Zweekly https://semaglutides.org/news/2026/06/obesity-journal-asks-whether-multi-dose-tirzepatide-pens-2026/2026-09-15T04:44:54Zweekly https://semaglutides.org/news/2026/06/rybelsus-3-7-14-mg-posted-fda-discontinuation-2026/2026-09-15T04:44:27Zweekly https://semaglutides.org/news/2026/06/randomized-trial-tirzepatide-pcos-menstrual-pregnancy-gains-2026/2026-09-15T04:44:22Zweekly https://semaglutides.org/news/2026/06/wegovy-new-starts-2026/2026-09-15T04:44:29Zweekly https://semaglutides.org/news/2026/06/cigna-drops-glp-1-coverage-own-employees-2026/2026-09-15T03:47:12Zweekly https://semaglutides.org/news/2026/06/phase-1b-trial-separates-what-gip-glp-1-2026/2026-09-15T03:47:20Zweekly https://semaglutides.org/news/2026/06/science-held-glp-1-vision-loss-mdl-2026/2026-09-15T03:47:32Zweekly https://semaglutides.org/news/2026/06/cvs-caremark-lifts-market-block-foundayo-2026/2026-09-15T03:47:34Zweekly https://semaglutides.org/news/2026/06/eli-lilly-registers-pre-approval-expanded-access-program-2026/2026-09-15T03:47:38Zweekly https://semaglutides.org/news/2026/06/survodutides-cardiovascular-outcomes-trial-reaches-primary-completion-2026/2026-09-15T04:44:43Zweekly https://semaglutides.org/news/2026/06/ozempic-injection-label-revised-2026/2026-09-15T05:24:46Zweekly https://semaglutides.org/news/2026/06/cagrisema-decision-date-2026/2026-09-15T03:47:47Zweekly https://semaglutides.org/news/2026/06/surpass-early-two-results-favor-starting-tirzepatide-early-2026/2026-09-15T03:47:41Zweekly https://semaglutides.org/news/2026/06/muscle-nutrition-glp1-2026/2026-09-15T04:44:49Zweekly https://semaglutides.org/news/2026/06/commentary-raises-bone-reproductive-eating-disorder-questions-adolescent-2026/2026-09-15T04:44:39Zweekly https://semaglutides.org/news/2026/06/embraze-muscle-preservation-2026/2026-09-15T07:58:35Zweekly https://semaglutides.org/news/2026/06/orforglipron-t2d-filing-2026/2026-09-15T04:44:59Zweekly https://semaglutides.org/news/2026/06/nature-metabolism-paper-maps-how-semaglutide-signals-hindbrain-2026/2026-09-15T07:05:05Zweekly https://semaglutides.org/news/2026/06/wegovy-label-adds-never-share-warning-flextouch-pen-2026/2026-09-15T04:45:00Zweekly https://semaglutides.org/news/2026/06/wegovy-label-revision-consolidates-pregnancy-lactation-pediatric-guidance-2026/2026-09-15T04:45:11Zweekly https://semaglutides.org/news/2026/06/viking-vanquish-2-enrollment-2026/2026-09-15T05:24:52Zweekly https://semaglutides.org/news/2026/05/fda-count-reaches-990-adverse-event-compounded-semaglutide-2026/2026-09-15T03:47:46Zweekly https://semaglutides.org/news/2026/05/nutrients-publishes-nutrition-framework-incretin-therapy-2026/2026-09-15T04:45:29Zweekly https://semaglutides.org/news/2026/05/stat-news-revisits-microdosing-still-popular-still-unsupported-2026/2026-09-15T07:06:20Zweekly https://semaglutides.org/news/2026/05/stat-microdosing-glp-1s-not-thing-there-no-2026/2026-09-15T04:45:22Zweekly https://semaglutides.org/news/2026/05/cvs-restores-zepbound-announcement-2026/2026-09-15T03:07:45Zweekly https://semaglutides.org/news/2026/05/all-three-major-pbms-agree-cover-foundayo-2026/2026-09-15T03:48:03Zweekly https://semaglutides.org/news/2026/05/north-carolina-treasurer-state-budget-will-not-restore-2026/2026-09-15T04:45:16Zweekly https://semaglutides.org/news/2026/05/novo-nordisk-confirms-amycretin-has-renamed-zenagamtide-2026/2026-09-15T05:24:48Zweekly https://semaglutides.org/news/2026/05/patients-unable-fill-generic-liraglutide-3-mg-2026/2026-09-15T05:24:58Zweekly https://semaglutides.org/news/2026/05/anvisa-approves-brazils-generic-semaglutide-pen-2026/2026-09-15T03:47:59Zweekly https://semaglutides.org/news/2026/05/lilly-buys-three-companies-one-build-infectious-disease-2026/2026-09-15T04:45:35Zweekly https://semaglutides.org/news/2026/05/nurse-practitioner-commentary-frames-microdosing-access-trust-problem-2026/2026-09-15T04:45:33Zweekly https://semaglutides.org/news/2026/05/glp-1-drugs-linked-lower-macular-degeneration-risk-2026/2026-09-15T05:25:09Zweekly https://semaglutides.org/news/2026/05/penn-researchers-mine-400-000-reddit-posts-glp-2026/2026-09-15T04:45:33Zweekly https://semaglutides.org/news/2026/05/bari-step-semaglutide-rescues-poor-weight-loss-bariatric-2026/2026-09-15T03:08:10Zweekly https://semaglutides.org/news/2026/05/narb-upholds-clinically-proven-claims-must-substantiated-regardless-2026/2026-09-15T03:48:03Zweekly https://semaglutides.org/news/2026/05/post-hoc-analysis-shows-13-weight-loss-adults-2026/2026-09-15T04:45:44Zweekly https://semaglutides.org/news/2026/05/retatrutide-triumph-1-2026/2026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/05/triumph-1-topline-retatrutide-reaches-28-3-weight-2026/2026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/05/chmp-wegovy-pill-opinion-2026/2026-09-15T03:48:10Zweekly https://semaglutides.org/news/2026/05/fda-1-700-adverse-events-tied-compounded-glp-2026/2026-09-15T03:48:13Zweekly https://semaglutides.org/news/2026/05/hims-offering-generic-semaglutide-canada-2026/2026-09-15T03:48:18Zweekly https://semaglutides.org/news/2026/05/narb-affirms-nad-tru-niagen-matter-2026/2026-09-15T03:48:37Zweekly https://semaglutides.org/news/2026/05/plos-medicine-pooled-analysis-puts-naion-risk-absolute-2026/2026-09-15T03:48:32Zweekly https://semaglutides.org/news/2026/05/compounded-to-branded-shift-2026/2026-09-15T04:45:47Zweekly https://semaglutides.org/news/2026/05/restaurant-survey-finds-glp-1-users-eat-often-2026/2026-09-15T04:45:46Zweekly https://semaglutides.org/news/2026/05/trumprx-prices-may-2026/2026-09-15T04:46:07Zweekly https://semaglutides.org/news/2026/05/eli-lilly-files-roadmap-brief-seeking-summary-judgment-2026/2026-09-15T03:48:34Zweekly https://semaglutides.org/news/2026/05/supreme-court-ends-novo-nordisks-inflation-reduction-act-2026/2026-09-15T04:46:06Zweekly https://semaglutides.org/news/2026/05/trumprx-expands-everyday-medicines-generics-2026/2026-09-15T04:46:07Zweekly https://semaglutides.org/news/2026/05/lilly-phase-2-obesity-trial-selective-gip-agonist-2026/2026-09-15T04:46:09Zweekly https://semaglutides.org/news/2026/05/academy-ophthalmology-tirzepatides-naion-risk-studied-2026/2026-09-15T03:48:48Zweekly https://semaglutides.org/news/2026/05/apotex-generic-semaglutide-injection-canada-2026/2026-09-15T03:48:45Zweekly https://semaglutides.org/news/2026/05/teva-posts-discontinuation-notice-generic-saxenda-ndc-2026/2026-09-15T04:46:27Zweekly https://semaglutides.org/news/2026/05/lilly-unicef-50m-2026/2026-09-15T05:25:11Zweekly https://semaglutides.org/news/2026/05/attain-maintain-tests-switching-injection-oral-glp-1-2026/2026-09-15T03:08:08Zweekly https://semaglutides.org/news/2026/05/eco-2026-adding-glp-1-behavioral-treatment-cuts/2026-09-15T03:48:48Zweekly https://semaglutides.org/news/2026/05/tirzepatide-reaches-nce-1-date-opening-door-generic-2026/2026-09-15T04:46:24Zweekly https://semaglutides.org/news/2026/05/eco-2026-wegovy-pill-responders/2026-09-15T04:46:39Zweekly https://semaglutides.org/news/2026/05/surmount-maintain-lancet-2026/2026-09-15T03:08:20Zweekly https://semaglutides.org/news/2026/05/detailed-attain-maintain-results-published-nature-medicine-2026/2026-09-15T03:49:16Zweekly https://semaglutides.org/news/2026/05/lilly-marks-150-ceremony-indianapolis-2026/2026-09-15T03:49:17Zweekly https://semaglutides.org/news/2026/05/lilly-foundayo-lower-dose-zepbound-maintain-weight-loss-2026/2026-09-15T03:49:10Zweekly https://semaglutides.org/news/2026/05/eco-2026-wegovy-hd-responders/2026-09-15T04:46:42Zweekly https://semaglutides.org/news/2026/05/hims-hers-posts-92-million-quarter-loss-branded-2026/2026-09-15T04:46:25Zweekly https://semaglutides.org/news/2026/05/wegovy-menopause-data-2026/2026-09-15T04:46:55Zweekly https://semaglutides.org/news/2026/05/oral-vk2735-shows-12-2-weight-loss-13-2026/2026-09-15T04:46:42Zweekly https://semaglutides.org/news/2026/05/fda-commissioner-marty-makary-resigns-kyle-diamantas-named-2026/2026-09-15T05:25:16Zweekly https://semaglutides.org/news/2026/05/surpass-cvot-kidney-analysis-23-lower-rate-major-2026/2026-09-15T03:49:23Zweekly https://semaglutides.org/news/2026/05/lilly-india-campaign-paused-2026/2026-09-15T05:25:07Zweekly https://semaglutides.org/news/2026/05/foundayo-weekly-scripts-modest-2026/2026-09-15T04:46:51Zweekly https://semaglutides.org/news/2026/05/omada-health-joins-lilly-employer-connect-independent-program-2026/2026-09-15T04:46:44Zweekly https://semaglutides.org/news/2026/05/medicare-glp1-bridge-announced-2026/2026-09-15T03:08:17Zweekly https://semaglutides.org/news/2026/05/mounjaro-passes-keytruda-worlds-best-selling-drug-2026/2026-09-15T03:08:31Zweekly https://semaglutides.org/news/2026/05/business-group-health-finds-67-large-employers-cover-2026/2026-09-15T03:49:16Zweekly https://semaglutides.org/news/2026/05/lilly-adds-4-5-billion-indiana-where-tirzepatide-2026/2026-09-15T03:49:17Zweekly https://semaglutides.org/news/2026/05/q1-2026-wegovy-pill-posts-dkk-2-26/2026-09-15T03:49:44Zweekly https://semaglutides.org/news/2026/05/doustdar-novo-nordisk-hunting-deals-ever-2026/2026-09-15T04:46:55Zweekly https://semaglutides.org/news/2026/05/lilly-renew-ibs-d-phase-2-trial-brenipatide-2026/2026-09-15T05:25:30Zweekly https://semaglutides.org/news/2026/05/ozempic-tablets-available-2026/2026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/05/ozempic-pill-united-states-type-2-diabetes-2026/2026-09-15T03:49:47Zweekly https://semaglutides.org/news/2026/05/rybelsus-relaunches-reformulated-ozempic-pill-2026/2026-09-15T03:49:45Zweekly https://semaglutides.org/news/2026/05/french-regulator-fines-lilly-novo-2026/2026-09-15T05:25:22Zweekly https://semaglutides.org/news/2026/05/apotex-wins-canadian-approval-apo-semaglutide-2026/2026-09-15T03:49:42Zweekly https://semaglutides.org/news/2026/05/balance-model-delayed-2026/2026-09-15T03:49:54Zweekly https://semaglutides.org/news/2026/05/colorado-makes-zepbound-only-weight-loss-glp-1-2026/2026-09-15T03:49:49Zweekly https://semaglutides.org/news/2026/05/health-canada-approves-second-generic-semaglutide-apotex-2026/2026-09-15T03:50:07Zweekly https://semaglutides.org/news/2026/05/novo-nordisk-date-ozempic-tablets-2026/2026-09-15T03:50:11Zweekly https://semaglutides.org/news/2026/05/503b-bulks-list-proposal-publishes-federal-register-2026/2026-09-15T03:50:18Zweekly https://semaglutides.org/news/2026/05/phase-2a-smoking-trial-misses-main-endpoint-cuts-2026/2026-09-15T04:47:21Zweekly https://semaglutides.org/news/2026/05/fda-503b-bulk-proposal-2026/2026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/05/iu-study-lilly-supports-47-520-indiana-jobs-2026/2026-09-15T03:50:23Zweekly https://semaglutides.org/news/2026/05/ozempic-prescribing-information-revised-still-no-naion-warning-2026/2026-09-15T03:50:14Zweekly https://semaglutides.org/news/2026/05/maritide-switch-study-2026/2026-09-15T04:47:06Zweekly https://semaglutides.org/news/2026/05/fda-approves-instructions-use-single-dose-ozempic-prefilled-2026/2026-09-15T04:47:05Zweekly https://semaglutides.org/news/2026/05/fda-approves-single-dose-prefilled-syringes-wegovy-2026/2026-09-15T04:47:33Zweekly https://semaglutides.org/news/2026/05/novo-nordisk-amaze-12-phase-3-trial-amycretin-2026/2026-09-15T04:47:28Zweekly https://semaglutides.org/news/2026/04/fda-proposes-exclude-semaglutide-tirzepatide-liraglutide-503b-bulks-2026/2026-09-15T03:08:42Zweekly https://semaglutides.org/news/2026/04/lilly-60-1-incretin-market-share-2026/2026-09-15T03:08:47Zweekly https://semaglutides.org/news/2026/04/nih-randomized-win-glp-1-drug-alcohol-use-2026/2026-09-15T03:08:53Zweekly https://semaglutides.org/news/2026/04/eating-disorder-clinicians-warn-cultural-swing-back-thin-2026/2026-09-15T03:50:27Zweekly https://semaglutides.org/news/2026/04/lancet-trial-semaglutide-cuts-heavy-drinking-alcohol-use-2026/2026-09-15T03:50:35Zweekly https://semaglutides.org/news/2026/04/lilly-q1-2026-detail-2026/2026-09-15T03:50:41Zweekly https://semaglutides.org/news/2026/04/mdl-3094-sets-expert-evidence-hearing-will-decide-2026/2026-09-15T03:50:50Zweekly https://semaglutides.org/news/2026/04/summary-judgment-briefing-filed-mdl-3094-warnings-adequacy-2026/2026-09-15T03:50:51Zweekly https://semaglutides.org/news/2026/04/systematic-review-quantifies-incretin-contraceptive-interaction-2026/2026-09-15T03:50:53Zweekly https://semaglutides.org/news/2026/04/glp1-alcohol-cbt-2026/2026-09-15T04:47:18Zweekly https://semaglutides.org/news/2026/04/empower-ruling-partial-2026/2026-09-15T05:25:25Zweekly https://semaglutides.org/news/2026/04/court-rules-lilly-v-empower-clinic-services-compounded-2026/2026-09-15T03:50:51Zweekly https://semaglutides.org/news/2026/04/roche-zealand-pharma-commit-petrelintide-phase-3-2026/2026-09-15T03:51:08Zweekly https://semaglutides.org/news/2026/04/health-canada-approves-generic-semaglutide-g7-2026/2026-09-15T03:08:58Zweekly https://semaglutides.org/news/2026/04/mdl-3094-daubert-deadline-2026/2026-09-15T03:51:10Zweekly https://semaglutides.org/news/2026/04/meta-analysis-49-395-pregnancies-finds-no-clear-2026/2026-09-15T03:51:19Zweekly https://semaglutides.org/news/2026/04/boehringer-ingelheims-survodutide-hits-16-6-weight-loss-2026/2026-09-15T03:51:21Zweekly https://semaglutides.org/news/2026/04/survodutide-posts-phase-3-readout-dual-glp-1-2026/2026-09-15T04:47:25Zweekly https://semaglutides.org/news/2026/04/hims-hers-adds-zepbound-zepbound-kwikpen-foundayo-via-2026/2026-09-15T03:51:26Zweekly https://semaglutides.org/news/2026/04/oral-sema-pediatric-t2d-2026/2026-09-15T04:47:23Zweekly https://semaglutides.org/news/2026/04/white-house-favored-nation-deal-regeneron-2026/2026-09-15T05:25:34Zweekly https://semaglutides.org/news/2026/04/goodrx-npr-document-12-million-people-losing-zepbound-2026/2026-09-15T03:51:26Zweekly https://semaglutides.org/news/2026/04/lean-prep-protocol-published-randomized-trial-lifting-weights-2026/2026-09-15T03:51:36Zweekly https://semaglutides.org/news/2026/04/fda-approves-21-use-storage-single-dose-tirzepatide-2026/2026-09-15T04:47:40Zweekly https://semaglutides.org/news/2026/04/multi-dose-tirzepatide-presentations-get-their-own-30-2026/2026-09-15T04:47:56Zweekly https://semaglutides.org/news/2026/04/updated-instructions-use-approved-tirzepatide-single-dose-pen-2026/2026-09-15T05:25:29Zweekly https://semaglutides.org/news/2026/04/cms-shelves-balance-model-medicare-part-d-extends-2026/2026-09-15T03:09:07Zweekly https://semaglutides.org/news/2026/04/amazon-nationwide-glp-1-program-through-one-medical-2026/2026-09-15T03:51:44Zweekly https://semaglutides.org/news/2026/04/iqvia-sizes-global-obesity-medicines-market-66-billion-2026/2026-09-15T03:51:49Zweekly https://semaglutides.org/news/2026/04/compounded-tirzepatide-impurity-described-peer-reviewed-journal-2026/2026-09-15T04:47:55Zweekly https://semaglutides.org/news/2026/04/trade-press-food-brands-adopting-glp-1-friendly-2026/2026-09-15T04:47:42Zweekly https://semaglutides.org/news/2026/04/lilly-agrees-acquire-kelonia-therapeutics-deal-worth-7-2026/2026-09-15T03:51:47Zweekly https://semaglutides.org/news/2026/04/second-court-lets-lillys-compounded-tirzepatide-advertising-claims-2026/2026-09-15T04:47:47Zweekly https://semaglutides.org/news/2026/04/deadline-passes-medicare-part-d-plans-join-balance-2026/2026-09-15T04:48:08Zweekly https://semaglutides.org/news/2026/04/india-fake-mounjaro-seizure-2026/2026-09-15T04:47:55Zweekly https://semaglutides.org/news/2026/04/adjust-t1d-post-hoc-analysis-shows-early-insulin-2026/2026-09-15T05:25:33Zweekly https://semaglutides.org/news/2026/04/indian-regulators-seize-260-counterfeit-mounjaro-pens-2026/2026-09-15T04:48:01Zweekly https://semaglutides.org/news/2026/04/zepbound-muscle-loss-preprint-2026/2026-09-15T04:48:06Zweekly https://semaglutides.org/news/2026/04/foundayo-first-week-scripts-2026/2026-09-15T04:48:14Zweekly https://semaglutides.org/news/2026/04/achieve-4-results-2026/2026-09-15T03:09:09Zweekly https://semaglutides.org/news/2026/04/lilly-q1-2026-results/2026-09-15T04:48:14Zweekly https://semaglutides.org/news/2026/04/wegovy-pill-price-step-2026/2026-09-15T05:25:37Zweekly https://semaglutides.org/news/2026/04/cms-proposes-extending-electronic-prior-authorization-standards-drugs-2026/2026-09-15T03:52:01Zweekly https://semaglutides.org/news/2026/04/fda-asks-lilly-heart-liver-data-newly-approved-2026/2026-09-15T03:51:57Zweekly https://semaglutides.org/news/2026/04/fda-asks-more-foundayo-safety-data-2026/2026-09-15T03:52:07Zweekly https://semaglutides.org/news/2026/04/fda-warning-letter-life-pharma-unapproved-glp-1-2026/2026-09-15T04:48:14Zweekly https://semaglutides.org/news/2026/04/review-maps-psoriasis-psoriatic-arthritis-research-pipeline-glp-2026/2026-09-15T05:26:02Zweekly https://semaglutides.org/news/2026/04/apotex-wins-fda-tentative-approval-generic-semaglutide-2026/2026-09-15T03:52:12Zweekly https://semaglutides.org/news/2026/04/india-generic-glp1-flood-2026/2026-09-15T04:48:19Zweekly https://semaglutides.org/news/2026/04/indian-generics-reshaping-glp-1-share-worlds-price-2026/2026-09-15T04:48:28Zweekly https://semaglutides.org/news/2026/04/foundayo-goes-sale-united-states-2026/2026-09-15T03:09:13Zweekly https://semaglutides.org/news/2026/04/foundayo-reaches-pharmacies-2026/2026-09-15T03:52:20Zweekly https://semaglutides.org/news/2026/04/georgetown-study-finds-glp-1-weight-loss-draws-2026/2026-09-15T03:52:18Zweekly https://semaglutides.org/news/2026/04/lilly-foundayo-oral-glp-1-2026/2026-09-15T03:52:26Zweekly https://semaglutides.org/news/2026/04/amazon-kiosks-foundayo-2026/2026-09-15T04:48:23Zweekly https://semaglutides.org/news/2026/04/fda-warning-letter-prorx-llc-sterility-quality-deficiencies-2026/2026-09-15T03:52:34Zweekly https://semaglutides.org/news/2026/04/wegovy-hd-goes-sale-nationwide-399-self-pay-2026/2026-09-15T03:52:37Zweekly https://semaglutides.org/news/2026/04/partnership-safe-medicines-compiles-fdas-research-chemical-warning-2026/2026-09-15T07:59:33Zweekly https://semaglutides.org/news/2026/04/foundayo-launch-2026/2026-09-15T03:09:18Zweekly https://semaglutides.org/news/2026/04/cms-adds-foundayo-medicare-glp-1-bridge-clarifies-2026/2026-09-15T03:52:39Zweekly https://semaglutides.org/news/2026/04/imputed-placebo-analysis-estimates-28-mace-reduction-tirzepatide-2026/2026-09-15T03:52:45Zweekly https://semaglutides.org/news/2026/04/multinational-study-1-8-million-older-adults-compares-2026/2026-09-15T04:48:31Zweekly https://semaglutides.org/news/2026/04/section-232-pharmaceutical-tariff-proclamation-sets-lillys-rate-2026/2026-09-15T03:09:25Zweekly https://semaglutides.org/news/2026/04/york-times-profiles-medvi-1-8-billion-ai-2026/2026-09-15T07:06:23Zweekly https://semaglutides.org/news/2026/04/wegovy-pill-vs-orforglipron-itc-2026/2026-09-15T04:48:49Zweekly https://semaglutides.org/news/2026/04/foundayo-approval-2026/2026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/04/fda-clarifies-compounding-rules-glp-1-supply-stabilizes-2026/2026-09-15T03:09:32Zweekly https://semaglutides.org/news/2026/04/fda-clarifies-essentially-copy-rule-four-prescription-threshold-2026/2026-09-15T03:09:35Zweekly https://semaglutides.org/news/2026/04/fda-sets-four-prescriptions-yardstick-copy-compounding-2026/2026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/04/fda-spells-what-counts-essentially-copy-compounded-glp-2026/2026-09-15T03:09:47Zweekly https://semaglutides.org/news/2026/04/foundayo-orforglipron-approval-creates-biggest-comparison-opportunity-2026/2026-09-15T03:09:59Zweekly https://semaglutides.org/news/2026/04/fda-restates-tirzepatide-neither-shortage-list-nor-503b-2026/2026-09-15T03:52:45Zweekly https://semaglutides.org/news/2026/04/foundayo-fastest-approval-2026/2026-09-15T03:52:54Zweekly https://semaglutides.org/news/2026/04/nhs-england-moves-tirzepatide-prescribing-gp-contract-2026/2026-09-15T03:53:07Zweekly https://semaglutides.org/news/2026/04/novo-nordisk-pushes-back-foundayo-comparisons-same-2026/2026-09-15T04:48:38Zweekly https://semaglutides.org/news/2026/04/foundayo-dosing-2026/2026-09-15T05:25:58Zweekly https://semaglutides.org/news/2026/04/tos-oma-oac-give-continuing-medication-during-maintenance-2026/2026-09-15T03:10:02Zweekly https://semaglutides.org/news/2026/04/first-wave-loe-markets-2026/2026-09-15T03:53:08Zweekly https://semaglutides.org/news/2026/04/part-d-glp1-coverage-requirement-2026/2026-09-15T03:53:12Zweekly https://semaglutides.org/news/2026/04/swedish-national-cohort-finds-semaglutide-linked-lower-risk-2026/2026-09-15T03:53:10Zweekly https://semaglutides.org/news/2026/04/wegovy-hd-launch-2026/2026-09-15T03:53:16Zweekly https://semaglutides.org/news/2026/04/wegovy-hd-united-states-2026/2026-09-15T04:48:47Zweekly https://semaglutides.org/news/2026/03/fda-warning-letter-gram-peptides-citing-tirzepatide-2026/2026-09-15T03:53:19Zweekly https://semaglutides.org/news/2026/03/fda-warns-research-peptide-sellers-gram-peptides-prime-2026/2026-09-15T03:53:32Zweekly https://semaglutides.org/news/2026/03/lilly-agrees-acquire-centessa-pharmaceuticals-6-3-billion-2026/2026-09-15T03:53:41Zweekly https://semaglutides.org/news/2026/03/wegovy-subscription-2026/2026-09-15T03:53:42Zweekly https://semaglutides.org/news/2026/03/opm-carrier-letter-2026-07-sets-plan-2027/2026-09-15T03:53:40Zweekly https://semaglutides.org/news/2026/03/lilly-narcolepsy-acquisition-2026/2026-09-15T04:48:43Zweekly https://semaglutides.org/news/2026/03/surpass-cvot-post-hoc-finds-broad-cardiorenal-benefit-2026/2026-09-15T03:53:50Zweekly https://semaglutides.org/news/2026/03/faers-analysis-finds-tirzepatide-negatively-associated-hair-loss-2026/2026-09-15T04:48:58Zweekly https://semaglutides.org/news/2026/03/viking-completes-enrollment-phase-3-vanquish-2-trial-2026/2026-09-15T04:49:16Zweekly https://semaglutides.org/news/2026/03/destination-xl-blames-glp-1s-size-volatility-apparel-2026/2026-09-15T03:53:46Zweekly https://semaglutides.org/news/2026/03/kff-puts-current-glp-1-use-12-adults-2026/2026-09-15T04:48:52Zweekly https://semaglutides.org/news/2026/03/ubt251-reduces-hba1c-2-16-chinese-phase-2-2026/2026-09-15T04:49:00Zweekly https://semaglutides.org/news/2026/03/meta-analysis-puts-number-what-resistance-training-changes-2026/2026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/03/ftc-creates-internal-healthcare-task-force-2026/2026-09-15T04:49:01Zweekly https://semaglutides.org/news/2026/03/india-price-war-2026/2026-09-15T03:54:08Zweekly https://semaglutides.org/news/2026/03/npr-covers-what-eat-glp-1-drugs-taking-2026/2026-09-15T04:49:05Zweekly https://semaglutides.org/news/2026/03/dozen-indian-generic-semaglutide-brands-one-2026/2026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/03/cnbc-quantifies-glp-1-hit-restaurant-dinner-traffic-2026/2026-09-15T03:54:06Zweekly https://semaglutides.org/news/2026/03/china-brazil-patent-expiry-2026/2026-09-15T03:10:21Zweekly https://semaglutides.org/news/2026/03/india-patent-expiry-2026/2026-09-15T03:10:15Zweekly https://semaglutides.org/news/2026/03/lilly-discloses-david-rickss-2025-pay-package-36-2026/2026-09-15T04:49:16Zweekly https://semaglutides.org/news/2026/03/wegovy-hd-approval-2026/2026-09-15T03:10:38Zweekly https://semaglutides.org/news/2026/03/imcivree-becomes-approved-treatment-acquired-hypothalamic-obesity-2026/2026-09-15T03:10:31Zweekly https://semaglutides.org/news/2026/03/dysesthesia-enters-semaglutide-label-dose-related-side-effect-2026/2026-09-15T03:54:11Zweekly https://semaglutides.org/news/2026/03/adpd-2026-evoke-full-data/2026-09-15T03:54:15Zweekly https://semaglutides.org/news/2026/03/lancet-psychiatry-semaglutide-linked-42-percent-lower-risk-2026/2026-09-15T03:54:11Zweekly https://semaglutides.org/news/2026/03/transcend-t2d-1-results-2026/2026-09-15T03:54:22Zweekly https://semaglutides.org/news/2026/03/wegovy-hd-approval-creates-dose-upgrade-query-cluster-2026/2026-09-15T03:54:46Zweekly https://semaglutides.org/news/2026/03/cnpv-program-glp1-2026/2026-09-15T03:54:42Zweekly https://semaglutides.org/news/2026/03/fda-approves-setmelanotide-acquired-hypothalamic-obesity-2026/2026-09-15T04:49:23Zweekly https://semaglutides.org/news/2026/03/wegovy-hd-dosing-2026/2026-09-15T04:49:23Zweekly https://semaglutides.org/news/2026/03/hsbc-downgrades-lilly-2026/2026-09-15T05:25:57Zweekly https://semaglutides.org/news/2026/03/lilly-phase-1b-study-brenipatide-overweight-obesity-2026/2026-09-15T05:26:03Zweekly https://semaglutides.org/news/2026/03/indiana-commits-1-billion-life-sciences-agriculture-2026/2026-09-15T03:54:37Zweekly https://semaglutides.org/news/2026/03/zepbound-kwikpen-self-pay-pricing-reaches-pharmacies-nationwide-2026/2026-09-15T03:10:36Zweekly https://semaglutides.org/news/2026/03/oculus-trial-stops-early-residual-stomach-contents-rise-2026/2026-09-15T03:54:42Zweekly https://semaglutides.org/news/2026/03/roche-phase-3-enicepatide-2026/2026-09-15T04:49:21Zweekly https://semaglutides.org/news/2026/03/structure-therapeutics-16-3-weight-loss-44-aleniglipron-2026/2026-09-15T04:49:24Zweekly https://semaglutides.org/news/2026/03/oscars-red-carpet-reignites-hollywood-thinness-debate-2026/2026-09-15T04:49:40Zweekly https://semaglutides.org/news/2026/03/all-15-ipay-2028-manufacturers-agree-negotiate-lilly-2026/2026-09-15T04:49:42Zweekly https://semaglutides.org/news/2026/03/all-15-drugmakers-agree-join-third-medicare-negotiation-2026/2026-09-15T05:25:56Zweekly https://semaglutides.org/news/2026/03/kroger-zepbound-kwikpen-2026/2026-09-15T05:26:07Zweekly https://semaglutides.org/news/2026/03/cleveland-clinic-finds-people-who-stop-glp-1s-2026/2026-09-15T03:54:46Zweekly https://semaglutides.org/news/2026/03/tirzepatide-b12-impurity-warning-2026/2026-09-15T03:54:54Zweekly https://semaglutides.org/news/2026/03/novo-holdings-assets-34-2025-2026/2026-09-15T03:55:06Zweekly https://semaglutides.org/news/2026/03/fda-retires-faers-adverse-event-monitoring-system-2026/2026-09-15T03:55:07Zweekly https://semaglutides.org/news/2026/03/fda-approves-biocons-generic-victoza-fifth-such-application-2026/2026-09-15T04:49:35Zweekly https://semaglutides.org/news/2026/03/lilly-china-3b-2026/2026-09-15T04:49:39Zweekly https://semaglutides.org/news/2026/03/preprint-uncharacterized-impurity-compounded-tirzepatide-plus-b12-products-2026/2026-09-15T04:49:43Zweekly https://semaglutides.org/news/2026/03/novo-hims-settlement-2026/2026-09-15T03:10:37Zweekly https://semaglutides.org/news/2026/03/cms-issues-balance-implementation-details-naming-zepbound-mounjaro-2026/2026-09-15T03:55:10Zweekly https://semaglutides.org/news/2026/03/abbvies-amylin-analog-abbv-295-posts-positive-phase-2026/2026-09-15T04:49:48Zweekly https://semaglutides.org/news/2026/03/amazon-zepbound-kwikpen-2026/2026-09-15T05:40:49Zweekly https://semaglutides.org/news/2026/03/hims-settlement-terms-2026/2026-09-15T04:50:02Zweekly https://semaglutides.org/news/2026/03/lilly-balance-model-statement-2026/2026-09-15T04:50:02Zweekly https://semaglutides.org/news/2026/03/axios-ipsos-finds-18-americans-have-weight-loss-2026/2026-09-15T04:49:58Zweekly https://semaglutides.org/news/2026/03/china-approves-ecnoglutide-chronic-weight-management-2026/2026-09-15T04:50:14Zweekly https://semaglutides.org/news/2026/03/who-foundation-lilly-obesity-2026/2026-09-15T05:26:19Zweekly https://semaglutides.org/news/2026/03/eli-lilly-employer-connect-selling-zepbound-employers-449-2026/2026-09-15T03:10:43Zweekly https://semaglutides.org/news/2026/03/fda-warning-letter-pade-2026/2026-09-15T03:10:49Zweekly https://semaglutides.org/news/2026/03/lilly-employer-connect-widen-workplace-obesity-coverage-2026/2026-09-15T04:50:09Zweekly https://semaglutides.org/news/2026/03/meta-regression-maps-shape-weight-regain-stopping-glp-2026/2026-09-15T03:10:57Zweekly https://semaglutides.org/news/2026/03/bmj-study-examines-glp-1-drugs-substance-use-2026/2026-09-15T04:50:09Zweekly https://semaglutides.org/news/2026/03/va-analysis-600-000-people-glp-1-drugs-2026/2026-09-15T04:50:21Zweekly https://semaglutides.org/news/2026/03/fda-30-warning-letters-2026/2026-09-15T03:11:06Zweekly https://semaglutides.org/news/2026/03/cms-publishes-medicare-glp-1-bridge-frequently-asked-2026/2026-09-15T03:55:20Zweekly https://semaglutides.org/news/2026/03/leadership-appointed-naion-mdl-2026/2026-09-15T04:50:20Zweekly https://semaglutides.org/news/2026/03/novo-two-year-low-2026/2026-09-15T04:50:29Zweekly https://semaglutides.org/news/2026/03/aaos-2026-mixed-musculoskeletal-findings-glp-1-users/2026-09-15T05:26:13Zweekly https://semaglutides.org/news/2026/03/march-2026-compounding-turning-point/2026-09-15T03:55:19Zweekly https://semaglutides.org/news/2026/03/us-label-no-naion-warning-2026/2026-09-15T03:55:24Zweekly https://semaglutides.org/news/2026/03/prime-therapeutics-claims-data-show-real-world-one-2026/2026-09-15T03:55:33Zweekly https://semaglutides.org/news/2026/03/two-large-claims-studies-disagree-tirzepatide-versus-semaglutide-2026/2026-09-15T03:55:40Zweekly https://semaglutides.org/news/2026/03/pooled-surpass-5-surpass-6-analysis-supports-adding-2026/2026-09-15T05:26:15Zweekly https://semaglutides.org/news/2026/02/hhs-secretary-restricted-peptides-will-return-category-1-2026/2026-09-15T04:50:40Zweekly https://semaglutides.org/news/2026/02/small-real-world-study-raises-cpap-adherence-question-2026/2026-09-15T05:26:32Zweekly https://semaglutides.org/news/2026/02/achieve-3-lancet-2026/2026-09-15T03:55:39Zweekly https://semaglutides.org/news/2026/02/massachusetts-group-insurance-commission-votes-eliminate-glp-1-2026/2026-09-15T03:55:44Zweekly https://semaglutides.org/news/2026/02/walgreens-adds-weight-management-virtual-healthcare-service-2026/2026-09-15T05:26:34Zweekly https://semaglutides.org/news/2026/02/general-mills-ceo-anti-obesity-drugs-will-have-2026/2026-09-15T03:55:53Zweekly https://semaglutides.org/news/2026/02/zepbound-label-drops-suicidality-warning-adds-intestinal-obstruction-2026/2026-09-15T03:55:56Zweekly https://semaglutides.org/news/2026/02/novo-nordisk-partners-vivtex-deal-worth-2-1-2026/2026-09-15T04:50:27Zweekly https://semaglutides.org/news/2026/02/uk-raids-seize-nearly-2-000-doses-labeled-2026/2026-09-15T04:50:30Zweekly https://semaglutides.org/news/2026/02/novo-list-price-cut-2026/2026-09-15T03:11:07Zweekly https://semaglutides.org/news/2026/02/2027-list-price-cut-guarantees-undated-cost-pages-2026/2026-09-15T03:56:05Zweekly https://semaglutides.org/news/2026/02/falsified-mounjaro-kwikpen-15-mg-pens-found-uk-2026/2026-09-15T03:56:04Zweekly https://semaglutides.org/news/2026/02/fda-approves-two-generic-saxenda-products-same-2026/2026-09-15T03:56:11Zweekly https://semaglutides.org/news/2026/02/mounjaro-approved-children-10-older-type-2-diabetes-2026/2026-09-15T03:56:09Zweekly https://semaglutides.org/news/2026/02/novo-nordisks-licensed-triple-agonist-ubt251-shows-19-2026/2026-09-15T03:56:20Zweekly https://semaglutides.org/news/2026/02/reduced-frequency-dosing-case-series-published-obesity-2026/2026-09-15T03:56:32Zweekly https://semaglutides.org/news/2026/02/employers-list-price-reset-2026/2026-09-15T04:50:45Zweekly https://semaglutides.org/news/2026/02/uk-gp-bonus-mounjaro-2026/2026-09-15T05:26:24Zweekly https://semaglutides.org/news/2026/02/drugs-com-records-zepbound-kwikpen-brands-newest-presentation-2026/2026-09-15T05:34:41Zweekly https://semaglutides.org/news/2026/02/cagrisema-loses-tirzepatide-redefine-4-novo-nordisk-shares-2026/2026-09-15T03:11:05Zweekly https://semaglutides.org/news/2026/02/redefine-4-miss-2026/2026-09-15T03:11:15Zweekly https://semaglutides.org/news/2026/02/lilly-zepbound-kwikpen-same-self-pay-price-vial-2026/2026-09-15T03:11:19Zweekly https://semaglutides.org/news/2026/02/fda-approves-four-dose-zepbound-kwikpen-putting-tirzepatide-2026/2026-09-15T03:56:35Zweekly https://semaglutides.org/news/2026/02/lilly-calls-zepbound-prescribed-weight-management-medication-2025-2026/2026-09-15T03:56:34Zweekly https://semaglutides.org/news/2026/02/zepbound-multi-dose-kwikpen-becomes-available-2026/2026-09-15T03:56:40Zweekly https://semaglutides.org/news/2026/02/eli-lilly-signs-company-specific-section-232-tariff-2026/2026-09-15T04:50:38Zweekly https://semaglutides.org/news/2026/02/cagrisema-next-trials-2026/2026-09-15T04:50:52Zweekly https://semaglutides.org/news/2026/02/lillydirect-extends-self-pay-pricing-zepbound-kwikpens-2026/2026-09-15T04:50:49Zweekly https://semaglutides.org/news/2026/02/fda-issues-30-warning-letters-telehealth-companies-marketing-2026/2026-09-15T03:11:24Zweekly https://semaglutides.org/news/2026/02/fda-warns-medvi-misbranded-compounded-glp-1-products-2026/2026-09-15T03:56:41Zweekly https://semaglutides.org/news/2026/02/circuit-upholds-health-plans-weight-loss-drug-exclusion-2026/2026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/02/hims-hers-agrees-acquire-eucalyptus-1-15-billion-2026/2026-09-15T04:50:54Zweekly https://semaglutides.org/news/2026/02/analysis-finds-bariatric-surgery-volume-13-glp-1-2026/2026-09-15T03:56:44Zweekly https://semaglutides.org/news/2026/02/tirzepatide-associated-fewer-asthma-flare-ups-adults-obesity-2026/2026-09-15T05:26:30Zweekly https://semaglutides.org/news/2026/02/european-commission-approves-wegovy-7-2-mg-2026/2026-09-15T03:56:56Zweekly https://semaglutides.org/news/2026/02/orforglipron-1-5b-stockpile-2026/2026-09-15T04:50:56Zweekly https://semaglutides.org/news/2026/02/largest-naion-study-date-va-cohort-finds-double-2026/2026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/02/novo-nordisk-signals-plans-wegovy-vials-2026/2026-09-15T05:26:33Zweekly https://semaglutides.org/news/2026/02/astrazeneca-oral-glp-1-won-both-phase-2b-2026/2026-09-15T04:50:56Zweekly https://semaglutides.org/news/2026/02/lilly-phase-3-testing-amylin-drug-top-weekly-2026/2026-09-15T04:51:13Zweekly https://semaglutides.org/news/2026/02/oral-ribupatide-posts-12-1-weight-loss-26-2026/2026-09-15T04:51:06Zweekly https://semaglutides.org/news/2026/02/novo-sues-hims-2026/2026-09-15T03:11:38Zweekly https://semaglutides.org/news/2026/02/hims-stock-drop-2026/2026-09-15T04:51:09Zweekly https://semaglutides.org/news/2026/02/lilly-agrees-acquire-orna-therapeutics-2-4-billion-2026/2026-09-15T04:51:23Zweekly https://semaglutides.org/news/2026/02/trinetx-cohort-links-glp-1-use-higher-hair-2026/2026-09-15T04:51:19Zweekly https://semaglutides.org/news/2026/02/glp1-super-bowl-2026/2026-09-15T03:11:56Zweekly https://semaglutides.org/news/2026/02/lady-gaga-ozempic-rumors-2026/2026-09-15T05:26:35Zweekly https://semaglutides.org/news/2026/02/fda-restricts-glp1-compounding-2026/2026-09-15T03:11:48Zweekly https://semaglutides.org/news/2026/02/fda-threatens-seizure-injunction-compounded-glp-1-marketing-2026/2026-09-15T03:11:52Zweekly https://semaglutides.org/news/2026/02/trumprx-launches-2026/2026-09-15T03:12:06Zweekly https://semaglutides.org/news/2026/02/bone-density-study-finds-greater-hip-bone-loss-2026/2026-09-15T04:51:23Zweekly https://semaglutides.org/news/2026/02/hims-49-pill-launch-2026/2026-09-15T03:12:15Zweekly https://semaglutides.org/news/2026/02/trumprx-gov-glp-1-coupons-2026/2026-09-15T03:12:13Zweekly https://semaglutides.org/news/2026/02/lilly-q4-2025-results/2026-09-15T03:57:00Zweekly https://semaglutides.org/news/2026/02/wegovy-pill-economics-2026/2026-09-15T03:57:06Zweekly https://semaglutides.org/news/2026/02/mhra-naion-dsu-2026/2026-09-15T03:57:10Zweekly https://semaglutides.org/news/2026/02/trumprx-gov-zepbound-mounjaro-listings-2026/2026-09-15T03:57:14Zweekly https://semaglutides.org/news/2026/02/trumprx-gov-becomes-gov-competitor-drug-pricing-queries-2026/2026-09-15T04:51:33Zweekly https://semaglutides.org/news/2026/02/novo-exec-departures-2026/2026-09-15T05:26:41Zweekly https://semaglutides.org/news/2026/02/lilly-2025-results-mounjaro-23-0-billion-zepbound-2026/2026-09-15T03:12:19Zweekly https://semaglutides.org/news/2026/02/lilly-2025-revenue-65-2-billion-45-guides-2026/2026-09-15T03:12:25Zweekly https://semaglutides.org/news/2026/02/novo-shares-plunge-feb-2026/2026-09-15T03:12:29Zweekly https://semaglutides.org/news/2026/02/fda-approves-rybelsus-ozempic-tablets-name-change-orphaning-2026/2026-09-15T03:57:22Zweekly https://semaglutides.org/news/2026/02/lilly-novo-nordisk-issue-sharply-diverging-2026-guidance/2026-09-15T03:57:21Zweekly https://semaglutides.org/news/2026/02/lilly-q4-2025-detail-2026/2026-09-15T03:57:26Zweekly https://semaglutides.org/news/2026/02/ozempic-pill-introduced-2026/2026-09-15T03:57:41Zweekly https://semaglutides.org/news/2026/02/novo-buybacks-2026/2026-09-15T04:52:02Zweekly https://semaglutides.org/news/2026/02/study-links-glp-1-receptor-agonists-blunted-thirst-2026/2026-09-15T04:51:30Zweekly https://semaglutides.org/news/2026/02/lilly-drops-three-pipeline-drugs-2026/2026-09-15T05:26:47Zweekly https://semaglutides.org/news/2026/02/full-2025-results-sales-dkk-309-1-billion-2026/2026-09-15T03:12:38Zweekly https://semaglutides.org/news/2026/02/novo-2026-guidance-shock/2026-09-15T03:12:45Zweekly https://semaglutides.org/news/2026/02/judge-dismisses-eli-lillys-case-against-willow-health-2026/2026-09-15T03:57:37Zweekly https://semaglutides.org/news/2026/02/pfizers-monthly-glp-1-hits-phase-2b-endpoint-2026/2026-09-15T03:57:48Zweekly https://semaglutides.org/news/2026/02/novo-2025-full-year-results/2026-09-15T04:51:53Zweekly https://semaglutides.org/news/2026/02/pfizer-shares-fall-phase-2b-data-berobenatide-2026/2026-09-15T04:51:49Zweekly https://semaglutides.org/news/2026/02/analysts-trim-obesity-drug-market-forecasts-30-2026/2026-09-15T03:12:46Zweekly https://semaglutides.org/news/2026/02/reimagine-2-results-2026/2026-09-15T03:57:52Zweekly https://semaglutides.org/news/2026/02/claims-analysis-shows-tirzepatide-displacing-time-cpap-2026/2026-09-15T03:57:48Zweekly https://semaglutides.org/news/2026/02/rest-trial-recruiting-randomized-test-tapering-versus-stopping-2026/2026-09-15T03:12:48Zweekly https://semaglutides.org/news/2026/02/zepbounds-suicidal-ideation-warning-removed-severe-gastrointestinal-section-2026/2026-09-15T03:12:59Zweekly https://semaglutides.org/news/2026/02/second-third-generic-saxenda-products-reach-pharmacies-2026/2026-09-15T03:58:01Zweekly https://semaglutides.org/news/2026/02/suicidal-behavior-ideation-section-removed-saxenda-label-2026/2026-09-15T03:58:05Zweekly https://semaglutides.org/news/2026/02/truveta-records-show-tirzepatide-outperforming-semaglutide-outside-trials-2026/2026-09-15T03:58:10Zweekly https://semaglutides.org/news/2026/02/court-dismisses-lillys-complaint-against-compounded-tirzepatide-telehealth-2026/2026-09-15T04:51:44Zweekly https://semaglutides.org/news/2026/02/fda-liposomal-rule-2026/2026-09-15T04:51:51Zweekly https://semaglutides.org/news/2026/02/lilly-runs-never-during-milan-cortina-winter-olympics-2026/2026-09-15T04:51:54Zweekly https://semaglutides.org/news/2026/02/surpass-switch-subgroup-analysis-finds-consistent-benefit-patient-2026/2026-09-15T05:26:52Zweekly https://semaglutides.org/news/2026/02/us-semaglutide-market-size-2026/2026-09-15T05:26:56Zweekly https://semaglutides.org/news/2026/01/astrazeneca-signs-obesity-deal-chinas-cspc-worth-18-2026/2026-09-15T03:58:16Zweekly https://semaglutides.org/news/2026/01/eu-declines-separate-hfpef-indication-tirzepatide-adds-summit-2026/2026-09-15T03:58:15Zweekly https://semaglutides.org/news/2026/01/rybelsus-becomes-ozempic-tablets-2026/2026-09-15T03:58:24Zweekly https://semaglutides.org/news/2026/01/lilly-pennsylvania-3-5b-2026/2026-09-15T03:58:28Zweekly https://semaglutides.org/news/2026/01/ricks-medicare-game-changer-2026/2026-09-15T04:52:01Zweekly https://semaglutides.org/news/2026/01/mhra-strengthens-pancreatitis-warnings-entire-glp-1-class-2026/2026-09-15T03:13:03Zweekly https://semaglutides.org/news/2026/01/chmp-refuses-eu-heart-failure-indication-accepts-summit-2026/2026-09-15T03:58:33Zweekly https://semaglutides.org/news/2026/01/president-eli-lilly-plans-six-manufacturing-plants-2026/2026-09-15T04:52:06Zweekly https://semaglutides.org/news/2026/01/kff-medicare-advantage-insurers-denied-4-1-million-2026/2026-09-15T03:58:41Zweekly https://semaglutides.org/news/2026/01/reuters-novo-outspent-lilly-two-one-glp-1-2026/2026-09-15T03:58:40Zweekly https://semaglutides.org/news/2026/01/novo-nordisks-glp-1-ad-spend-nearly-500-2026/2026-09-15T04:52:07Zweekly https://semaglutides.org/news/2026/01/ira-round-three-selection-2026/2026-09-15T03:13:07Zweekly https://semaglutides.org/news/2026/01/roches-enicepatide-posts-22-5-placebo-adjusted-weight-2026/2026-09-15T03:58:50Zweekly https://semaglutides.org/news/2026/01/sun-pharma-india-generic-2026/2026-09-15T04:52:31Zweekly https://semaglutides.org/news/2026/01/lilly-weight-stigma-film-2026/2026-09-15T05:27:06Zweekly https://semaglutides.org/news/2026/01/eu-adds-pediatric-indication-surmount-5-data-mounjaro-2026/2026-09-15T04:52:56Zweekly https://semaglutides.org/news/2026/01/zepbound-kwikpen-instructions-use-issued-ahead-devices-2026/2026-09-15T05:26:52Zweekly https://semaglutides.org/news/2026/01/fda-approves-mounjaro-kwikpen-zepbound-kwikpen-2026/2026-09-15T03:13:16Zweekly https://semaglutides.org/news/2026/01/surmount-maintain-completes-testing-step-dose-instead-stopping-2026/2026-09-15T03:58:51Zweekly https://semaglutides.org/news/2026/01/fda-warning-letter-genogenix-unapproved-glp-1-peptides-2026/2026-09-15T04:52:37Zweekly https://semaglutides.org/news/2026/01/kff-counts-13-state-medicaid-programs-covering-glp-2026/2026-09-15T03:13:14Zweekly https://semaglutides.org/news/2026/01/fda-warning-letter-boothwyn-pharmacy-compounded-glp-1-2026/2026-09-15T07:58:29Zweekly https://semaglutides.org/news/2026/01/jefferies-estimates-glp-1s-could-save-airlines-580-2026/2026-09-15T03:59:00Zweekly https://semaglutides.org/news/2026/01/cnpv-review-delays-reported-2026/2026-09-15T04:52:29Zweekly https://semaglutides.org/news/2026/01/surmount-post-hoc-analysis-finds-no-increase-depression-2026/2026-09-15T04:52:23Zweekly https://semaglutides.org/news/2026/01/surmount-osa-mediation-analysis-separates-weight-effects-sleep-2026/2026-09-15T04:52:39Zweekly https://semaglutides.org/news/2026/01/compounder-antitrust-suit-2026/2026-09-15T03:59:07Zweekly https://semaglutides.org/news/2026/01/fda-approves-orbiculars-generic-victoza-later-sold-cipla-2026/2026-09-15T04:52:50Zweekly https://semaglutides.org/news/2026/01/tirzepatide-associated-lower-dementia-risk-semaglutide-sglt2-inhibitors-2026/2026-09-15T04:53:00Zweekly https://semaglutides.org/news/2026/01/fda-asks-drugmakers-drop-suicidal-thoughts-warning-glp-2026/2026-09-15T03:13:20Zweekly https://semaglutides.org/news/2026/01/obesity-association-publishes-2026-pharmacologic-treatment-standards-ranking/2026-09-15T03:13:40Zweekly https://semaglutides.org/news/2026/01/fda-asks-removal-suicidal-ideation-warning-stranding-generation-2026/2026-09-15T03:59:13Zweekly https://semaglutides.org/news/2026/01/jpm-2026-glp1-mood/2026-09-15T04:53:11Zweekly https://semaglutides.org/news/2026/01/alabama-settles-clinic-unapproved-weight-loss-drugs-2026/2026-09-15T04:52:54Zweekly https://semaglutides.org/news/2026/01/lilly-nvidia-ai-lab-2026/2026-09-15T05:27:10Zweekly https://semaglutides.org/news/2026/01/novo-nordisks-wegovy-pill-ad-debuts-during-golden-2026/2026-09-15T03:59:10Zweekly https://semaglutides.org/news/2026/01/year-of-the-obesity-pill-2026/2026-09-15T04:52:56Zweekly https://semaglutides.org/news/2026/01/taltz-zepbound-psa-topline-2026/2026-09-15T03:59:17Zweekly https://semaglutides.org/news/2026/01/bmj-meta-analysis-quantifies-weight-regain-stopping-obesity-2026/2026-09-15T03:59:21Zweekly https://semaglutides.org/news/2026/01/fda-approves-multi-dose-tirzepatide-vials-both-brands-2026/2026-09-15T03:59:38Zweekly https://semaglutides.org/news/2026/01/lilly-buys-ventyx-2026/2026-09-15T04:53:16Zweekly https://semaglutides.org/news/2026/01/zepbound-multi-dose-vial-instructions-use-issued-30-2026/2026-09-15T05:27:05Zweekly https://semaglutides.org/news/2026/01/arrowhead-tirzepatide-combo-2026/2026-09-15T04:53:19Zweekly https://semaglutides.org/news/2026/01/lilly-nimbus-oral-obesity-2026/2026-09-15T05:27:09Zweekly https://semaglutides.org/news/2026/01/wegovy-pill-launch-2026/2026-09-15T03:13:32Zweekly https://semaglutides.org/news/2026/01/wegovy-pill-oral-glp-1-approved-obesity-2026/2026-09-15T03:13:46Zweekly https://semaglutides.org/news/2026/01/faers-analysis-finds-probable-tirzepatide-optic-neuropathy-signal-2026/2026-09-15T04:53:13Zweekly https://semaglutides.org/news/2026/01/fda-grants-breakthrough-therapy-designation-pemvidutide-mash-2026/2026-09-15T04:53:14Zweekly https://semaglutides.org/news/2026/01/goodrx-wegovy-pill-price-2026/2026-09-15T04:53:15Zweekly https://semaglutides.org/news/2026/01/novo-nordisks-canadian-data-exclusivity-semaglutide-expires-2026/2026-09-15T03:13:47Zweekly https://semaglutides.org/news/2026/01/canada-patent-expiry-2026/2026-09-15T03:59:39Zweekly https://semaglutides.org/news/2026/01/michigan-medicaid-restricts-glp-1-obesity-coverage-bmi-2026/2026-09-15T03:13:49Zweekly https://semaglutides.org/news/2026/01/semaglutide-exclusivity-expiring-outside-united-states-2026/2026-09-15T03:13:56Zweekly https://semaglutides.org/news/2026/01/harvard-pilgrim-excludes-all-weight-loss-drugs-bcbs-2026/2026-09-15T03:59:43Zweekly https://semaglutides.org/news/2026/01/lilly-publishes-updated-list-prices-incretin-portfolio-2026/2026-09-15T03:59:40Zweekly https://semaglutides.org/news/2026/01/mounjaro-joins-chinas-national-reimbursement-drug-list-2026/2026-09-15T03:59:46Zweekly https://semaglutides.org/news/2026/01/north-dakota-becomes-state-require-aca-marketplace-small-2026/2026-09-15T03:59:50Zweekly https://semaglutides.org/news/2026/01/cms-interoperability-prior-authorization-rule-turnaround-times-take-2026/2026-09-15T04:53:37Zweekly https://semaglutides.org/news/2026/01/express-scripts-optum-rx-set-their-2026-tirzepatide/2026-09-15T04:53:38Zweekly https://semaglutides.org/news/2026/01/kansas-state-employee-health-plan-raises-glp-1-2026/2026-09-15T04:53:39Zweekly https://semaglutides.org/news/2026/01/lilly-raises-list-prices-mounjaro-zepbound-while-cash-2026/2026-09-15T04:53:43Zweekly https://semaglutides.org/news/2026/01/massachusetts-gic-requires-vida-health-prescribing-weight-loss-2026/2026-09-15T04:53:34Zweekly https://semaglutides.org/news/2026/01/medicare-part-d-pocket-cap-rises-2-100-2026/2026-09-15T04:53:45Zweekly https://semaglutides.org/news/2026/01/ira-round-one-effective-2026/2026-09-15T04:53:56Zweekly https://semaglutides.org/news/2026/01/novo-nordisk-narrows-patient-assistance-program-ozempic-2026/2026-09-15T04:53:56Zweekly https://semaglutides.org/news/2026/01/employer-coverage-cuts-drive-surge-insurance-denial-appeal-2026/2026-09-15T04:00:11Zweekly https://semaglutides.org/news/2026/01/suicidal-behavior-ideation-warning-removed-wegovy-label-2026/2026-09-15T04:00:07Zweekly https://semaglutides.org/news/2026/01/cvs-formulary-stable-2026/2026-09-15T04:53:56Zweekly https://semaglutides.org/news/2026/01/final-vk2735-phase-2-injection-results-published-obesity-2026/2026-09-15T04:53:57Zweekly https://semaglutides.org/news/2026/01/never-share-kwikpen-warning-added-both-tirzepatide-labels-2026/2026-09-15T04:54:12Zweekly https://semaglutides.org/news/2026/01/jersey-becomes-26th-state-enact-anti-copay-accumulator-2026/2026-09-15T04:54:08Zweekly https://semaglutides.org/news/2026/01/rybelsus-rename-rationale-2026/2026-09-15T04:54:33Zweekly https://semaglutides.org/news/2026/01/tirtle1-published-randomized-trial-tirzepatide-type-1-diabetes-2026/2026-09-15T04:54:19Zweekly https://semaglutides.org/news/2026/01/china-approves-sciwinds-ecnoglutide-type-2-diabetes-2026/2026-09-15T05:27:24Zweekly https://semaglutides.org/news/2026/01/health-canada-rybelsus-cv-2026/2026-09-15T05:27:32Zweekly https://semaglutides.org/news/2026/01/mounjaro-label-revision-adds-kwikpen-never-share-warning-2026/2026-09-15T05:27:50Zweekly https://semaglutides.org/news/2026/01/vanessa-williams-ties-mounjaro-use-menopause-2026/2026-09-15T05:27:44Zweekly https://semaglutides.org/news/2026/01/wegovy-7-2-mg-approved-united-kingdom-2026/2026-09-15T05:27:29Zweekly https://semaglutides.org/news/2025/12/oprah-reveals-she-stopped-glp-1s-regained-20-2025/2026-09-15T03:14:06Zweekly https://semaglutides.org/news/2025/12/novo-worst-year-2025/2026-09-15T04:00:19Zweekly https://semaglutides.org/news/2025/12/lilly-novo-china-price-cuts-2025/2026-09-15T05:27:40Zweekly https://semaglutides.org/news/2025/12/axios-fitness-industry-pivoting-glp-1-users-2025/2026-09-15T04:54:13Zweekly https://semaglutides.org/news/2025/12/cms-introduces-balance-model-glp-1-coverage-medicare-2025/2026-09-15T03:14:15Zweekly https://semaglutides.org/news/2025/12/fda-approval-wegovy-pill-opens-highest-growth-query-2025/2026-09-15T03:14:20Zweekly https://semaglutides.org/news/2025/12/wegovy-pill-approved-2025/2026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/12/jama-target-trial-emulation-links-incretin-drugs-lower-2025/2026-09-15T04:54:15Zweekly https://semaglutides.org/news/2025/12/fda-expands-mounjaro-children-aged-10-older-2025/2026-09-15T03:14:21Zweekly https://semaglutides.org/news/2025/12/altimmunes-pemvidutide-hits-key-48-endpoints-phase-2b-2025/2026-09-15T04:54:25Zweekly https://semaglutides.org/news/2025/12/white-house-largest-set-favored-nation-pricing-deals-2025/2026-09-15T04:54:50Zweekly https://semaglutides.org/news/2025/12/journal-marketing-research-publishes-definitive-glp-1-grocery-2025/2026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/12/novo-nordisk-files-cagrisema-fda-2025/2026-09-15T03:14:41Zweekly https://semaglutides.org/news/2025/12/orforglipron-holds-weight-loss-patients-switch-off-injections-2025/2026-09-15T03:14:57Zweekly https://semaglutides.org/news/2025/12/surpass-cvot-published-tirzepatide-non-inferior-dulaglutide-2025/2026-09-15T03:14:51Zweekly https://semaglutides.org/news/2025/12/cagrisema-nda-filed-2025/2026-09-15T04:00:18Zweekly https://semaglutides.org/news/2025/12/kailera-opens-global-kainetic-phase-3-program-ribupatide-2025/2026-09-15T04:54:43Zweekly https://semaglutides.org/news/2025/12/surpass-cvot-published-england-journal-medicine-2025-2/2026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/12/lilly-canada-price-cuts-2025/2026-09-15T05:27:46Zweekly https://semaglutides.org/news/2025/12/weightwatchers-relaunch-2025/2026-09-15T04:54:42Zweekly https://semaglutides.org/news/2025/12/mdl-3163-created-2025/2026-09-15T03:15:06Zweekly https://semaglutides.org/news/2025/12/jpml-creates-mdl-3163-eli-lillys-motion-declining-2025/2026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/12/north-carolina-medicaid-restores-glp-1-coverage-obesity-2025/2026-09-15T04:54:51Zweekly https://semaglutides.org/news/2025/12/fda-pressure-on-orforglipron-review-2025/2026-09-15T04:54:52Zweekly https://semaglutides.org/news/2025/12/eu-backs-mounjaro-pediatric-2025/2026-09-15T05:27:49Zweekly https://semaglutides.org/news/2025/12/mounjaro-approved-children-10-older-type-2-diabetes-2025/2026-09-15T03:15:12Zweekly https://semaglutides.org/news/2025/12/retatrutide-delivers-71-2-pounds-average-weight-loss-2025/2026-09-15T03:15:15Zweekly https://semaglutides.org/news/2025/12/retatrutides-phase-3-win-28-7-weight-loss-2025/2026-09-15T03:15:25Zweekly https://semaglutides.org/news/2025/12/surpass-cvot-published-england-journal-medicine-2025/2026-09-15T03:15:31Zweekly https://semaglutides.org/news/2025/12/destination-xl-fullbeauty-agree-merge-consolidating-plus-size-2025/2026-09-15T04:55:07Zweekly https://semaglutides.org/news/2025/12/nejm-perspective-calls-generic-liraglutide-overlooked-option-2025/2026-09-15T04:00:17Zweekly https://semaglutides.org/news/2025/12/lilly-alabama-6b-2025/2026-09-15T04:00:22Zweekly https://semaglutides.org/news/2025/12/periods-opens-properly-powered-trial-tirzepatide-pcos-2025/2026-09-15T04:00:38Zweekly https://semaglutides.org/news/2025/12/safe-drugs-act-2025-introduced-congress/2026-09-15T04:00:40Zweekly https://semaglutides.org/news/2025/12/large-analysis-finds-no-increase-obesity-related-cancers-2025/2026-09-15T04:54:58Zweekly https://semaglutides.org/news/2025/12/adas-2026-standards-care-name-semaglutide-tirzepatide-preferred-2025/2026-09-15T03:15:35Zweekly https://semaglutides.org/news/2025/12/redefine-4-completes-novo-nordisks-cagrisema-tested-directly-2025/2026-09-15T04:00:53Zweekly https://semaglutides.org/news/2025/12/structure-therapeutics-15-3-weight-loss-oral-aleniglipron-2025/2026-09-15T04:00:52Zweekly https://semaglutides.org/news/2025/12/mounjaro-china-reimbursement-2025/2026-09-15T04:55:03Zweekly https://semaglutides.org/news/2025/12/nobel-laureate-carolyn-bertozzi-returns-lilly-board-2025/2026-09-15T05:27:55Zweekly https://semaglutides.org/news/2025/12/fda-seizes-counterfeit-ozempic-labeled-authentic-lot-number-2025/2026-09-15T03:15:33Zweekly https://semaglutides.org/news/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-2025/2026-09-15T03:15:32Zweekly https://semaglutides.org/news/2025/12/evoke-ctad-presentation-2025/2026-09-15T04:00:52Zweekly https://semaglutides.org/news/2025/12/analysis-shows-aca-marketplace-glp-1-coverage-shrinking-2025/2026-09-15T04:00:45Zweekly https://semaglutides.org/news/2025/12/faers-analysis-counts-hundreds-compounded-tirzepatide-adverse-events-2025/2026-09-15T04:01:12Zweekly https://semaglutides.org/news/2025/12/lilly-submits-complete-responses-both-kwikpen-applications-2025/2026-09-15T04:55:07Zweekly https://semaglutides.org/news/2025/12/eli-lilly-cuts-zepbound-single-dose-vial-prices-2025/2026-09-15T03:15:45Zweekly https://semaglutides.org/news/2025/12/mayo-clinic-proceedings-puts-gi-side-effect-rates-2025/2026-09-15T04:01:07Zweekly https://semaglutides.org/news/2025/12/uk-agreement-raise-uk-drug-prices-25-2025/2026-09-15T04:55:15Zweekly https://semaglutides.org/news/2025/12/mounjaro-adds-pediatric-indication-severe-gastrointestinal-adverse-reactions-2025/2026-09-15T03:16:02Zweekly https://semaglutides.org/news/2025/12/cornell-numerator-quantify-how-glp-1-use-changes-2025/2026-09-15T04:01:08Zweekly https://semaglutides.org/news/2025/12/oculus-trial-randomizes-patients-hold-continue-their-glp-2025/2026-09-15T04:01:17Zweekly https://semaglutides.org/news/2025/12/bunnie-xo-describes-suicidal-ideation-glp-1-2025/2026-09-15T04:55:13Zweekly https://semaglutides.org/news/2025/12/customs-intercepting-thousands-glp-1-peptide-shipments-china-2025/2026-09-15T04:55:17Zweekly https://semaglutides.org/news/2025/12/retatrutide-triumph-4-2025/2026-09-15T04:55:24Zweekly https://semaglutides.org/news/2025/12/oprah-winfrey-describes-stopping-glp-1-twelve-restarting-2025/2026-09-15T05:28:03Zweekly https://semaglutides.org/news/2025/11/novo-nordisk-files-fda-approval-wegovy-7-2-2025/2026-09-15T04:55:29Zweekly https://semaglutides.org/news/2025/11/cms-negotiated-price-semaglutide-2025/2026-09-15T03:16:06Zweekly https://semaglutides.org/news/2025/11/circana-projects-glp-1-households-will-drive-third-2025/2026-09-15T04:01:21Zweekly https://semaglutides.org/news/2025/11/amycretin-phase-2-weight-loss-hba1c-gains-type-2025/2026-09-15T04:55:24Zweekly https://semaglutides.org/news/2025/11/novo-nordisk-expands-amycretin-program-type-2-diabetes-2025/2026-09-15T04:55:30Zweekly https://semaglutides.org/news/2025/11/open-label-study-80-percent-response-hidradenitis-suppurativa-2025/2026-09-15T05:28:06Zweekly https://semaglutides.org/news/2025/11/evoke-alzheimers-failure-2025/2026-09-15T03:16:01Zweekly https://semaglutides.org/news/2025/11/lizzo-ozempic-boom-erasing-plus-size-people-2025/2026-09-15T04:01:24Zweekly https://semaglutides.org/news/2025/11/novo-shares-evoke-2025/2026-09-15T04:55:32Zweekly https://semaglutides.org/news/2025/11/eli-lilly-becomes-drugmaker-worth-1-trillion-2025/2026-09-15T03:16:03Zweekly https://semaglutides.org/news/2025/11/attain-maintain-completes-testing-switch-injections-oral-glp-2025/2026-09-15T04:55:45Zweekly https://semaglutides.org/news/2025/11/lilly-direct-to-employer-2025/2026-09-15T04:55:41Zweekly https://semaglutides.org/news/2025/11/mazdutide-9-mg-reaches-20-1-weight-loss-2025/2026-09-15T04:55:43Zweekly https://semaglutides.org/news/2025/11/novo-199-intro-offer-2025/2026-09-15T03:16:08Zweekly https://semaglutides.org/news/2025/11/brain-recordings-suggest-tirzepatides-effect-food-noise-may-2025/2026-09-15T04:56:51Zweekly https://semaglutides.org/news/2025/11/goodrx-39-weight-loss-telehealth-subscription-lists-199-2025/2026-09-15T05:40:53Zweekly https://semaglutides.org/news/2025/11/tirzepatide-specific-suicidality-analysis-finds-no-safety-signal-2025/2026-09-15T04:55:49Zweekly https://semaglutides.org/news/2025/11/tirzepatide-binge-eating-signal-2025/2026-09-15T05:28:04Zweekly https://semaglutides.org/news/2025/11/kff-finds-18-adults-have-ever-used-glp-2025/2026-09-15T03:16:16Zweekly https://semaglutides.org/news/2025/11/novo-egm-board-takeover-2025/2026-09-15T03:16:30Zweekly https://semaglutides.org/news/2025/11/extraordinary-general-meeting-installs-lars-rebien-sorensen-chair-2025/2026-09-15T04:01:41Zweekly https://semaglutides.org/news/2025/11/lilly-files-supplement-would-remove-zepbounds-suicidal-ideation-2025/2026-09-15T04:56:18Zweekly https://semaglutides.org/news/2025/11/novo-otc-wegovy-comment-2025/2026-09-15T04:55:58Zweekly https://semaglutides.org/news/2025/11/pfizer-closes-metsera-2025/2026-09-15T04:01:34Zweekly https://semaglutides.org/news/2025/11/sandoz-signals-unbranded-semaglutide-canada-mid-2026-2025/2026-09-15T04:55:59Zweekly https://semaglutides.org/news/2025/11/lilly-drops-cvs-for-employees-2025/2026-09-15T05:28:05Zweekly https://semaglutides.org/news/2025/11/pharmacy-questions-mfn-2025/2026-09-15T05:28:22Zweekly https://semaglutides.org/news/2025/11/tan-france-zepbound-campaign-2025/2026-09-15T04:56:06Zweekly https://semaglutides.org/news/2025/11/wegovy-mash-liver-analysis-2025/2026-09-15T04:56:12Zweekly https://semaglutides.org/news/2025/11/rhythm-long-term-phase-2-enrollment-oral-mc4r-2025/2026-09-15T05:28:46Zweekly https://semaglutides.org/news/2025/11/real-world-study-finds-semaglutide-tirzepatide-equally-protective-2025/2026-09-15T04:01:40Zweekly https://semaglutides.org/news/2025/11/pfizer-wins-metsera-2025/2026-09-15T03:16:36Zweekly https://semaglutides.org/news/2025/11/reporters-flag-gaps-tirzepatide-pricing-deal-2025/2026-09-15T04:56:09Zweekly https://semaglutides.org/news/2025/11/lilly-agrees-trump-administration-cut-zepbound-prices-2025/2026-09-15T03:16:34Zweekly https://semaglutides.org/news/2025/11/mfn-glp1-pricing-deal-2025/2026-09-15T03:16:42Zweekly https://semaglutides.org/news/2025/11/lilly-government-agree-tirzepatide-pricing-including-50-medicare-2025/2026-09-15T03:16:40Zweekly https://semaglutides.org/news/2025/11/trump-glp-1-price-deals-calls-them-fat-2025/2026-09-15T03:16:49Zweekly https://semaglutides.org/news/2025/11/white-house-deal-sets-245-medicare-price-trumprx-2025/2026-09-15T03:17:03Zweekly https://semaglutides.org/news/2025/11/eloralintide-phase-2-results-published-moving-lilly-beyond-2025/2026-09-15T04:01:47Zweekly https://semaglutides.org/news/2025/11/eloralintide-phase-2-20-percent-2025/2026-09-15T04:01:51Zweekly https://semaglutides.org/news/2025/11/lillys-amylin-analog-eloralintide-shows-20-1-weight-2025/2026-09-15T04:01:51Zweekly https://semaglutides.org/news/2025/11/mfn-tariff-relief-vouchers-2025/2026-09-15T04:02:00Zweekly https://semaglutides.org/news/2025/11/rfk-jr-reverses-course-backs-expanded-glp-1-2025/2026-09-15T04:02:08Zweekly https://semaglutides.org/news/2025/11/lilly-adds-carole-ho-adrienne-brown-executive-committee-2025/2026-09-15T04:56:16Zweekly https://semaglutides.org/news/2025/11/lilly-expects-march-2026-approval-2025/2026-09-15T07:58:51Zweekly https://semaglutides.org/news/2025/11/mfn-other-drugs-2025/2026-09-15T04:56:35Zweekly https://semaglutides.org/news/2025/11/lilly-authored-review-restates-tirzepatides-mechanism-discrepancy-2025/2026-09-15T05:28:21Zweekly https://semaglutides.org/news/2025/11/tirzepatide-lowers-uric-acid-surmount-1-post-hoc-2025/2026-09-15T05:28:22Zweekly https://semaglutides.org/news/2025/11/metsera-bidding-war-2025/2026-09-15T04:02:17Zweekly https://semaglutides.org/news/2025/11/obesityweek-2025-oral-sema/2026-09-15T05:28:33Zweekly https://semaglutides.org/news/2025/11/stat-news-documents-glp-1-microdosing-boom-2025/2026-09-15T04:02:13Zweekly https://semaglutides.org/news/2025/11/hengrui-kailera-19-2-weight-loss-chinese-phase-2025/2026-09-15T04:56:35Zweekly https://semaglutides.org/news/2025/11/annals-internal-medicine-study-finds-tirzepatide-semaglutide-have-2025/2026-09-15T04:02:19Zweekly https://semaglutides.org/news/2025/11/lilly-netherlands-3b-2025/2026-09-15T04:56:31Zweekly https://semaglutides.org/news/2025/11/novo-15m-compounded-estimate-2025/2026-09-15T04:56:41Zweekly https://semaglutides.org/news/2025/11/pfizer-sues-novo-nordisk-metsera-bidding-war-2025/2026-09-15T04:56:56Zweekly https://semaglutides.org/news/2025/11/post-hoc-analysis-lower-albuminuria-tirzepatide-surmount-obesity-2025/2026-09-15T04:56:58Zweekly https://semaglutides.org/news/2025/11/zepbound-overtakes-wegovy-2025/2026-09-15T03:17:07Zweekly https://semaglutides.org/news/2025/11/federal-pricing-agreement-cuts-lillys-direct-consumer-zepbound-2025/2026-09-15T04:02:23Zweekly https://semaglutides.org/news/2025/11/federal-pricing-agreement-sets-mounjaro-245-medicare-medicaid-2025/2026-09-15T04:02:30Zweekly https://semaglutides.org/news/2025/11/surmount-4-post-hoc-grades-cardiometabolic-reversal-how-2025/2026-09-15T04:02:43Zweekly https://semaglutides.org/news/2025/11/aasld-updates-mash-practice-guidance-semaglutide-2025/2026-09-15T04:57:01Zweekly https://semaglutides.org/news/2025/11/off-scales-publishes-corporate-history-ozempic-2025/2026-09-15T04:57:01Zweekly https://semaglutides.org/news/2025/10/novo-layoffs-complete-2025/2026-09-15T05:28:21Zweekly https://semaglutides.org/news/2025/10/zepbound-tops-keytruda-2025/2026-09-15T03:17:05Zweekly https://semaglutides.org/news/2025/10/cochrane-review-delivers-cautious-verdict-liraglutide-obesity-2025/2026-09-15T04:02:45Zweekly https://semaglutides.org/news/2025/10/novo-nordisk-unsolicited-counterbid-metsera-2025/2026-09-15T04:02:50Zweekly https://semaglutides.org/news/2025/10/lilly-q3-2025-revenue-17-6-billion-54/2026-09-15T04:56:57Zweekly https://semaglutides.org/news/2025/10/protocol-published-randomized-semaglutide-trial-opioid-use-disorder-2025/2026-09-15T05:28:41Zweekly https://semaglutides.org/news/2025/10/lillydirect-walmart-retail-pickup-direct-consumer-prices-2025/2026-09-15T04:02:44Zweekly https://semaglutides.org/news/2025/10/lillydirect-walmart-pickup-2025/2026-09-15T04:02:50Zweekly https://semaglutides.org/news/2025/10/lilly-puerto-rico-1-2b-2025/2026-09-15T04:57:08Zweekly https://semaglutides.org/news/2025/10/lilly-nvidia-drug-discovery-supercomputer-2025/2026-09-15T04:57:15Zweekly https://semaglutides.org/news/2025/10/fda-classifies-class-ii-recall-prorx-compounded-semaglutide-2025/2026-09-15T04:57:19Zweekly https://semaglutides.org/news/2025/10/lilly-files-cardiovascular-outcomes-supplements-both-tirzepatide-brands-2025/2026-09-15T04:57:50Zweekly https://semaglutides.org/news/2025/10/lilly-sues-two-texas-companies-tirzepatide-replicas-2025/2026-09-15T04:57:19Zweekly https://semaglutides.org/news/2025/10/shaq-osa-campaign-2025/2026-09-15T05:28:43Zweekly https://semaglutides.org/news/2025/10/mazdutide-beats-semaglutide-head-head-phase-3-glp-2025/2026-09-15T04:57:19Zweekly https://semaglutides.org/news/2025/10/lilly-agrees-acquire-adverum-biotechnologies-2025/2026-09-15T07:58:47Zweekly https://semaglutides.org/news/2025/10/chmp-recommends-adding-surmount-5-eu-mounjaro-label-2025/2026-09-15T04:57:35Zweekly https://semaglutides.org/news/2025/10/cipla-india-brand-2025/2026-09-15T05:28:50Zweekly https://semaglutides.org/news/2025/10/lancet-analysis-select-finds-cardiovascular-benefit-adiposity-levels-2025/2026-09-15T04:57:37Zweekly https://semaglutides.org/news/2025/10/novo-board-resignations-2025/2026-09-15T03:17:13Zweekly https://semaglutides.org/news/2025/10/terns-pharmaceuticals-abandons-oral-glp-1-weak-phase-2025/2026-09-15T04:57:37Zweekly https://semaglutides.org/news/2025/10/obesityweek-2025-preview/2026-09-15T05:29:05Zweekly https://semaglutides.org/news/2025/10/rybelsus-cv-indication-2025/2026-09-15T03:17:12Zweekly https://semaglutides.org/news/2025/10/trump-150-glp1-target-2025/2026-09-15T04:03:04Zweekly https://semaglutides.org/news/2025/10/achieve-2-achieve-5-succeed-2025/2026-09-15T04:03:22Zweekly https://semaglutides.org/news/2025/10/synergy-outcomes-mash-phase-3-skips-liver-biopsy-2025/2026-09-15T04:03:19Zweekly https://semaglutides.org/news/2025/10/achieve-2-achieve-5-results-2025/2026-09-15T04:57:42Zweekly https://semaglutides.org/news/2025/10/fda-approves-october-2025-gastrointestinal-labeling-changes-semaglutide/2026-09-15T04:03:16Zweekly https://semaglutides.org/news/2025/10/fda-asks-lilly-update-zepbound-label-intestinal-obstruction-2025/2026-09-15T04:57:42Zweekly https://semaglutides.org/news/2025/10/kailera-therapeutics-raises-600-million-push-ribupatide-global-2025/2026-09-15T04:57:50Zweekly https://semaglutides.org/news/2025/10/novo-layoffs-begin-2025/2026-09-15T04:57:59Zweekly https://semaglutides.org/news/2025/10/novo-nordisk-agrees-buy-akero-therapeutics-5-2-2025/2026-09-15T04:03:23Zweekly https://semaglutides.org/news/2025/10/delaware-court-issues-opinion-lilly-v-strive-pharmacy-2025/2026-09-15T04:03:23Zweekly https://semaglutides.org/news/2025/10/north-carolina-renegotiates-cvs-caremark-right-bargain-directly-2025/2026-09-15T04:57:53Zweekly https://semaglutides.org/news/2025/10/novo-nordisk-cutting-9-000-jobs-worldwide-2025/2026-09-15T04:03:32Zweekly https://semaglutides.org/news/2025/10/target-trial-emulation-finds-largest-alcohol-use-disorder-2025/2026-09-15T04:58:03Zweekly https://semaglutides.org/news/2025/10/systematic-review-finds-glp-1-drugs-improve-idiopathic-2025/2026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/10/randomized-trial-tirzepatide-alcohol-use-disorder-enrolling-2025/2026-09-15T04:58:05Zweekly https://semaglutides.org/news/2025/10/glp-1-scientists-pass-again-nobel-prize-2025/2026-09-15T05:29:06Zweekly https://semaglutides.org/news/2025/10/lilly-india-manufacturing-1b-2025/2026-09-15T05:29:02Zweekly https://semaglutides.org/news/2025/10/network-meta-analysis-56-obesity-drug-trials-published-2025/2026-09-15T04:03:50Zweekly https://semaglutides.org/news/2025/10/study-finds-cost-not-side-effects-main-reason-2025/2026-09-15T04:03:46Zweekly https://semaglutides.org/news/2025/10/ema-opens-tirzepatide-warfarin-interaction-signal-2025/2026-09-15T04:58:11Zweekly https://semaglutides.org/news/2025/10/easo-first-line-glp1-2025/2026-09-15T04:58:12Zweekly https://semaglutides.org/news/2025/10/va-study-finds-liraglutide-comparable-semaglutide-kidney-heart-2025/2026-09-15T04:03:48Zweekly https://semaglutides.org/news/2025/10/north-carolina-medicaid-ends-coverage-glp-1s-obesity-2025/2026-09-15T04:58:18Zweekly https://semaglutides.org/news/2025/10/all-semaglutide-labels-gain-severe-gastrointestinal-adverse-reactions-2025/2026-09-15T03:17:29Zweekly https://semaglutides.org/news/2025/10/surpass-peds-published-tirzepatide-cuts-hba1c-2-23-2025/2026-09-15T04:03:52Zweekly https://semaglutides.org/news/2025/10/costco-wegovy-499-2025/2026-09-15T04:58:35Zweekly https://semaglutides.org/news/2025/10/mhra-dismantles-what-calls-worlds-largest-unlicensed-weight-2025/2026-09-15T04:58:27Zweekly https://semaglutides.org/news/2025/10/severe-gastrointestinal-reactions-warning-added-liraglutide-labels-2025/2026-09-15T04:58:26Zweekly https://semaglutides.org/news/2025/10/glp1-usage-surveys-2025/2026-09-15T04:58:51Zweekly https://semaglutides.org/news/2025/10/viking-therapeutics-vk2735-maintenance-reduced-frequency-dosing-study-2025/2026-09-15T04:58:29Zweekly https://semaglutides.org/news/2025/09/trumprx-announced-2025/2026-09-15T03:17:33Zweekly https://semaglutides.org/news/2025/09/favored-nation-manufacturer-deal-2025/2026-09-15T04:58:35Zweekly https://semaglutides.org/news/2025/09/step-mri-substudy-body-composition-semaglutide-7-2-2025/2026-09-15T04:03:55Zweekly https://semaglutides.org/news/2025/09/fda-approves-inluriyo-imlunestrant-esr1-mutated-advanced-breast-2025/2026-09-15T04:58:44Zweekly https://semaglutides.org/news/2025/09/fda-updates-tirzepatide-breastfeeding-labeling-2025/2026-09-15T04:58:45Zweekly https://semaglutides.org/news/2025/09/lilly-halts-one-bimagrumab-plus-tirzepatide-trial-type-2025/2026-09-15T05:29:11Zweekly https://semaglutides.org/news/2025/09/lilly-india-obesity-pill-plan-2025/2026-09-15T05:29:07Zweekly https://semaglutides.org/news/2025/09/zepbound-labeling-supplement-031-approved-2025/2026-09-15T05:29:25Zweekly https://semaglutides.org/news/2025/09/package-insert-medication-guide-updates-approved-both-brands-2025/2026-09-15T05:34:58Zweekly https://semaglutides.org/news/2025/09/court-lets-eli-lillys-personalized-advertising-claim-against-2025/2026-09-15T04:03:56Zweekly https://semaglutides.org/news/2025/09/bmj-group-retracts-apple-cider-vinegar-weight-loss-2025/2026-09-15T04:04:12Zweekly https://semaglutides.org/news/2025/09/lilly-houston-6-5b-2025/2026-09-15T04:04:19Zweekly https://semaglutides.org/news/2025/09/iqvia-publishes-analysis-tirzepatide-2025/2026-09-15T04:58:50Zweekly https://semaglutides.org/news/2025/09/pfizer-agrees-buy-metsera-7-3-billion-2025/2026-09-15T04:04:18Zweekly https://semaglutides.org/news/2025/09/fda-issues-import-alert-66-80-glp-1-2025/2026-09-15T04:04:23Zweekly https://semaglutides.org/news/2025/09/surpass-peds-published-phase-3-tirzepatide-results-children-2025/2026-09-15T04:04:25Zweekly https://semaglutides.org/news/2025/09/china-approves-mazdutide-type-2-diabetes-2025/2026-09-15T04:58:52Zweekly https://semaglutides.org/news/2025/09/study-documents-racial-inequity-semaglutide-prescribing-among-people-2025/2026-09-15T04:58:52Zweekly https://semaglutides.org/news/2025/09/oasis-4-published-oral-semaglutide-25-mg-produces-2025/2026-09-15T03:17:42Zweekly https://semaglutides.org/news/2025/09/surpass-cvot-presented-full-easd-2025-vienna/2026-09-15T03:17:41Zweekly https://semaglutides.org/news/2025/09/editorial-warns-muscle-loss-glp-1-drugs-older-2025/2026-09-15T04:59:00Zweekly https://semaglutides.org/news/2025/09/orforglipron-beats-oral-semaglutide-head-head-type-2-2025/2026-09-15T03:17:48Zweekly https://semaglutides.org/news/2025/09/oasis-4-published-2025/2026-09-15T03:17:47Zweekly https://semaglutides.org/news/2025/09/achieve-3-topline-2025/2026-09-15T04:04:27Zweekly https://semaglutides.org/news/2025/09/surpass-peds-results-2025/2026-09-15T04:04:46Zweekly https://semaglutides.org/news/2025/09/liberate-randomized-test-tirzepatide-binge-eating-disorder-2025/2026-09-15T04:59:02Zweekly https://semaglutides.org/news/2025/09/stop-knee-oa-trial-tirzepatide-knee-replacement-continues-2025/2026-09-15T04:59:10Zweekly https://semaglutides.org/news/2025/09/attain-1-published-lillys-oral-glp-1-pill-2025/2026-09-15T03:17:54Zweekly https://semaglutides.org/news/2025/09/fda-hhs-compounder-letters-2025/2026-09-15T03:18:02Zweekly https://semaglutides.org/news/2025/09/lilly-virginia-plant-2025/2026-09-15T04:59:16Zweekly https://semaglutides.org/news/2025/09/lilly-names-goochland-county-virginia-four-plants-2025/2026-09-15T04:59:21Zweekly https://semaglutides.org/news/2025/09/inform-survey-46-percent-drop-constant-food-thoughts-2025/2026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/09/step-published-semaglutide-7-2-mg-pushes-weight-2025/2026-09-15T03:18:10Zweekly https://semaglutides.org/news/2025/09/step-t2d-13-2-weight-loss-7-2-2025/2026-09-15T04:59:09Zweekly https://semaglutides.org/news/2025/09/novo-9000-layoffs-2025/2026-09-15T07:59:17Zweekly https://semaglutides.org/news/2025/09/fda-ad-warning-letters-2025/2026-09-15T03:18:22Zweekly https://semaglutides.org/news/2025/09/fda-sends-hims-hers-warning-letter-compounded-semaglutide-2025/2026-09-15T03:18:14Zweekly https://semaglutides.org/news/2025/09/dtc-advertising-eo-2025/2026-09-15T04:04:49Zweekly https://semaglutides.org/news/2025/09/fda-warning-letters-cite-eli-lilly-minimizing-zepbound-2025/2026-09-15T04:04:54Zweekly https://semaglutides.org/news/2025/09/fda-warns-novo-nordisk-oprah-special-video-2025/2026-09-15T04:04:57Zweekly https://semaglutides.org/news/2025/09/fda-warning-letter-treats-compounded-retatrutide-unapproved-drug-2025/2026-09-15T04:59:16Zweekly https://semaglutides.org/news/2025/09/lilly-tunelab-opening-ai-drug-discovery-models-outside-2025/2026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/09/lilly-remedium-gene-therapy-2025/2026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/09/surmount-maintain-design-paper-published-2025/2026-09-15T05:29:35Zweekly https://semaglutides.org/news/2025/09/fda-creates-glp-1-api-green-list-import-2025/2026-09-15T03:18:29Zweekly https://semaglutides.org/news/2025/09/nc-medicaid-will-stop-covering-glp-1s-weight-2025/2026-09-15T04:04:48Zweekly https://semaglutides.org/news/2025/09/truveta-quantifies-switching-caused-zepbound-exclusion-2025/2026-09-15T04:04:51Zweekly https://semaglutides.org/news/2025/09/novo-nordisk-tells-ema-will-stop-marketing-victoza-2025/2026-09-15T04:59:29Zweekly https://semaglutides.org/news/2025/09/cvs-zepbound-class-action-filed-2025/2026-09-15T04:59:35Zweekly https://semaglutides.org/news/2025/09/truveta-publishes-data-what-cvs-switch-did-prescribing-2025/2026-09-15T04:59:36Zweekly https://semaglutides.org/news/2025/09/byetta-bydureon-approvals-formally-cease-exist-2025/2026-09-15T04:05:24Zweekly https://semaglutides.org/news/2025/09/patients-file-erisa-class-action-zepbound-formulary-removal-2025/2026-09-15T04:05:23Zweekly https://semaglutides.org/news/2025/09/academy-sleep-medicine-publishes-prescribing-guidance-tirzepatide-osa-2025/2026-09-15T04:59:32Zweekly https://semaglutides.org/news/2025/09/naperiglipron-trials-halted-2025/2026-09-15T05:29:41Zweekly https://semaglutides.org/news/2025/09/lilly-raises-uk-mounjaro-list-prices-170-2025/2026-09-15T04:05:16Zweekly https://semaglutides.org/news/2025/09/gallup-obesity-rate-falling-37-0-glp-1-2025/2026-09-15T03:18:33Zweekly https://semaglutides.org/news/2025/09/chrissy-teigen-she-used-ozempic-pregnancy-loss-2025/2026-09-15T04:59:41Zweekly https://semaglutides.org/news/2025/09/eadv-cohort-increased-hair-loss-incidence-glp-1-2025/2026-09-15T04:59:48Zweekly https://semaglutides.org/news/2025/09/network-meta-analysis-ranks-tirzepatide-doses-above-semaglutide-2025/2026-09-15T04:59:39Zweekly https://semaglutides.org/news/2025/08/tricare-ends-weight-loss-drug-coverage-tricare-life-2025/2026-09-15T04:05:20Zweekly https://semaglutides.org/news/2025/08/wegovy-vs-tirzepatide-rwe-2025/2026-09-15T04:59:49Zweekly https://semaglutides.org/news/2025/08/retatrutide-gym-use-2025/2026-09-15T05:00:04Zweekly https://semaglutides.org/news/2025/08/denmark-halves-2025-growth-forecast-citing-novo-nordisk/2026-09-15T04:05:24Zweekly https://semaglutides.org/news/2025/08/court-finds-no-proximate-cause-lillys-suit-against-2025/2026-09-15T05:30:37Zweekly https://semaglutides.org/news/2025/08/lilly-jd-health-china-2025/2026-09-15T05:29:37Zweekly https://semaglutides.org/news/2025/08/teva-generic-glp-1-indicated-weight-loss-2025/2026-09-15T03:18:37Zweekly https://semaglutides.org/news/2025/08/obesity-pillars-publishes-concrete-nutrition-numbers-glp-1-2025/2026-09-15T04:05:28Zweekly https://semaglutides.org/news/2025/08/lilly-pauses-uk-mounjaro-orders-2025/2026-09-15T05:29:38Zweekly https://semaglutides.org/news/2025/08/attain-2-completes-orforglipron-obesity-package-2025/2026-09-15T03:18:40Zweekly https://semaglutides.org/news/2025/08/serena-williams-goes-public-zepbound-joins-ro-2025/2026-09-15T03:18:53Zweekly https://semaglutides.org/news/2025/08/eli-lilly-asks-jpml-centralize-glp-1-vision-2025/2026-09-15T04:05:51Zweekly https://semaglutides.org/news/2025/08/ozempic-499-cash-2025/2026-09-15T04:05:48Zweekly https://semaglutides.org/news/2025/08/wegovy-mash-approval-2025/2026-09-15T03:18:54Zweekly https://semaglutides.org/news/2025/08/mdl-objective-testing-2025/2026-09-15T07:59:08Zweekly https://semaglutides.org/news/2025/08/lilly-uk-mounjaro-price-hike-2025/2026-09-15T04:05:55Zweekly https://semaglutides.org/news/2025/08/lilly-superluminal-ai-deal-2025/2026-09-15T05:29:57Zweekly https://semaglutides.org/news/2025/08/novo-nordisk-expands-legal-campaign-against-compounded-semaglutide-2025/2026-09-15T04:05:53Zweekly https://semaglutides.org/news/2025/08/ricks-buys-lilly-stock-2025/2026-09-15T05:30:19Zweekly https://semaglutides.org/news/2025/08/texas-sues-eli-lilly-adding-state-litigation-layer-2025/2026-09-15T05:29:52Zweekly https://semaglutides.org/news/2025/08/texas-sues-lilly-kickbacks-2025/2026-09-15T05:29:54Zweekly https://semaglutides.org/news/2025/08/target-trial-emulation-finds-semaglutide-tirzepatide-linked-higher-2025/2026-09-15T04:05:55Zweekly https://semaglutides.org/news/2025/08/texas-attorney-general-sues-eli-lilly-mounjaro-zepbound-2025/2026-09-15T04:59:56Zweekly https://semaglutides.org/news/2025/08/attain-1-topline-27-3-pounds-lost-highest-2025/2026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/08/doustdar-becomes-ceo-2025/2026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/08/lilly-q2-2025-results-2025/2026-09-15T04:05:58Zweekly https://semaglutides.org/news/2025/08/orforglipron-attain-2025/2026-09-15T04:06:24Zweekly https://semaglutides.org/news/2025/08/orforglipron-delivers-27-3-pounds-average-weight-loss-2025/2026-09-15T04:06:16Zweekly https://semaglutides.org/news/2025/08/kym-whitley-named-one-zepbounds-two-paid-brand-2025/2026-09-15T04:59:55Zweekly https://semaglutides.org/news/2025/08/novo-guidance-cut-august-2025/2026-09-15T04:06:25Zweekly https://semaglutides.org/news/2025/08/surmount-osa-patient-outcomes-show-sleep-quality-life-2025/2026-09-15T05:00:03Zweekly https://semaglutides.org/news/2025/08/fda-withdraws-byetta-bydureon-approvals-2025/2026-09-15T04:06:27Zweekly https://semaglutides.org/news/2025/08/novo-nordisk-files-suits-against-12-compounding-defendants-2025/2026-09-15T05:00:13Zweekly https://semaglutides.org/news/2025/08/mdl-judge-rules-what-evidence-supports-gastroparesis-claim-2025/2026-09-15T03:19:14Zweekly https://semaglutides.org/news/2025/08/wegovy-label-adds-acute-kidney-injury-warning-2025/2026-09-15T04:06:31Zweekly https://semaglutides.org/news/2025/08/wegovys-indications-section-rewritten-without-bmi-numbers-2025/2026-09-15T04:06:36Zweekly https://semaglutides.org/news/2025/08/cdc-26-5-adults-diagnosed-diabetes-used-glp-2025/2026-09-15T05:00:33Zweekly https://semaglutides.org/news/2025/08/wegovy-72mg-filed-2025/2026-09-15T05:00:17Zweekly https://semaglutides.org/news/2025/07/lilly-surpass-cvot-topline-non-inferior-heart-events-2025/2026-09-15T03:19:18Zweekly https://semaglutides.org/news/2025/07/surpass-cvot-topline-2025/2026-09-15T03:19:24Zweekly https://semaglutides.org/news/2025/07/white-house-sends-pricing-demand-letters-drugmakers-2025/2026-09-15T04:06:47Zweekly https://semaglutides.org/news/2025/07/lilly-files-multi-dose-vial-supplements-both-tirzepatide-2025/2026-09-15T05:00:14Zweekly https://semaglutides.org/news/2025/07/cnn-ozempic-face-driving-cosmetic-surgery-boom-2025/2026-09-15T05:00:22Zweekly https://semaglutides.org/news/2025/07/profit-warning-wipes-70-billion-off-novo-nordisks-2025/2026-09-15T03:19:26Zweekly https://semaglutides.org/news/2025/07/dr-reddys-generic-plan-2025/2026-09-15T04:06:50Zweekly https://semaglutides.org/news/2025/07/fda-approves-lupins-generic-victoza-2025/2026-09-15T05:00:19Zweekly https://semaglutides.org/news/2025/07/zepbound-happy-gilmore-campaign-2025/2026-09-15T05:29:58Zweekly https://semaglutides.org/news/2025/07/ohio-pharmacy-board-publishes-glp-1-compounding-guidance-2025/2026-09-15T05:00:30Zweekly https://semaglutides.org/news/2025/07/senate-dtc-telehealth-report-2025/2026-09-15T05:00:32Zweekly https://semaglutides.org/news/2025/07/surmount-1-analysis-shows-slow-starters-still-succeed-2025/2026-09-15T05:00:40Zweekly https://semaglutides.org/news/2025/07/kinsey-institute-finds-glp-1s-changing-sex-dating-2025/2026-09-15T05:00:37Zweekly https://semaglutides.org/news/2025/07/surmount-5-confirms-tirzepatide-beats-semaglutide-weight-head-2025/2026-09-15T03:20:38Zweekly https://semaglutides.org/news/2025/07/zepbound-kwikpen-canada-2025/2026-09-15T05:30:22Zweekly https://semaglutides.org/news/2025/07/zepbound-kwikpen-approved-canada-2025/2026-09-15T05:00:39Zweekly https://semaglutides.org/news/2025/07/endocrine-society-review-finds-real-world-databases-do-2025/2026-09-15T05:00:48Zweekly https://semaglutides.org/news/2025/07/all-six-zepbound-doses-become-available-through-lillydirect-2025/2026-09-15T05:01:20Zweekly https://semaglutides.org/news/2025/07/pilot-study-tirzepatide-raises-testosterone-improves-erectile-function-2025/2026-09-15T05:30:17Zweekly https://semaglutides.org/news/2025/07/cvs-caremark-forces-largest-molecule-switch-class-date-2025/2026-09-15T03:19:46Zweekly https://semaglutides.org/news/2025/07/cvs-zepbound-class-action-2025/2026-09-15T03:19:47Zweekly https://semaglutides.org/news/2025/07/ftc-charges-telehealth-company-nextmed-deceptive-glp-1-2025/2026-09-15T05:00:49Zweekly https://semaglutides.org/news/2025/07/weightwatchers-emerges-bankruptcy-clinical-business-intact-2025/2026-09-15T08:00:13Zweekly https://semaglutides.org/news/2025/06/fda-lists-intestinal-obstruction-fecal-impaction-class-signal-2025/2026-09-15T04:06:57Zweekly https://semaglutides.org/news/2025/06/who-naion-statement-2025/2026-09-15T08:00:04Zweekly https://semaglutides.org/news/2025/06/lilly-commit-trials-pairing-tirzepatide-biologic-inflammatory-bowel-2025/2026-09-15T04:07:01Zweekly https://semaglutides.org/news/2025/06/mhra-genomics-england-hunting-genetic-cause-glp-1-2025/2026-09-15T05:00:55Zweekly https://semaglutides.org/news/2025/06/glp1-persistence-improves-2025/2026-09-15T05:00:58Zweekly https://semaglutides.org/news/2025/06/weightwatchers-emerges-2025/2026-09-15T05:01:34Zweekly https://semaglutides.org/news/2025/06/novo-ends-hims-deal-2025/2026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/06/adjust-t1d-randomized-evidence-semaglutide-type-1-diabetes-2025/2026-09-15T04:07:07Zweekly https://semaglutides.org/news/2025/06/maritide-ada-2025/2026-09-15T04:07:24Zweekly https://semaglutides.org/news/2025/06/60-insurers-pledge-simplify-prior-authorization-2025/2026-09-15T04:07:22Zweekly https://semaglutides.org/news/2025/06/believe-shows-activin-pathway-drug-can-protect-muscle-2025/2026-09-15T05:01:07Zweekly https://semaglutides.org/news/2025/06/england-mass-nhs-rollout-tirzepatide-through-gps-2025/2026-09-15T05:01:28Zweekly https://semaglutides.org/news/2025/06/eu-regulators-back-ozempic-label-update-peripheral-artery-2025/2026-09-15T05:01:12Zweekly https://semaglutides.org/news/2025/06/nhs-primary-care-funding-mandate-tirzepatide-england-2025/2026-09-15T05:01:15Zweekly https://semaglutides.org/news/2025/06/redefine-1-2-published-cagrisema-passes-20-weight-2025/2026-09-15T03:19:56Zweekly https://semaglutides.org/news/2025/06/surmount-mmo-design-published-incretin-outcome-trial-covering-2025/2026-09-15T07:59:48Zweekly https://semaglutides.org/news/2025/06/achieve-1-nejm-ada-2025/2026-09-15T04:07:26Zweekly https://semaglutides.org/news/2025/06/step-up-7-2mg-data-2025/2026-09-15T04:07:27Zweekly https://semaglutides.org/news/2025/06/lizzo-admits-she-tried-ozempic-denials-2025/2026-09-15T04:07:45Zweekly https://semaglutides.org/news/2025/06/lilly-files-mounjaro-pediatric-supplement-2025/2026-09-15T05:01:31Zweekly https://semaglutides.org/news/2025/06/apitegromab-zepbound-muscle-2025/2026-09-15T05:01:31Zweekly https://semaglutides.org/news/2025/06/asmbs-head-head-study-finds-bariatric-surgery-far-2025/2026-09-15T04:07:43Zweekly https://semaglutides.org/news/2025/06/lilly-agrees-acquire-verve-therapeutics-1-3-billion-2025/2026-09-15T05:01:37Zweekly https://semaglutides.org/news/2025/06/lilly-offers-every-zepbound-dose-single-dose-vial-2025/2026-09-15T04:07:49Zweekly https://semaglutides.org/news/2025/06/diabetes-runs-point-counterpoint-agonizing-versus-antagonizing-gip-2025/2026-09-15T05:01:48Zweekly https://semaglutides.org/news/2025/06/ema-naion-conclusion-2025/2026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/06/federal-judge-rules-fda-novo-merits-semaglutide-shortage-2025/2026-09-15T03:20:18Zweekly https://semaglutides.org/news/2025/06/kidney-analysis-surmount-1-surmount-2-finds-no-2025/2026-09-15T05:01:48Zweekly https://semaglutides.org/news/2025/06/eloralintide-phase-1-2025/2026-09-15T05:01:48Zweekly https://semaglutides.org/news/2025/06/novo-nordisk-briefly-regains-title-europes-valuable-company-2025/2026-09-15T05:02:00Zweekly https://semaglutides.org/news/2025/06/amycretin-phase-3-2025/2026-09-15T04:07:56Zweekly https://semaglutides.org/news/2025/06/surpass-cvot-completes-four-follow-2025/2026-09-15T07:59:47Zweekly https://semaglutides.org/news/2025/06/surmount-cn-follow-measures-regain-26-tirzepatide-stopped-2025/2026-09-15T05:01:56Zweekly https://semaglutides.org/news/2025/06/lilly-juvena-muscle-650m-2025/2026-09-15T05:30:13Zweekly https://semaglutides.org/news/2025/06/cleveland-clinic-study-explains-trial-versus-real-world-2025/2026-09-15T03:20:17Zweekly https://semaglutides.org/news/2025/06/ema-adds-sudden-vision-loss-european-semaglutide-labels-2025/2026-09-15T03:20:12Zweekly https://semaglutides.org/news/2025/06/ema-declares-naion-very-rare-side-effect-semaglutide-2025/2026-09-15T03:21:21Zweekly https://semaglutides.org/news/2025/06/uk-regulator-issues-contraception-alert-covering-mounjaro-2025/2026-09-15T05:02:00Zweekly https://semaglutides.org/news/2025/06/lilly-camurus-long-acting-2025/2026-09-15T05:30:16Zweekly https://semaglutides.org/news/2025/06/china-approves-mazdutide-worlds-glp-1-glucagon-dual-2025/2026-09-15T04:08:02Zweekly https://semaglutides.org/news/2025/06/regeneron-licenses-phase-3-ready-glp-1-gip-2025/2026-09-15T07:59:41Zweekly https://semaglutides.org/news/2025/05/review-lays-evidence-behind-both-gip-directions-2025/2026-09-15T05:02:34Zweekly https://semaglutides.org/news/2025/05/alopecia-added-mounjaro-label-validating-long-running-search-2025/2026-09-15T05:02:17Zweekly https://semaglutides.org/news/2025/05/fda-adds-alopecia-mounjaro-label-drops-two-limitations-2025/2026-09-15T05:02:14Zweekly https://semaglutides.org/news/2025/05/mounjaro-package-insert-revised-2025/2026-09-15T05:35:05Zweekly https://semaglutides.org/news/2025/05/lilly-agrees-acquire-siteone-therapeutics-1-billion-2025/2026-09-15T05:30:33Zweekly https://semaglutides.org/news/2025/05/503b-deadline-2025/2026-09-15T03:20:29Zweekly https://semaglutides.org/news/2025/05/fdas-compounding-allowance-semaglutide-expires-2025/2026-09-15T04:08:09Zweekly https://semaglutides.org/news/2025/05/connecticuts-attorney-general-warns-clinics-spas-tirzepatide-products-2025/2026-09-15T04:08:40Zweekly https://semaglutides.org/news/2025/05/cigna-evernorth-200-cap-2025/2026-09-15T05:02:18Zweekly https://semaglutides.org/news/2025/05/lilly-open-letter-insurance-coverage-2025/2026-09-15T05:02:25Zweekly https://semaglutides.org/news/2025/05/novo-ceo-ousted-2025/2026-09-15T03:20:37Zweekly https://semaglutides.org/news/2025/05/select-early-benefit-2025/2026-09-15T05:02:32Zweekly https://semaglutides.org/news/2025/05/mfn-executive-order-2025/2026-09-15T03:20:48Zweekly https://semaglutides.org/news/2025/05/surpass-t1d-2-adds-20-long-term-arm-2025/2026-09-15T04:08:18Zweekly https://semaglutides.org/news/2025/05/surmount-5-tirzepatide-beats-semaglutide-head-head-obesity-2025/2026-09-15T03:20:54Zweekly https://semaglutides.org/news/2025/05/wellness-pivot-glp1-2025/2026-09-15T05:02:34Zweekly https://semaglutides.org/news/2025/05/lilly-executive-transitions-2025/2026-09-15T05:02:37Zweekly https://semaglutides.org/news/2025/05/district-court-grants-summary-judgment-fda-tirzepatide-case-2025/2026-09-15T03:21:01Zweekly https://semaglutides.org/news/2025/05/court-upholds-fda-authority-tirzepatide-shortage-list-2025/2026-09-15T04:08:21Zweekly https://semaglutides.org/news/2025/05/generic-phentermine-topiramate-er-2025/2026-09-15T04:08:29Zweekly https://semaglutides.org/news/2025/05/weightwatchers-bankruptcy-2025/2026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/05/novo-nordisk-permanent-injunctions-against-compounders-2025/2026-09-15T04:08:33Zweekly https://semaglutides.org/news/2025/05/lilly-withdraws-heart-failure-application-tirzepatide-2025/2026-09-15T04:08:38Zweekly https://semaglutides.org/news/2025/05/cvs-caremark-will-drop-zepbound-standard-commercial-formularies-2025/2026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/05/cvs-wegovy-preferred-2025/2026-09-15T03:21:16Zweekly https://semaglutides.org/news/2025/05/cvs-caremark-zepbound-formulary-removal-producing-largest-forced-2025/2026-09-15T04:08:52Zweekly https://semaglutides.org/news/2025/05/lilly-q1-2025-results-2025/2026-09-15T04:08:59Zweekly https://semaglutides.org/news/2025/05/liraglutide-labels-drop-pregnancy-contraindication-2025/2026-09-15T05:02:34Zweekly https://semaglutides.org/news/2025/05/meta-analysis-flags-thyroid-colorectal-cancer-signals-glp-2025/2026-09-15T05:02:43Zweekly https://semaglutides.org/news/2025/04/essence-part-1-shows-semaglutide-reverses-liver-inflammation-2025/2026-09-15T03:21:24Zweekly https://semaglutides.org/news/2025/04/compounded-semaglutide-aers-2025/2026-09-15T05:02:52Zweekly https://semaglutides.org/news/2025/04/novo-telehealth-partnerships-2025/2026-09-15T03:21:33Zweekly https://semaglutides.org/news/2025/04/charles-barkley-becomes-ros-glp-1-celebrity-ambassador-2025/2026-09-15T04:08:54Zweekly https://semaglutides.org/news/2025/04/gip-receptor-blockade-shown-work-through-different-pathway-2025/2026-09-15T04:09:04Zweekly https://semaglutides.org/news/2025/04/surpass-t1d-1-properly-powered-incretin-trial-type-2025/2026-09-15T04:09:17Zweekly https://semaglutides.org/news/2025/04/legal-trade-press-tallies-scale-lillys-tirzepatide-litigation-2025/2026-09-15T05:30:35Zweekly https://semaglutides.org/news/2025/04/federal-court-denies-injunction-sought-compounders-semaglutide-2025/2026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/04/texas-federal-court-leaves-fda-shortage-decision-place-2025/2026-09-15T04:09:10Zweekly https://semaglutides.org/news/2025/04/fda-warning-letter-texas-outsourcer-2025/2026-09-15T05:03:04Zweekly https://semaglutides.org/news/2025/04/eli-lilly-sues-four-telehealth-companies-compounded-tirzepatide-2025/2026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/04/reporting-puts-compounded-tirzepatide-low-99-2025/2026-09-15T05:02:52Zweekly https://semaglutides.org/news/2025/04/novo-centerwell-expansion-2025/2026-09-15T05:30:37Zweekly https://semaglutides.org/news/2025/04/503a-deadline-2025/2026-09-15T03:21:53Zweekly https://semaglutides.org/news/2025/04/zepbound-reaches-nearly-339-000-weekly-prescriptions-2025/2026-09-15T04:09:20Zweekly https://semaglutides.org/news/2025/04/achieve-1-topline-2025/2026-09-15T03:21:48Zweekly https://semaglutides.org/news/2025/04/lemme-glp-1-daily-federal-class-action-voluntarily-2025/2026-09-15T05:02:56Zweekly https://semaglutides.org/news/2025/04/anaesthesia-meta-analysis-retained-stomach-contents-no-measurable-2025/2026-09-15T07:57:39Zweekly https://semaglutides.org/news/2025/04/counterfeit-ozempic-2025/2026-09-15T04:09:28Zweekly https://semaglutides.org/news/2025/04/pfizer-discontinues-oral-glp-1-danuglipron-liver-injury-2025/2026-09-15T04:09:23Zweekly https://semaglutides.org/news/2025/04/itc-issues-general-exclusion-order-infringing-tirzepatide-imports-2025/2026-09-15T03:22:00Zweekly https://semaglutides.org/news/2025/04/fda-seizes-counterfeit-ozempic-supply-chain-2025/2026-09-15T04:09:30Zweekly https://semaglutides.org/news/2025/04/surpass-switch-finds-switching-beats-dose-escalation-people-2025/2026-09-15T04:09:41Zweekly https://semaglutides.org/news/2025/04/meta-analysis-quantifies-weight-regain-stopping-glp-1-2025/2026-09-15T04:09:46Zweekly https://semaglutides.org/news/2025/04/trump-drops-medicare-obesity-proposal-2025/2026-09-15T04:09:48Zweekly https://semaglutides.org/news/2025/04/novo-nordisk-reshuffles-executive-management-2025/2026-09-15T05:30:34Zweekly https://semaglutides.org/news/2025/04/fda-issues-two-warning-letters-empower-pharmacy-2025/2026-09-15T04:09:54Zweekly https://semaglutides.org/news/2025/04/meitheal-liraglutide-injection-during-victoza-shortage-2025/2026-09-15T05:03:31Zweekly https://semaglutides.org/news/2025/04/knownwell-lillydirect-2025/2026-09-15T05:31:15Zweekly https://semaglutides.org/news/2025/04/commerce-opens-section-232-national-security-investigation-pharmaceutical-2025/2026-09-15T04:09:59Zweekly https://semaglutides.org/news/2025/04/lilly-sues-strive-empower-compounded-tirzepatide-2025/2026-09-15T04:10:05Zweekly https://semaglutides.org/news/2025/04/hims-adds-zepbound-lilly-objects-2025/2026-09-15T05:03:10Zweekly https://semaglutides.org/news/2025/04/essence-published-semaglutide-resolves-mash-treated-patients-2025/2026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/04/2025-breakthrough-prize-life-sciences-goes-five-glp/2026-09-15T04:10:09Zweekly https://semaglutides.org/news/2025/04/obesity-medicine-association-acofp-publish-primary-care-roadmap-2025/2026-09-15T05:03:09Zweekly https://semaglutides.org/news/2025/04/weightwatchers-relaunches-glp-1-offering-tailored-companion-program-2025/2026-09-15T05:03:07Zweekly https://semaglutides.org/news/2025/03/soul-acc-nejm-2025/2026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/03/stride-pad-results-2025/2026-09-15T04:10:18Zweekly https://semaglutides.org/news/2025/03/summit-analysis-flags-measurement-problem-kidney-function-during-2025/2026-09-15T05:03:12Zweekly https://semaglutides.org/news/2025/03/englands-icbs-must-funding-tirzepatide-specialist-weight-management-2025/2026-09-15T05:03:19Zweekly https://semaglutides.org/news/2025/03/mounjaro-india-launch-2025/2026-09-15T05:03:26Zweekly https://semaglutides.org/news/2025/03/enforcement-discretion-ends-503b-outsourcing-facilities-compounding-tirzepatide-2025/2026-09-15T03:22:22Zweekly https://semaglutides.org/news/2025/03/washington-regulator-issues-stop-service-order-glp-1-2025/2026-09-15T05:03:31Zweekly https://semaglutides.org/news/2025/03/ricks-pay-package-2025/2026-09-15T05:31:02Zweekly https://semaglutides.org/news/2025/03/fda-confirms-tirzepatide-compounding-timeline-ruling-2025/2026-09-15T04:10:15Zweekly https://semaglutides.org/news/2025/03/class-action-filed-lemme-glp-1-daily-supplement-2025/2026-09-15T04:10:27Zweekly https://semaglutides.org/news/2025/03/cagrisema-redefine2-2025/2026-09-15T05:03:26Zweekly https://semaglutides.org/news/2025/03/claims-study-increased-hair-loss-risk-semaglutide-women-2025/2026-09-15T05:03:25Zweekly https://semaglutides.org/news/2025/03/trial-tirzepatide-polycystic-kidney-disease-enrolling-2025/2026-09-15T05:03:36Zweekly https://semaglutides.org/news/2025/03/teladoc-lifemd-lillydirect-self-pay-zepbound-integrations-2025/2026-09-15T05:03:59Zweekly https://semaglutides.org/news/2025/03/telehealth-shifts-to-branded-zepbound-2025/2026-09-15T05:03:39Zweekly https://semaglutides.org/news/2025/03/court-denies-compounders-injunction-tirzepatide-2025/2026-09-15T03:22:23Zweekly https://semaglutides.org/news/2025/03/novocare-pharmacy-499-2025/2026-09-15T03:22:26Zweekly https://semaglutides.org/news/2025/03/court-refuses-block-tirzepatide-delisting-2025/2026-09-15T05:03:59Zweekly https://semaglutides.org/news/2025/03/surmount-j-japanese-obesity-results-2025/2026-09-15T05:03:56Zweekly https://semaglutides.org/news/2025/02/lilly-anti-knockoff-ad-campaign-2025/2026-09-15T05:30:50Zweekly https://semaglutides.org/news/2025/02/scott-disick-confirms-mounjaro-use-kardashians-2025/2026-09-15T05:30:53Zweekly https://semaglutides.org/news/2025/02/lilly-27-billion-us-plants-2025/2026-09-15T03:22:25Zweekly https://semaglutides.org/news/2025/02/lilly-cuts-zepbound-cash-price-2025/2026-09-15T04:10:35Zweekly https://semaglutides.org/news/2025/02/surmount-1-dxa-sub-study-puts-numbers-tirzepatide-2025/2026-09-15T04:10:38Zweekly https://semaglutides.org/news/2025/02/outsourcing-facilities-association-sues-fda-semaglutide-delisting-2025/2026-09-15T04:10:41Zweekly https://semaglutides.org/news/2025/02/fda-shortage-resolved-2025/2026-09-15T03:22:41Zweekly https://semaglutides.org/news/2025/02/ofa-sues-over-semaglutide-2025/2026-09-15T05:03:48Zweekly https://semaglutides.org/news/2025/02/orforglipron-stockpile-2025/2026-09-15T05:04:01Zweekly https://semaglutides.org/news/2025/02/503a-compounding-tirzepatide-copies-loses-shortage-protection-2025/2026-09-15T03:22:45Zweekly https://semaglutides.org/news/2025/02/enforcement-discretion-ends-503a-pharmacies-compounding-tirzepatide-2025/2026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/02/novo-nordisk-alleges-fraud-1-3-billion-kbp-2025/2026-09-15T05:03:57Zweekly https://semaglutides.org/news/2025/02/european-commission-adopts-mounjaro-sleep-apnea-labeling-variation-2025/2026-09-15T05:04:11Zweekly https://semaglutides.org/news/2025/02/tirzepatide-linked-less-papilledema-vision-loss-idiopathic-intracranial-2025/2026-09-15T05:30:56Zweekly https://semaglutides.org/news/2025/02/randomized-trial-semaglutide-alcohol-use-disorder-published-2025/2026-09-15T03:22:56Zweekly https://semaglutides.org/news/2025/02/jama-psychiatry-trial-finds-low-dose-semaglutide-cuts-2025/2026-09-15T05:04:30Zweekly https://semaglutides.org/news/2025/02/fda-clarifies-tirzepatide-compounding-deadlines-2025/2026-09-15T05:04:14Zweekly https://semaglutides.org/news/2025/02/fda-tirzepatide-enforcement-discretion-2025/2026-09-15T05:30:55Zweekly https://semaglutides.org/news/2025/02/lilly-mash-oncology-deals-2025/2026-09-15T05:31:11Zweekly https://semaglutides.org/news/2025/02/hims-hers-runs-super-bowl-ad-glp-1-2025/2026-09-15T03:24:05Zweekly https://semaglutides.org/news/2025/02/two-senators-ask-fda-act-hims-hers-super-2025/2026-09-15T04:10:45Zweekly https://semaglutides.org/news/2025/02/fda-approves-four-pack-zepbound-vial-presentation-2025/2026-09-15T05:31:08Zweekly https://semaglutides.org/news/2025/02/zepbound-package-insert-carton-labeling-revised-2025/2026-09-15T05:35:16Zweekly https://semaglutides.org/news/2025/02/lilly-2024-revenue-45-0-billion-32-2025/2026-09-15T04:10:48Zweekly https://semaglutides.org/news/2025/02/scale-kids-published-liraglutide-lowers-bmi-children-aged-2025/2026-09-15T04:11:03Zweekly https://semaglutides.org/news/2025/02/lilly-q4-2024-results-2025/2026-09-15T05:04:28Zweekly https://semaglutides.org/news/2025/02/full-2024-results-sales-dkk-290-4-billion-2025/2026-09-15T04:11:05Zweekly https://semaglutides.org/news/2025/02/exenatide-fails-largest-glp-1-trial-parkinsons-disease-2025/2026-09-15T04:11:05Zweekly https://semaglutides.org/news/2025/01/fda-issues-action-letters-both-tirzepatide-kwikpen-applications-2025/2026-09-15T04:11:12Zweekly https://semaglutides.org/news/2025/01/fda-adds-kidney-indication-ozempic-based-flow-2025/2026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/01/ozempic-ckd-approval-2025/2026-09-15T03:23:12Zweekly https://semaglutides.org/news/2025/01/colorado-moves-limit-glp-1-coverage-state-employees-2025/2026-09-15T05:04:17Zweekly https://semaglutides.org/news/2025/01/semaglutide-ira-selected-2025/2026-09-15T03:23:15Zweekly https://semaglutides.org/news/2025/01/high-dose-wegovy-falls-short-2025/2026-09-15T05:04:18Zweekly https://semaglutides.org/news/2025/01/lancet-commission-proposes-replacing-bmi-based-eligibility-clinical-2025/2026-09-15T04:11:17Zweekly https://semaglutides.org/news/2025/01/lilly-2025-guidance-cut-2025/2026-09-15T05:04:31Zweekly https://semaglutides.org/news/2025/01/lilly-agrees-acquire-scorpion-therapeutics-pi3k-alpha-program-2025/2026-09-15T05:31:14Zweekly https://semaglutides.org/news/2025/01/lilly-sues-two-med-spas-2025/2026-09-15T05:31:12Zweekly https://semaglutides.org/news/2025/01/three-surmount-1-data-show-93-relative-drop-2025/2026-09-15T03:23:24Zweekly https://semaglutides.org/news/2025/01/analysis-defines-when-tirzepatide-weight-loss-plateaus-2025/2026-09-15T05:04:29Zweekly https://semaglutides.org/news/2025/01/medicare-covers-zepbound-osa-2025/2026-09-15T03:23:19Zweekly https://semaglutides.org/news/2025/01/cornell-numerator-quantify-glp-1-grocery-effect-2025/2026-09-15T03:23:25Zweekly https://semaglutides.org/news/2025/01/lilly-joins-compounder-suit-2025/2026-09-15T05:04:34Zweekly https://semaglutides.org/news/2025/01/eli-lilly-intervenes-tirzepatide-shortage-case-defend-fda-2025/2026-09-15T05:04:40Zweekly https://semaglutides.org/news/2025/01/ozempic-gastroparesis-label-2025/2026-09-15T05:04:44Zweekly https://semaglutides.org/news/2024/12/fda-lists-naion-potential-signal-glp-1-class-2024/2026-09-15T04:11:25Zweekly https://semaglutides.org/news/2024/12/japan-approves-zepbound-obesity-disease-2024/2026-09-15T04:11:31Zweekly https://semaglutides.org/news/2024/12/hikma-fda-approved-generic-victoza-2024/2026-09-15T05:04:45Zweekly https://semaglutides.org/news/2024/12/elon-musk-posts-ozempic-santa-2024/2026-09-15T05:04:46Zweekly https://semaglutides.org/news/2024/12/nice-final-mounjaro-nhs-2024/2026-09-15T05:04:48Zweekly https://semaglutides.org/news/2024/12/fda-approves-true-generic-victoza-2024/2026-09-15T03:23:39Zweekly https://semaglutides.org/news/2024/12/itc-ruling-knockoff-imports-2024/2026-09-15T05:04:49Zweekly https://semaglutides.org/news/2024/12/cagrisema-redefine1-2024/2026-09-15T03:23:49Zweekly https://semaglutides.org/news/2024/12/zepbound-osa-label-2024/2026-09-15T03:23:51Zweekly https://semaglutides.org/news/2024/12/fda-reaffirms-tirzepatide-shortage-resolved-2024/2026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/12/fda-issues-formal-declaratory-order-ending-tirzepatide-shortage-2024/2026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/12/fda-reaffirms-tirzepatide-shortage-resolution-wind-clocks-2024/2026-09-15T03:24:10Zweekly https://semaglutides.org/news/2024/12/catalent-deal-closes-2024/2026-09-15T04:11:38Zweekly https://semaglutides.org/news/2024/12/ema-mounjaro-osa-no-new-approval-2024/2026-09-15T05:31:18Zweekly https://semaglutides.org/news/2024/12/european-regulators-conclude-tirzepatide-causes-dysesthesia-delayed-gastric-2024/2026-09-15T04:11:35Zweekly https://semaglutides.org/news/2024/12/rfk-jr-softens-glp-1s-saying-they-have-2024/2026-09-15T04:11:40Zweekly https://semaglutides.org/news/2024/12/chmp-recommends-adding-sleep-apnea-trial-data-eu-2024/2026-09-15T05:04:58Zweekly https://semaglutides.org/news/2024/12/eu-adds-kidney-outcome-data-ozempic-label-2024/2026-09-15T05:05:05Zweekly https://semaglutides.org/news/2024/12/zepbound-ro-vials-2024/2026-09-15T05:05:06Zweekly https://semaglutides.org/news/2024/12/fda-issues-what-consultants-describe-only-supplement-side-2024/2026-09-15T04:11:45Zweekly https://semaglutides.org/news/2024/12/rybelsus-r2-approval-2024/2026-09-15T04:12:03Zweekly https://semaglutides.org/news/2024/12/lilly-15-billion-buyback-seventh-straight-15-dividend-2024/2026-09-15T05:31:23Zweekly https://semaglutides.org/news/2024/12/nhs-restricts-mounjaro-rollout-2024/2026-09-15T05:05:06Zweekly https://semaglutides.org/news/2024/12/lilly-wisconsin-3b-2024/2026-09-15T05:05:04Zweekly https://semaglutides.org/news/2024/12/surmount-5-topline-2024/2026-09-15T03:24:24Zweekly https://semaglutides.org/news/2024/12/conagra-puts-glp-1-friendly-label-healthy-choice-2024/2026-09-15T04:12:03Zweekly https://semaglutides.org/news/2024/12/endoscopy-meta-analysis-finds-four-fold-higher-odds-2024/2026-09-15T04:12:05Zweekly https://semaglutides.org/news/2024/12/tennessee-officials-seize-300-counterfeit-glp-1-vials-2024/2026-09-15T04:12:10Zweekly https://semaglutides.org/news/2024/12/glp-1-prescription-volume-passes-9-million-2024/2026-09-15T04:12:10Zweekly https://semaglutides.org/news/2024/11/fda-adds-1-7-mg-adolescent-dose-severe-2024/2026-09-15T05:05:06Zweekly https://semaglutides.org/news/2024/11/maritide-phase-2-2024/2026-09-15T04:12:24Zweekly https://semaglutides.org/news/2024/11/cms-proposes-obesity-coverage-2024/2026-09-15T04:12:36Zweekly https://semaglutides.org/news/2024/11/generic-exenatide-reaches-pharmacies-2024/2026-09-15T05:05:43Zweekly https://semaglutides.org/news/2024/11/lilly-laekna-muscle-2024/2026-09-15T05:31:51Zweekly https://semaglutides.org/news/2024/11/google-broadens-site-reputation-abuse-policy-any-third-2024/2026-09-15T05:05:22Zweekly https://semaglutides.org/news/2024/11/procter-gambles-jon-moeller-joins-lilly-board-karen-2024/2026-09-15T05:31:27Zweekly https://semaglutides.org/news/2024/11/circulation-analysis-finds-summit-benefits-spread-symptoms-function-2024/2026-09-15T05:05:23Zweekly https://semaglutides.org/news/2024/11/summit-mechanistic-analysis-shows-less-circulatory-overload-less-2024/2026-09-15T05:05:24Zweekly https://semaglutides.org/news/2024/11/summit-published-aha-2024/2026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/11/tori-spelling-she-used-mounjaro-her-fifth-child-2024/2026-09-15T05:31:31Zweekly https://semaglutides.org/news/2024/11/jim-gaffigan-he-lost-50-pounds-mounjaro-2024/2026-09-15T05:05:46Zweekly https://semaglutides.org/news/2024/11/three-surmount-1-data-show-94-percent-lower-2024/2026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/11/surmount-1-176-week-detail-2024/2026-09-15T04:12:33Zweekly https://semaglutides.org/news/2024/11/aspiration-warning-appears-semaglutide-tirzepatide-liraglutide-labels-2024/2026-09-15T03:24:22Zweekly https://semaglutides.org/news/2024/11/fda-finalizes-gastrointestinal-aspiration-labeling-mounjaro-2024/2026-09-15T04:12:39Zweekly https://semaglutides.org/news/2024/11/three-mounjaro-labeling-supplements-approved-together-2024/2026-09-15T05:35:17Zweekly https://semaglutides.org/news/2024/10/semaglutide-listed-available-2024/2026-09-15T04:12:35Zweekly https://semaglutides.org/news/2024/10/step-9-knee-oa-2024/2026-09-15T04:12:40Zweekly https://semaglutides.org/news/2024/10/lilly-q3-2024-miss-2024/2026-09-15T05:05:25Zweekly https://semaglutides.org/news/2024/10/five-medical-societies-reverse-course-patients-can-keep-2024/2026-09-15T03:24:31Zweekly https://semaglutides.org/news/2024/10/astrazeneca-discontinues-byetta-united-states-2024/2026-09-15T03:24:47Zweekly https://semaglutides.org/news/2024/10/smart-trial-albuminuria-reduction-kidney-disease-without-diabetes-2024/2026-09-15T05:05:39Zweekly https://semaglutides.org/news/2024/10/lilly-launches-zepbound-denmark-2024/2026-09-15T05:31:35Zweekly https://semaglutides.org/news/2024/10/fda-remands-tirzepatide-shortage-decision-re-evaluation-2024/2026-09-15T04:12:59Zweekly https://semaglutides.org/news/2024/10/novo-ddc-petition-2024/2026-09-15T04:13:06Zweekly https://semaglutides.org/news/2024/10/soul-topline-2024/2026-09-15T03:24:49Zweekly https://semaglutides.org/news/2024/10/fda-adds-surmount-3-surmount-4-data-zepbound-2024/2026-09-15T05:05:40Zweekly https://semaglutides.org/news/2024/10/five-zepbound-labeling-supplements-approved-once-2024/2026-09-15T05:31:40Zweekly https://semaglutides.org/news/2024/10/fda-letter-signals-enforcement-discretion-during-remand-2024/2026-09-15T04:13:10Zweekly https://semaglutides.org/news/2024/10/lilly-uk-employment-trial-2024/2026-09-15T05:05:43Zweekly https://semaglutides.org/news/2024/10/court-remands-tirzepatide-shortage-decision-fda-2024/2026-09-15T04:13:08Zweekly https://semaglutides.org/news/2024/10/fda-reconsiders-tirzepatide-delisting-2024/2026-09-15T04:13:05Zweekly https://semaglutides.org/news/2024/10/review-questions-how-completely-gastric-emptying-effect-fades-2024/2026-09-15T05:31:44Zweekly https://semaglutides.org/news/2024/10/outsourcing-facilities-association-sues-fda-tirzepatide-shortage-delisting-2024/2026-09-15T04:13:21Zweekly https://semaglutides.org/news/2024/10/ofa-sues-fda-2024/2026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/10/tirzepatide-delisted-shortage-2024/2026-09-15T03:25:01Zweekly https://semaglutides.org/news/2024/10/fda-declares-tirzepatide-shortage-resolved-october-2-2024/2026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/10/lilly-medicine-foundry-2024/2026-09-15T04:13:30Zweekly https://semaglutides.org/news/2024/10/kathy-bates-pushes-back-she-just-did-ozempic-2024/2026-09-15T05:05:52Zweekly https://semaglutides.org/news/2024/10/multi-society-guidance-replaces-standalone-anesthesia-advice-glp-2024/2026-09-15T05:05:59Zweekly https://semaglutides.org/news/2024/10/novo-generic-patent-settlements-2024/2026-09-15T05:06:02Zweekly https://semaglutides.org/news/2024/09/novo-nordisks-ceo-grilled-bernie-sanders-glp-1-2024/2026-09-15T03:25:07Zweekly https://semaglutides.org/news/2024/09/ceo-jorgensen-testifies-senate-help-committee-ozempic-wegovy-2024/2026-09-15T04:13:35Zweekly https://semaglutides.org/news/2024/09/fda-warning-letters-research-chemicals-2024/2026-09-15T05:06:01Zweekly https://semaglutides.org/news/2024/09/eu-regulators-recommend-wegovy-label-update-obesity-related-2024/2026-09-15T05:06:05Zweekly https://semaglutides.org/news/2024/09/lilly-ireland-1-8b-2024/2026-09-15T05:31:42Zweekly https://semaglutides.org/news/2024/09/tga-registers-mounjaro-chronic-weight-management-australia-2024/2026-09-15T05:32:03Zweekly https://semaglutides.org/news/2024/09/lilly-new-cfo-2024/2026-09-15T05:31:59Zweekly https://semaglutides.org/news/2024/09/fda-orders-class-wide-anesthesia-warning-glp-1-2024/2026-09-15T03:25:16Zweekly https://semaglutides.org/news/2024/09/fda-issues-section-505-o-4-letter-pulmonary-2024/2026-09-15T04:13:39Zweekly https://semaglutides.org/news/2024/09/lasker-award-honors-glp-1-discovery-2024/2026-09-15T04:13:45Zweekly https://semaglutides.org/news/2024/09/scale-kids-liraglutide-results-children-aged-6-12-2024/2026-09-15T05:06:05Zweekly https://semaglutides.org/news/2024/08/pooled-analysis-suggests-semaglutide-cuts-heart-failure-events-2024/2026-09-15T04:13:38Zweekly https://semaglutides.org/news/2024/08/zepbound-vials-399-2024/2026-09-15T03:25:18Zweekly https://semaglutides.org/news/2024/08/lilly-releases-zepbound-single-dose-vials-2024/2026-09-15T04:13:53Zweekly https://semaglutides.org/news/2024/08/evidence-gip-receptor-agonism-eases-glp-1-gut-2024/2026-09-15T05:06:09Zweekly https://semaglutides.org/news/2024/08/surmount-1-three-year-diabetes-prevention-2024/2026-09-15T03:25:19Zweekly https://semaglutides.org/news/2024/08/ftc-finalizes-rule-consumer-reviews-testimonials-2024/2026-09-15T05:06:16Zweekly https://semaglutides.org/news/2024/08/lilly-warns-doctors-copycats-2024/2026-09-15T05:06:18Zweekly https://semaglutides.org/news/2024/08/novo-nordisk-withdraws-fda-heart-failure-application-wegovy-2024/2026-09-15T05:06:18Zweekly https://semaglutides.org/news/2024/08/fda-all-tirzepatide-doses-available-2024/2026-09-15T04:13:58Zweekly https://semaglutides.org/news/2024/08/summit-hfpef-topline-2024/2026-09-15T04:14:02Zweekly https://semaglutides.org/news/2024/08/novo-eleven-lawsuits-2024/2026-09-15T05:06:23Zweekly https://semaglutides.org/news/2024/07/step-10-reverses-prediabetes-81-participants-2024/2026-09-15T04:14:08Zweekly https://semaglutides.org/news/2024/07/fda-warns-overdoses-compounded-semaglutide-dosing-errors-2024/2026-09-15T04:14:06Zweekly https://semaglutides.org/news/2024/07/tirzepatide-china-obesity-approval-2024/2026-09-15T05:06:22Zweekly https://semaglutides.org/news/2024/07/simone-biles-mounjaro-campaign-2024/2026-09-15T05:31:56Zweekly https://semaglutides.org/news/2024/07/jama-internal-medicine-tirz-vs-sema-2024/2026-09-15T04:14:13Zweekly https://semaglutides.org/news/2024/07/lilly-agrees-acquire-morphic-holding-3-2-billion-2024/2026-09-15T05:06:22Zweekly https://semaglutides.org/news/2024/07/naion-harvard-study-2024/2026-09-15T03:25:34Zweekly https://semaglutides.org/news/2024/07/president-biden-senator-sanders-publish-joint-op-ed-2024/2026-09-15T05:06:32Zweekly https://semaglutides.org/news/2024/06/novo-nordisks-listed-shares-close-all-time-high-2024/2026-09-15T03:25:33Zweekly https://semaglutides.org/news/2024/06/china-approves-wegovy-long-term-weight-management-2024/2026-09-15T04:14:19Zweekly https://semaglutides.org/news/2024/06/fda-approves-generic-qsymia-2024/2026-09-15T04:14:28Zweekly https://semaglutides.org/news/2024/06/teva-authorized-generic-victoza-2024/2026-09-15T03:25:36Zweekly https://semaglutides.org/news/2024/06/novo-nordisk-4-1-billion-plant-clayton-north-2024/2026-09-15T04:14:28Zweekly https://semaglutides.org/news/2024/06/surmount-osa-shows-tirzepatide-roughly-halves-sleep-apnea-2024/2026-09-15T03:25:48Zweekly https://semaglutides.org/news/2024/06/fda-listing-anomaly-hybio-liraglutide-pen-recorded-marketed-2024/2026-09-15T05:31:59Zweekly https://semaglutides.org/news/2024/06/lilly-publishes-open-letter-counterfeit-compounded-tirzepatide-2024/2026-09-15T03:25:49Zweekly https://semaglutides.org/news/2024/06/lilly-files-further-legal-actions-against-med-spas-2024/2026-09-15T05:06:32Zweekly https://semaglutides.org/news/2024/06/cell-metabolism-paper-maps-tirzepatides-effects-fat-cells-2024/2026-09-15T04:14:41Zweekly https://semaglutides.org/news/2024/06/synergy-nash-shows-tirzepatide-resolves-fatty-liver-disease-2024/2026-09-15T04:14:32Zweekly https://semaglutides.org/news/2024/06/surmount-adolescents-2-comorbidity-resolution-endpoint-2024/2026-09-15T05:06:45Zweekly https://semaglutides.org/news/2024/06/counterfeit-online-sales-2024/2026-09-15T05:07:06Zweekly https://semaglutides.org/news/2024/06/lilly-files-six-lawsuits-against-med-spas-selling-2024/2026-09-15T05:06:36Zweekly https://semaglutides.org/news/2024/06/mdl-3094-reassigned-judge-karen-s-marston-2024/2026-09-15T05:06:58Zweekly https://semaglutides.org/news/2024/05/novo-nine-lawsuits-2024/2026-09-15T05:06:49Zweekly https://semaglutides.org/news/2024/05/surmount-cn-china-obesity-trial-results-jama-2024/2026-09-15T05:06:48Zweekly https://semaglutides.org/news/2024/05/flow-published-2024/2026-09-15T03:25:50Zweekly https://semaglutides.org/news/2024/05/lilly-indiana-5-3b-2024/2026-09-15T04:14:44Zweekly https://semaglutides.org/news/2024/05/australia-bans-compounded-tirzepatide-compounded-incretins-2024/2026-09-15T05:06:52Zweekly https://semaglutides.org/news/2024/05/tirzepatide-china-diabetes-approval-2024/2026-09-15T05:07:08Zweekly https://semaglutides.org/news/2024/05/fda-warns-compounded-label-strength-expression-can-cause-2024/2026-09-15T05:07:08Zweekly https://semaglutides.org/news/2024/05/novo-nordisk-trial-touching-alcohol-use-framed-liver-2024/2026-09-15T05:07:06Zweekly https://semaglutides.org/news/2024/05/lilly-spa-settlement-2024/2026-09-15T05:32:02Zweekly https://semaglutides.org/news/2024/05/kelly-clarkson-her-weight-loss-drug-not-ozempic-2024/2026-09-15T04:14:46Zweekly https://semaglutides.org/news/2024/05/select-four-data-show-weight-loss-holds-208-2024/2026-09-15T04:14:58Zweekly https://semaglutides.org/news/2024/05/google-enforcing-site-reputation-abuse-policy-reshaping-commercial-2024/2026-09-15T05:07:17Zweekly https://semaglutides.org/news/2024/05/johann-hari-publishes-magic-pill-mass-market-glp-2024/2026-09-15T05:07:26Zweekly https://semaglutides.org/news/2024/05/hims-hers-compounded-semaglutide-injections-2024/2026-09-15T04:14:53Zweekly https://semaglutides.org/news/2024/05/kff-finds-12-adults-have-ever-taken-glp-2024/2026-09-15T04:15:00Zweekly https://semaglutides.org/news/2024/05/nestl-vital-pursuit-glp-1-users-2024/2026-09-15T04:15:04Zweekly https://semaglutides.org/news/2024/05/real-world-study-links-semaglutide-half-rate-alcohol-2024/2026-09-15T05:07:30Zweekly https://semaglutides.org/news/2024/04/billie-jean-king-ties-her-glp-1-use-2024/2026-09-15T05:07:43Zweekly https://semaglutides.org/news/2024/04/lilly-buys-nexus-plant-2024/2026-09-15T05:07:25Zweekly https://semaglutides.org/news/2024/04/eu-approves-six-additional-mounjaro-strengths-multi-dose-2024/2026-09-15T05:07:43Zweekly https://semaglutides.org/news/2024/04/step-hfpef-dm-extends-heart-failure-benefit-people-2024/2026-09-15T05:07:34Zweekly https://semaglutides.org/news/2024/04/surmount-osa-topline-2024/2026-09-15T03:26:01Zweekly https://semaglutides.org/news/2024/04/zepbound-mounjaro-supply-june-2024/2026-09-15T05:07:42Zweekly https://semaglutides.org/news/2024/04/ema-suicidality-conclusion-2024/2026-09-15T04:15:07Zweekly https://semaglutides.org/news/2024/04/lilly-loses-compounder-ruling-2024/2026-09-15T05:32:11Zweekly https://semaglutides.org/news/2024/04/step-hfpef-dm-2024/2026-09-15T05:07:52Zweekly https://semaglutides.org/news/2024/04/costco-adds-members-weight-loss-program-including-glp-2024/2026-09-15T05:07:47Zweekly https://semaglutides.org/news/2024/04/fda-adds-zepbound-drug-shortage-list-2024/2026-09-15T04:15:13Zweekly https://semaglutides.org/news/2024/03/snl-airs-ozempic-ramadan-2024/2026-09-15T05:07:54Zweekly https://semaglutides.org/news/2024/03/fda-approves-zepbound-single-dose-vials-2024/2026-09-15T04:15:22Zweekly https://semaglutides.org/news/2024/03/zepbound-carton-medication-guide-insert-revisions-approved-2024/2026-09-15T05:35:10Zweekly https://semaglutides.org/news/2024/03/whoopi-goldberg-sunny-hostin-disclose-mounjaro-use-view-2024/2026-09-15T04:15:27Zweekly https://semaglutides.org/news/2024/03/oprah-glp1-special-2024/2026-09-15T03:26:08Zweekly https://semaglutides.org/news/2024/03/zepbound-new-scripts-pass-wegovy-2024/2026-09-15T04:15:31Zweekly https://semaglutides.org/news/2024/03/zepbound-amazon-pharmacy-2024/2026-09-15T05:08:01Zweekly https://semaglutides.org/news/2024/03/lilly-runs-big-night-shame-oscar-night-2024/2026-09-15T04:15:28Zweekly https://semaglutides.org/news/2024/03/wegovy-cv-indication-2024/2026-09-15T03:26:24Zweekly https://semaglutides.org/news/2024/03/zepbound-passes-wegovy-weekly-prescriptions-time-2024/2026-09-15T03:26:16Zweekly https://semaglutides.org/news/2024/03/market-capitalization-passes-600-billion-amycretin-data-2024/2026-09-15T04:15:38Zweekly https://semaglutides.org/news/2024/03/evernorth-pbm-financial-guarantee-glp-1-spend-2024/2026-09-15T04:15:42Zweekly https://semaglutides.org/news/2024/03/lilly-impurity-warning-knockoffs-2024/2026-09-15T04:15:45Zweekly https://semaglutides.org/news/2024/03/flow-topline-2024/2026-09-15T03:26:23Zweekly https://semaglutides.org/news/2024/03/semaglutide-hiv-liver-2024/2026-09-15T05:32:18Zweekly https://semaglutides.org/news/2024/03/s-lite-only-controlled-test-exercise-glp-1-2024/2026-09-15T04:16:00Zweekly https://semaglutides.org/news/2024/03/bmj-journal-publishes-apple-cider-vinegar-weight-loss-2024/2026-09-15T05:08:05Zweekly https://semaglutides.org/news/2024/03/west-virginia-peia-cancels-1-000-person-glp-2024/2026-09-15T05:08:01Zweekly https://semaglutides.org/news/2024/02/oprah-winfrey-leaves-weightwatchers-board-2024/2026-09-15T04:16:00Zweekly https://semaglutides.org/news/2024/02/guideline-evidence-review-finds-almost-no-data-weight-2024/2026-09-15T05:08:09Zweekly https://semaglutides.org/news/2024/02/population-pharmacokinetic-model-pins-tirzepatides-half-life-5-2024/2026-09-15T05:08:09Zweekly https://semaglutides.org/news/2024/02/cms-finalizes-prior-authorization-timelines-exclude-drugs-2024/2026-09-15T05:08:10Zweekly https://semaglutides.org/news/2024/02/zepbound-first-quarter-sales-2024/2026-09-15T05:08:31Zweekly https://semaglutides.org/news/2024/02/novo-catalent-deal-announced-2024/2026-09-15T03:26:18Zweekly https://semaglutides.org/news/2024/02/tirzepatide-blood-pressure-2024/2026-09-15T05:08:20Zweekly https://semaglutides.org/news/2024/02/step-7-12-1-weight-loss-predominantly-east-2024/2026-09-15T05:32:15Zweekly https://semaglutides.org/news/2024/02/mdl-3094-created-2024/2026-09-15T03:26:34Zweekly https://semaglutides.org/news/2024/02/jpml-creates-mdl-3094-eli-lilly-named-defendant-2024/2026-09-15T03:26:43Zweekly https://semaglutides.org/news/2024/01/full-2023-results-sales-31-dkk-232-3-2024/2026-09-15T07:58:39Zweekly https://semaglutides.org/news/2024/01/fda-finds-no-evidence-glp-1-drugs-cause-2024/2026-09-15T04:16:02Zweekly https://semaglutides.org/news/2024/01/mounjaro-limited-availability-2024/2026-09-15T05:32:16Zweekly https://semaglutides.org/news/2024/01/north-carolina-state-health-plan-votes-drop-glp-2024/2026-09-15T04:16:19Zweekly https://semaglutides.org/news/2024/01/fda-suicidality-review-2024/2026-09-15T04:16:12Zweekly https://semaglutides.org/news/2024/01/lilly-lillydirect-direct-patient-platform-major-drugmaker-2024/2026-09-15T03:26:46Zweekly https://semaglutides.org/news/2024/01/lillydirect-launch-detail-2024/2026-09-15T03:26:47Zweekly https://semaglutides.org/news/2024/01/lilly-open-letter-cosmetic-use-2024/2026-09-15T05:08:24Zweekly https://semaglutides.org/news/2024/01/lillydirect-launch-2024/2026-09-15T04:16:30Zweekly https://semaglutides.org/news/2024/01/nature-medicine-suicidality-2024/2026-09-15T04:16:34Zweekly https://semaglutides.org/news/2023/12/fda-seizes-thousands-counterfeit-ozempic-pens-2023/2026-09-15T04:16:32Zweekly https://semaglutides.org/news/2023/12/lilly-fauna-bio-2023/2026-09-15T05:32:24Zweekly https://semaglutides.org/news/2023/12/zepbound-ro-body-program-2023/2026-09-15T05:32:20Zweekly https://semaglutides.org/news/2023/12/surmount-4-jama-2023/2026-09-15T03:27:00Zweekly https://semaglutides.org/news/2023/12/european-commission-adds-chronic-weight-management-mounjaro-2023/2026-09-15T04:16:34Zweekly https://semaglutides.org/news/2023/12/zepbound-pharmacy-launch-2023/2026-09-15T04:16:39Zweekly https://semaglutides.org/news/2023/12/surmount-4-confirms-rapid-regain-stopping-tirzepatide-2023/2026-09-15T04:16:47Zweekly https://semaglutides.org/news/2023/12/oprah-winfrey-tells-people-she-uses-weight-loss-2023/2026-09-15T07:59:20Zweekly https://semaglutides.org/news/2023/11/tirzepatide-users-drink-less-alcohol-2023/2026-09-15T05:08:26Zweekly https://semaglutides.org/news/2023/11/itc-institutes-investigation-no-337-ta-1377-tirzepatide-2023/2026-09-15T05:08:33Zweekly https://semaglutides.org/news/2023/11/tirzepatide-vs-semaglutide-rwe-2023/2026-09-15T05:08:22Zweekly https://semaglutides.org/news/2023/11/novo-nordisk-commits-2-1-billion-euros-expand-2023/2026-09-15T05:32:43Zweekly https://semaglutides.org/news/2023/11/lilly-germany-plant-2023/2026-09-15T05:08:36Zweekly https://semaglutides.org/news/2023/11/lilly-files-zepbound-kwikpen-application-2023/2026-09-15T05:08:45Zweekly https://semaglutides.org/news/2023/11/select-aha-nejm-2023/2026-09-15T03:27:06Zweekly https://semaglutides.org/news/2023/11/ema-backs-mounjaro-obesity-2023/2026-09-15T05:32:35Zweekly https://semaglutides.org/news/2023/11/chmp-recommends-eu-weight-management-indication-mounjaro-2023/2026-09-15T05:08:43Zweekly https://semaglutides.org/news/2023/11/fda-approves-zepbound-2023/2026-09-15T03:27:18Zweekly https://semaglutides.org/news/2023/11/zepbound-approved-weight-management-carrying-suicidal-ideation-warning-2023/2026-09-15T03:27:22Zweekly https://semaglutides.org/news/2023/11/zepbound-approval-label-2023/2026-09-15T03:27:16Zweekly https://semaglutides.org/news/2023/11/mhra-mounjaro-weight-loss-2023/2026-09-15T04:16:59Zweekly https://semaglutides.org/news/2023/11/zepbound-approval-splits-tirzepatide-search-demand-two-brand-2023/2026-09-15T04:17:08Zweekly https://semaglutides.org/news/2023/11/zepbound-1-059-87-flat-all-doses-2023/2026-09-15T04:17:10Zweekly https://semaglutides.org/news/2023/11/ema-requests-suicidality-data-2023/2026-09-15T04:17:03Zweekly https://semaglutides.org/news/2023/11/sharon-osbourne-warns-ozempic-dropping-below-100-pounds-2023/2026-09-15T04:17:10Zweekly https://semaglutides.org/news/2023/11/novo-q3-2023-sales/2026-09-15T05:08:42Zweekly https://semaglutides.org/news/2023/10/gelesis-files-chapter-7-liquidation-putting-plenitys-availability-2023/2026-09-15T05:09:04Zweekly https://semaglutides.org/news/2023/10/lilly-files-section-337-complaint-itc-against-11-2023/2026-09-15T04:17:17Zweekly https://semaglutides.org/news/2023/10/lilly-itc-import-action-2023/2026-09-15T05:08:48Zweekly https://semaglutides.org/news/2023/10/tirzepatide-birth-control-interaction-2023/2026-09-15T05:08:51Zweekly https://semaglutides.org/news/2023/10/surmount-adolescents-tirzepatide-weight-trial-teenagers-2023/2026-09-15T05:09:03Zweekly https://semaglutides.org/news/2023/10/surmount-3-lancet-2023/2026-09-15T04:17:30Zweekly https://semaglutides.org/news/2023/10/jama-research-letter-links-glp-1-weight-loss-2023/2026-09-15T03:27:26Zweekly https://semaglutides.org/news/2023/10/walmart-glp-1-users-buying-less-food-2023/2026-09-15T03:27:28Zweekly https://semaglutides.org/news/2023/10/lilly-obesity-unit-leadership-2023/2026-09-15T05:32:40Zweekly https://semaglutides.org/news/2023/10/goldman-sachs-sizes-anti-obesity-drug-market-100-2023/2026-09-15T04:17:28Zweekly https://semaglutides.org/news/2023/10/eu-uk-counterfeit-ozempic-2023/2026-09-15T05:09:17Zweekly https://semaglutides.org/news/2023/09/lilly-files-mounjaro-kwikpen-application-fda-2023/2026-09-15T05:09:20Zweekly https://semaglutides.org/news/2023/09/ozempic-ileus-warning-2023/2026-09-15T03:27:36Zweekly https://semaglutides.org/news/2023/09/lilly-first-compounding-suits-2023/2026-09-15T04:17:40Zweekly https://semaglutides.org/news/2023/09/consumerlab-finds-problems-nearly-45-berberine-goldenseal-supplements-2023/2026-09-15T05:09:15Zweekly https://semaglutides.org/news/2023/09/nice-backs-mounjaro-diabetes-2023/2026-09-15T05:34:58Zweekly https://semaglutides.org/news/2023/09/novo-most-valuable-europe-2023/2026-09-15T03:27:56Zweekly https://semaglutides.org/news/2023/09/lilly-sues-compounders-2023/2026-09-15T05:09:10Zweekly https://semaglutides.org/news/2023/09/lilly-files-round-lawsuits-products-sold-tirzepatide-2023/2026-09-15T05:09:23Zweekly https://semaglutides.org/news/2023/08/step-hfpef-published-2023/2026-09-15T04:17:40Zweekly https://semaglutides.org/news/2023/08/peterson-kff-publishes-versus-peer-country-price-gap-2023/2026-09-15T05:09:20Zweekly https://semaglutides.org/news/2023/08/peterson-kff-puts-tirzepatide-three-times-netherlands-price-2023/2026-09-15T05:09:27Zweekly https://semaglutides.org/news/2023/08/tracy-morgan-tells-today-his-weight-loss-ozempic-2023/2026-09-15T05:09:50Zweekly https://semaglutides.org/news/2023/08/wegovy-supply-warning-2023/2026-09-15T05:09:40Zweekly https://semaglutides.org/news/2023/08/novo-nordisk-agrees-buy-inversago-pharma-1-billion-2023/2026-09-15T05:32:56Zweekly https://semaglutides.org/news/2023/08/select-topline-2023/2026-09-15T03:27:50Zweekly https://semaglutides.org/news/2023/08/lilly-record-high-mounjaro-2023/2026-09-15T05:09:38Zweekly https://semaglutides.org/news/2023/08/first-gastroparesis-suits-2023/2026-09-15T04:17:34Zweekly https://semaglutides.org/news/2023/07/fda-approves-mounjaro-single-dose-vials-never-marketed-2023/2026-09-15T05:09:42Zweekly https://semaglutides.org/news/2023/07/mounjaro-label-revision-adds-carton-medication-guide-package-2023/2026-09-15T05:32:41Zweekly https://semaglutides.org/news/2023/07/surmount-3-4-topline-2023/2026-09-15T04:17:45Zweekly https://semaglutides.org/news/2023/07/liraglutide-injection-goes-fda-drug-shortage-list-2023/2026-09-15T04:17:59Zweekly https://semaglutides.org/news/2023/07/lilly-agrees-acquire-versanis-bio-1-925-billion-2023/2026-09-15T05:09:40Zweekly https://semaglutides.org/news/2023/07/lilly-buys-versanis-2023/2026-09-15T05:09:42Zweekly https://semaglutides.org/news/2023/07/tirzepatide-labeling-changed-add-ileus-alongside-similar-semaglutide-2023/2026-09-15T04:18:08Zweekly https://semaglutides.org/news/2023/06/asa-tells-anesthesiologists-hold-glp-1-drugs-elective-2023/2026-09-15T04:18:02Zweekly https://semaglutides.org/news/2023/06/poison-control-case-series-documents-10-fold-compounded-2023/2026-09-15T05:09:58Zweekly https://semaglutides.org/news/2023/06/retatrutide-phase-2-nejm-2023/2026-09-15T03:27:51Zweekly https://semaglutides.org/news/2023/06/oasis-1-shows-daily-semaglutide-pill-can-match-2023/2026-09-15T04:18:10Zweekly https://semaglutides.org/news/2023/06/surmount-2-tirzepatide-weight-loss-type-2-diabetes-2023/2026-09-15T04:18:07Zweekly https://semaglutides.org/news/2023/06/orforglipron-phase-2-nejm-2023/2026-09-15T04:18:15Zweekly https://semaglutides.org/news/2023/06/phase-2-obesity-results-14-7-weight-loss-2023/2026-09-15T04:18:36Zweekly https://semaglutides.org/news/2023/06/novo-first-compounding-lawsuits-2023/2026-09-15T04:18:24Zweekly https://semaglutides.org/news/2023/06/selective-gip-receptor-agonist-produces-weight-loss-without-2023/2026-09-15T05:09:56Zweekly https://semaglutides.org/news/2023/06/amy-schumer-calls-celebrities-stop-lying-ozempic-2023/2026-09-15T04:18:47Zweekly https://semaglutides.org/news/2023/06/gracie-mcgraw-pcos-mounjaro-2023/2026-09-15T05:32:52Zweekly https://semaglutides.org/news/2023/06/cystatin-c-analysis-confirms-tirzepatide-kidney-signal-not-2023/2026-09-15T05:33:00Zweekly https://semaglutides.org/news/2023/06/counterfeit-ozempic-us-pharmacy-2023/2026-09-15T05:10:03Zweekly https://semaglutides.org/news/2023/05/fda-warns-compounded-semaglutide-2023/2026-09-15T04:18:43Zweekly https://semaglutides.org/news/2023/05/charles-barkley-mounjaro-2023/2026-09-15T05:32:59Zweekly https://semaglutides.org/news/2023/05/surpass-ap-combo-asia-pacific-results-against-insulin-2023/2026-09-15T05:09:59Zweekly https://semaglutides.org/news/2023/05/wegovy-starter-dose-limits-2023/2026-09-15T04:18:47Zweekly https://semaglutides.org/news/2023/05/randomized-trial-finds-exenatide-lowers-intracranial-pressure-iih-2023/2026-09-15T05:33:03Zweekly https://semaglutides.org/news/2023/04/surmount-2-topline-2023/2026-09-15T04:18:40Zweekly https://semaglutides.org/news/2023/04/surmount-5-trial-launched-2023/2026-09-15T04:18:49Zweekly https://semaglutides.org/news/2023/04/lilly-breaks-ground-lebanon-adds-1-6-billion-2023/2026-09-15T05:10:20Zweekly https://semaglutides.org/news/2023/03/novo-nordisk-suspended-uk-pharmaceutical-trade-association-2023/2026-09-15T05:10:12Zweekly https://semaglutides.org/news/2023/03/jimmy-kimmels-oscars-monologue-turns-ozempic-punchline-2023/2026-09-15T03:28:03Zweekly https://semaglutides.org/news/2023/03/lilly-cuts-insulin-list-prices-70-caps-patient-2023/2026-09-15T04:19:06Zweekly https://semaglutides.org/news/2023/03/japan-approves-wegovy-narrow-obesity-indication-2023/2026-09-15T05:10:21Zweekly https://semaglutides.org/news/2023/03/rosie-odonnell-posts-mounjaro-tiktok-2023/2026-09-15T05:33:17Zweekly https://semaglutides.org/news/2023/02/lilly-q4-2022-mounjaro-miss-2023/2026-09-15T05:33:19Zweekly https://semaglutides.org/news/2023/02/full-2022-results-sales-26-dkk-177-0-2023/2026-09-15T05:10:20Zweekly https://semaglutides.org/news/2023/01/chelsea-handler-she-took-ozempic-without-knowing-2023/2026-09-15T05:10:36Zweekly https://semaglutides.org/news/2023/01/lilly-rtp-450m-2023/2026-09-15T05:10:18Zweekly https://semaglutides.org/news/2023/01/rybelsus-first-line-2023/2026-09-15T05:10:28Zweekly https://semaglutides.org/news/2023/01/novo-nordisk-sues-mylan-generic-semaglutide-anda-2023/2026-09-15T05:10:39Zweekly https://semaglutides.org/news/2023/01/academy-pediatrics-issues-childhood-obesity-clinical-practice-guideline-2023/2026-09-15T03:28:00Zweekly https://semaglutides.org/news/2023/01/ozempic-face-term-2023/2026-09-15T05:10:36Zweekly https://semaglutides.org/news/2023/01/remi-bader-her-binge-eating-worsened-stopping-ozempic-2023/2026-09-15T05:11:05Zweekly https://semaglutides.org/news/2023/01/berberine-goes-viral-natures-ozempic-2023/2026-09-15T04:19:09Zweekly https://semaglutides.org/news/2022/12/wegovy-adolescents-2022/2026-09-15T04:19:17Zweekly https://semaglutides.org/news/2022/12/step-teens-2022/2026-09-15T05:10:37Zweekly https://semaglutides.org/news/2022/12/tga-registers-mounjaro-australia-2022/2026-09-15T05:33:15Zweekly https://semaglutides.org/news/2022/12/fda-lists-mounjaro-shortage-2022/2026-09-15T03:28:01Zweekly https://semaglutides.org/news/2022/12/fda-adds-tirzepatide-injection-drug-shortage-list-2022/2026-09-15T03:28:26Zweekly https://semaglutides.org/news/2022/12/step-teens-published-semaglutide-cuts-bmi-16-1-2022/2026-09-15T03:28:19Zweekly https://semaglutides.org/news/2022/12/lilly-2023-launch-plans-2022/2026-09-15T05:33:20Zweekly https://semaglutides.org/news/2022/12/fda-expands-wegovy-patients-12-older-obesity-2022/2026-09-15T03:28:27Zweekly https://semaglutides.org/news/2022/11/health-canada-issues-notice-compliance-mounjaro-2022/2026-09-15T05:10:52Zweekly https://semaglutides.org/news/2022/11/setmelanotide-phase-3-results-published-bardet-biedl-syndrome-2022/2026-09-15T05:10:52Zweekly https://semaglutides.org/news/2022/11/step-teens-16-1-percent-bmi-reduction-adolescents-2022/2026-09-15T07:59:40Zweekly https://semaglutides.org/news/2022/11/step-teens-extends-semaglutide-evidence-adolescents-2022/2026-09-15T04:19:17Zweekly https://semaglutides.org/news/2022/11/mounjaro-first-full-quarter-2022/2026-09-15T05:11:00Zweekly https://semaglutides.org/news/2022/10/sanofi-will-pull-adlyxin-2022/2026-09-15T05:11:19Zweekly https://semaglutides.org/news/2022/10/step-5-shows-two-durability-semaglutide-weight-loss-2022/2026-09-15T04:19:16Zweekly https://semaglutides.org/news/2022/10/tirzepatide-obesity-fast-track-2022/2026-09-15T05:10:56Zweekly https://semaglutides.org/news/2022/10/elon-musk-credits-wegovy-his-weight-loss-twitter-2022/2026-09-15T04:19:32Zweekly https://semaglutides.org/news/2022/10/surpass-4-post-hoc-analysis-shows-slower-kidney-2022/2026-09-15T04:19:42Zweekly https://semaglutides.org/news/2022/10/ozempic-goes-viral-2022/2026-09-15T04:20:12Zweekly https://semaglutides.org/news/2022/10/glp-1-prescriptions-pass-2-5-million-demand-2022/2026-09-15T05:11:09Zweekly https://semaglutides.org/news/2022/09/japan-approves-mounjaro-type-2-diabetes-2022/2026-09-15T05:11:09Zweekly https://semaglutides.org/news/2022/09/grade-puts-liraglutide-through-independent-five-test-2022/2026-09-15T04:19:45Zweekly https://semaglutides.org/news/2022/09/surpass-4-post-hoc-analysis-slower-kidney-function-2022/2026-09-15T05:11:12Zweekly https://semaglutides.org/news/2022/09/european-commission-authorizes-mounjaro-2022/2026-09-15T04:19:51Zweekly https://semaglutides.org/news/2022/09/mounjaro-early-demand-2022/2026-09-15T05:33:27Zweekly https://semaglutides.org/news/2022/09/australia-registers-wegovy-artg-2022/2026-09-15T07:58:03Zweekly https://semaglutides.org/news/2022/09/novo-nordisk-acquires-forma-therapeutics-1-1-billion-2022/2026-09-15T07:59:23Zweekly https://semaglutides.org/news/2022/08/surpass-j-mono-j-combo-japanese-phase-3-2022/2026-09-15T05:11:29Zweekly https://semaglutides.org/news/2022/08/ozempic-shortage-listed-2022/2026-09-15T04:19:45Zweekly https://semaglutides.org/news/2022/07/chmp-adopts-positive-opinion-mounjaro-2022/2026-09-15T05:11:33Zweekly https://semaglutides.org/news/2022/06/qsymia-approved-patients-aged-12-older-2022/2026-09-15T05:11:29Zweekly https://semaglutides.org/news/2022/06/surmount-1-sets-obesity-benchmark-20-9-weight-2022/2026-09-15T03:28:30Zweekly https://semaglutides.org/news/2022/06/surpass-4-kidney-signal-2022/2026-09-15T05:11:31Zweekly https://semaglutides.org/news/2022/06/surpass-3-mri-sub-study-large-drop-liver-2022/2026-09-15T05:11:36Zweekly https://semaglutides.org/news/2022/05/lilly-indiana-two-plants-2022/2026-09-15T04:20:03Zweekly https://semaglutides.org/news/2022/05/step-1-extension-shows-two-thirds-lost-weight-2022/2026-09-15T03:28:30Zweekly https://semaglutides.org/news/2022/05/fda-approves-tirzepatide-dual-gip-glp-1-receptor-2022/2026-09-15T03:28:38Zweekly https://semaglutides.org/news/2022/05/mounjaro-approved-thyroid-c-cell-boxed-warning-2022/2026-09-15T03:29:02Zweekly https://semaglutides.org/news/2022/05/mounjaro-first-label-details-2022/2026-09-15T03:28:55Zweekly https://semaglutides.org/news/2022/05/mounjaro-approval-creates-brand-term-means-one-thing-2022/2026-09-15T05:12:19Zweekly https://semaglutides.org/news/2022/05/mounjaro-oral-contraceptive-warning-no-semaglutide-product-carries-2022/2026-09-15T04:20:15Zweekly https://semaglutides.org/news/2022/05/wegovy-demand-outruns-supply-2022/2026-09-15T04:20:11Zweekly https://semaglutides.org/news/2022/04/surmount-1-topline-2022/2026-09-15T03:28:52Zweekly https://semaglutides.org/news/2022/04/mechanism-action-trial-compares-tirzepatide-semaglutide-using-glucose-2022/2026-09-15T04:20:15Zweekly https://semaglutides.org/news/2022/04/step-1-extension-shows-weight-comes-back-semaglutide-2022/2026-09-15T03:29:02Zweekly https://semaglutides.org/news/2022/03/ozempic-2mg-approval-2022/2026-09-15T05:11:50Zweekly https://semaglutides.org/news/2022/03/pnas-paper-explains-structural-basis-tirzepatides-dual-agonism-2022/2026-09-15T04:20:23Zweekly https://semaglutides.org/news/2022/03/wegovy-shortage-listed-2022/2026-09-15T03:28:59Zweekly https://semaglutides.org/news/2022/02/cryo-em-structures-tirzepatide-bound-both-incretin-receptors-2022/2026-09-15T05:11:52Zweekly https://semaglutides.org/news/2022/01/step-8-shows-semaglutide-beats-liraglutide-3-0-2022/2026-09-15T03:29:13Zweekly https://semaglutides.org/news/2022/01/european-commission-authorizes-wegovy-2022/2026-09-15T04:20:28Zweekly https://semaglutides.org/news/2021/12/full-2021-sales-dkk-140-8-billion-share/2026-09-15T05:11:52Zweekly https://semaglutides.org/news/2021/11/novo-nordisk-agrees-buy-dicerna-pharmaceuticals-3-3-2021/2026-09-15T05:33:49Zweekly https://semaglutides.org/news/2021/11/wegovy-supply-disruption-2021/2026-09-15T04:20:49Zweekly https://semaglutides.org/news/2021/09/lilly-files-mounjaro-drug-application-2021/2026-09-15T05:33:39Zweekly https://semaglutides.org/news/2021/07/obesity-society-publishes-definitive-supplement-review-16-315-2021/2026-09-15T03:29:19Zweekly https://semaglutides.org/news/2021/07/sustain-forte-supports-ozempic-2-mg-dose-2021/2026-09-15T05:11:50Zweekly https://semaglutides.org/news/2021/06/surpass-2-shows-tirzepatide-beats-semaglutide-1-mg-2021/2026-09-15T03:29:26Zweekly https://semaglutides.org/news/2021/06/surpass-1-shows-tirzepatide-monotherapy-cuts-hba1c-two-2021/2026-09-15T04:20:44Zweekly https://semaglutides.org/news/2021/06/fda-approves-wegovy-2021/2026-09-15T03:29:34Zweekly https://semaglutides.org/news/2021/06/wegovy-launch-price-2021/2026-09-15T04:20:49Zweekly https://semaglutides.org/news/2021/05/gip-receptor-agonism-shown-sensitize-insulin-without-weight-2021/2026-09-15T05:11:56Zweekly https://semaglutides.org/news/2021/05/s-lite-shows-exercise-plus-glp-1-beats-2021/2026-09-15T03:29:41Zweekly https://semaglutides.org/news/2021/04/brain-gip-receptors-shown-required-dual-agonist-advantage-2021/2026-09-15T05:12:12Zweekly https://semaglutides.org/news/2021/03/step-4-shows-what-happens-when-semaglutide-stops-2021/2026-09-15T03:30:26Zweekly https://semaglutides.org/news/2021/03/step-4-maintenance-2021/2026-09-15T05:33:37Zweekly https://semaglutides.org/news/2021/03/step-1-publishes-weight-loss-curve-anchors-every-2021/2026-09-15T03:29:43Zweekly https://semaglutides.org/news/2021/03/step-2-shows-smaller-weight-loss-people-type-2021/2026-09-15T04:20:43Zweekly https://semaglutides.org/news/2021/02/step-3-reaches-16-0-weight-loss-intensive-2021/2026-09-15T05:12:07Zweekly https://semaglutides.org/news/2021/02/step-1-nejm-2021/2026-09-15T03:29:54Zweekly https://semaglutides.org/news/2021/01/award-11-adds-3-mg-4-5-mg-2021/2026-09-15T05:12:09Zweekly https://semaglutides.org/news/2021/01/study-quantifies-how-much-semaglutide-cuts-food-intake-2021/2026-09-15T04:20:53Zweekly https://semaglutides.org/news/2020/12/emisphere-technologies-acquisition-completes-1-35-billion-2020/2026-09-15T04:21:04Zweekly https://semaglutides.org/news/2020/12/fda-approves-saxenda-adolescents-12-older-glp-1-2020/2026-09-15T04:21:58Zweekly https://semaglutides.org/news/2020/12/wegovy-filed-2020/2026-09-15T05:12:13Zweekly https://semaglutides.org/news/2020/11/imcivree-setmelanotide-approved-rare-genetic-obesity-2020/2026-09-15T04:21:18Zweekly https://semaglutides.org/news/2020/11/chugai-lilly-publish-how-orforglipron-activates-human-glp-2020/2026-09-15T05:12:19Zweekly https://semaglutides.org/news/2020/10/setmelanotide-phase-3-results-published-pomc-lepr-deficiency-2020/2026-09-15T05:12:41Zweekly https://semaglutides.org/news/2020/10/ada-publishes-practical-guidance-switching-between-glp-1s-2020/2026-09-15T05:12:25Zweekly https://semaglutides.org/news/2020/07/tirzepatide-defined-imbalanced-biased-dual-agonist-2020/2026-09-15T04:21:22Zweekly https://semaglutides.org/news/2020/06/novo-nordisk-buys-corvidia-therapeutics-acquiring-ziltivekimab-2020/2026-09-15T05:12:43Zweekly https://semaglutides.org/news/2020/06/tirzepatides-gastric-emptying-effect-shown-fade-repeat-dosing-2020/2026-09-15T05:12:48Zweekly https://semaglutides.org/news/2020/05/scale-teens-published-liraglutide-reduces-bmi-adolescents-obesity-2020/2026-09-15T04:21:24Zweekly https://semaglutides.org/news/2020/04/sustain-10-quantifies-semaglutide-advantage-liraglutide-2020/2026-09-15T05:12:37Zweekly https://semaglutides.org/news/2020/02/fda-requests-withdrawal-lorcaserin-belviq-cancer-signal-2020/2026-09-15T03:29:54Zweekly https://semaglutides.org/news/2020/01/ozempic-cv-indication-2020/2026-09-15T04:21:25Zweekly https://semaglutides.org/news/2020/01/lilly-manufacturing-buildout-strength-tirzepatide-phase-2-data-2020/2026-09-15T03:29:57Zweekly https://semaglutides.org/news/2019/09/fda-approves-rybelsus-2019/2026-09-15T03:30:18Zweekly https://semaglutides.org/news/2019/09/rybelsus-fasting-rules-2019/2026-09-15T05:33:54Zweekly https://semaglutides.org/news/2019/07/pioneer-4-shows-glp-1-tablet-can-match-2019/2026-09-15T04:21:37Zweekly https://semaglutides.org/news/2019/07/nature-medicine-publishes-human-akkermansia-muciniphila-trial-2019/2026-09-15T05:12:35Zweekly https://semaglutides.org/news/2019/06/pioneer-6-2019/2026-09-15T04:21:43Zweekly https://semaglutides.org/news/2019/06/rewind-gives-trulicity-cardiovascular-indication-2019/2026-09-15T03:30:13Zweekly https://semaglutides.org/news/2019/04/ellipse-trial-opens-victoza-children-aged-10-older-2019/2026-09-15T04:21:53Zweekly https://semaglutides.org/news/2019/04/pioneer-3-published-jama-oral-semaglutide-beats-sitagliptin-2019/2026-09-15T04:21:52Zweekly https://semaglutides.org/news/2019/04/fda-clears-plenity-hydrogel-weight-management-device-2019/2026-09-15T05:12:51Zweekly https://semaglutides.org/news/2019/03/oral-semaglutide-filed-2019/2026-09-15T05:12:51Zweekly https://semaglutides.org/news/2019/01/lilly-agrees-buy-loxo-oncology-8-billion-2019/2026-09-15T05:13:15Zweekly https://semaglutides.org/news/2019/01/sales-reach-dkk-122-0-billion-oral-semaglutide-2019/2026-09-15T05:14:26Zweekly https://semaglutides.org/news/2018/10/phase-2-tirzepatide-results-published-lancet-2018/2026-09-15T04:21:55Zweekly https://semaglutides.org/news/2018/10/lilly-publishes-tirzepatide-discovery-paper-2018/2026-09-15T03:30:30Zweekly https://semaglutides.org/news/2018/10/harmony-outcomes-positive-drug-already-off-market-2018/2026-09-15T05:13:05Zweekly https://semaglutides.org/news/2018/08/novo-nordisk-ozempic-jingle-remaking-1974-pop-hit-2018/2026-09-15T05:13:12Zweekly https://semaglutides.org/news/2018/06/step-program-begins-2018/2026-09-15T05:13:06Zweekly https://semaglutides.org/news/2018/03/japan-approves-ozempic-type-2-diabetes-2018/2026-09-15T05:13:10Zweekly https://semaglutides.org/news/2018/02/european-commission-authorizes-ozempic-eu-wide-2018/2026-09-15T04:22:07Zweekly https://semaglutides.org/news/2018/02/sustain-7-establishes-semaglutide-potent-glp-1-era-2018/2026-09-15T03:30:21Zweekly https://semaglutides.org/news/2018/02/ozempic-us-launch-2018/2026-09-15T05:13:27Zweekly https://semaglutides.org/news/2018/01/lilly-licenses-orforglipron-chugai-2018/2026-09-15T05:13:23Zweekly https://semaglutides.org/news/2017/12/sustain-3-beats-exenatide-extended-release-2017/2026-09-15T05:13:22Zweekly https://semaglutides.org/news/2017/12/fda-approves-ozempic-2017/2026-09-15T03:30:27Zweekly https://semaglutides.org/news/2017/12/ozempic-boxed-warning-2017/2026-09-15T03:30:43Zweekly https://semaglutides.org/news/2017/10/bydureon-bcise-autoinjector-approved-2017/2026-09-15T07:58:17Zweekly https://semaglutides.org/news/2017/10/fda-advisory-committee-semaglutide-2017/2026-09-15T05:13:25Zweekly https://semaglutides.org/news/2017/10/semaglutide-shown-delay-hour-gastric-emptying-people-obesity-2017/2026-09-15T05:13:32Zweekly https://semaglutides.org/news/2017/09/exscel-misses-weekly-exenatide-not-superior-placebo-2017/2026-09-15T04:22:10Zweekly https://semaglutides.org/news/2017/06/near-atomic-structure-activated-glp-1-receptor-published-2017/2026-09-15T05:13:40Zweekly https://semaglutides.org/news/2017/03/sustain-4-shows-semaglutide-beats-insulin-glargine-a1c-2017/2026-09-15T05:13:41Zweekly https://semaglutides.org/news/2017/02/three-scale-data-shows-liraglutide-delays-type-2-2017/2026-09-15T04:22:22Zweekly https://semaglutides.org/news/2017/01/sustain-1-published-phase-3-semaglutide-results-2017/2026-09-15T05:13:45Zweekly https://semaglutides.org/news/2017/01/david-ricks-becomes-chief-executive-eli-lilly-2017/2026-09-15T03:30:47Zweekly https://semaglutides.org/news/2017/01/lars-fruergaard-jorgensen-becomes-ceo-sales-flatline-dkk-2017/2026-09-15T05:13:44Zweekly https://semaglutides.org/news/2016/12/semaglutide-nda-filed-2016/2026-09-15T05:13:47Zweekly https://semaglutides.org/news/2016/11/soliqua-xultophy-insulin-plus-glp-1-combinations-2016/2026-09-15T05:14:02Zweekly https://semaglutides.org/news/2016/11/sustain-6-results-2016/2026-09-15T04:22:29Zweekly https://semaglutides.org/news/2016/11/sustain-6-gives-semaglutide-two-randomized-safety-record-2016/2026-09-15T04:22:29Zweekly https://semaglutides.org/news/2016/09/sustain-6-shows-semaglutide-cuts-heart-events-type-2016/2026-09-15T03:31:00Zweekly https://semaglutides.org/news/2016/07/leader-shows-liraglutide-cuts-cardiovascular-events-type-2-2016/2026-09-15T03:31:03Zweekly https://semaglutides.org/news/2016/07/jama-network-meta-analysis-ranks-approved-weight-drugs-2016/2026-09-15T05:14:11Zweekly https://semaglutides.org/news/2016/07/fda-approves-adlyxin-lixisenatide-2016/2026-09-15T05:33:55Zweekly https://semaglutides.org/news/2016/06/leader-shows-liraglutide-cuts-cardiovascular-death-2016/2026-09-15T03:30:58Zweekly https://semaglutides.org/news/2016/03/scale-sleep-apnea-shows-liraglutide-reduces-apnea-events-2016/2026-09-15T05:14:13Zweekly https://semaglutides.org/news/2015/12/elixa-lixisenatide-cardiovascular-neutral-2015/2026-09-15T05:14:01Zweekly https://semaglutides.org/news/2015/11/lean-glp-1-liver-histology-signal-2015/2026-09-15T05:14:02Zweekly https://semaglutides.org/news/2015/08/scale-diabetes-quantifies-smaller-weight-result-type-2-2015/2026-09-15T04:22:31Zweekly https://semaglutides.org/news/2015/07/scale-obesity-prediabetes-published-nejm-2015/2026-09-15T04:22:43Zweekly https://semaglutides.org/news/2014/12/saxenda-glp-1-approved-weight-management-2014/2026-09-15T03:31:02Zweekly https://semaglutides.org/news/2014/12/saxenda-approved-glp-1-weight-management-2014/2026-09-15T03:31:20Zweekly https://semaglutides.org/news/2014/10/award-6-ties-weekly-dulaglutide-daily-liraglutide-2014/2026-09-15T05:14:01Zweekly https://semaglutides.org/news/2014/09/trulicity-dulaglutide-marketing-2014/2026-09-15T04:22:40Zweekly https://semaglutides.org/news/2014/09/fda-approves-contrave-naltrexone-bupropion-er-boxed-warning-2014/2026-09-15T05:14:29Zweekly https://semaglutides.org/news/2014/01/tanzeum-albiglutide-approved-withdrawn-three-later-2014/2026-09-15T05:33:57Zweekly https://semaglutides.org/news/2013/07/scale-maintenance-shows-liraglutide-holds-off-regained-weight-2013/2026-09-15T05:14:18Zweekly https://semaglutides.org/news/2013/01/duration-6-publishes-weekly-exenatide-loses-daily-liraglutide-2013/2026-09-15T05:14:20Zweekly https://semaglutides.org/news/2012/07/fda-approves-qsymia-phentermine-topiramate-er-2012/2026-09-15T04:23:04Zweekly https://semaglutides.org/news/2012/01/fda-approves-bydureon-once-weekly-glp-1-2012/2026-09-15T04:23:04Zweekly https://semaglutides.org/news/2011/10/zyprexa-loses-patent-protection-opening-yz-patent-cliff-2011/2026-09-15T08:00:34Zweekly https://semaglutides.org/news/2010/10/fda-requests-withdrawal-sibutramine-meridia-scout-trial-2010/2026-09-15T04:22:57Zweekly https://semaglutides.org/news/2010/01/victoza-liraglutide-reaches-market-type-2-diabetes-2010/2026-09-15T03:31:18Zweekly https://semaglutides.org/news/2009/07/lead-6-shows-liraglutide-beats-twice-daily-exenatide-2009/2026-09-15T04:23:11Zweekly https://semaglutides.org/news/2008/05/berberine-matches-metformin-glucose-control-36-patient-pilot-2008/2026-09-15T05:14:29Zweekly https://semaglutides.org/news/2007/02/fda-approves-alli-only-counter-weight-loss-drug-2007/2026-09-15T04:23:14Zweekly https://semaglutides.org/news/2005/04/fda-approves-byetta-exenatide-glp-1-receptor-agonist-2005/2026-09-15T03:31:37Zweekly https://semaglutides.org/news/2005/03/fda-approves-symlin-pramlintide-amylin-analog-2005/2026-09-15T05:34:08Zweekly https://semaglutides.org/news/2004/01/xendos-publishes-orlistat-cuts-diabetes-progression-four-2004/2026-09-15T04:23:29Zweekly https://semaglutides.org/news/2004/01/fda-bans-dietary-supplements-containing-ephedrine-alkaloids-2004/2026-09-15T04:23:51Zweekly https://semaglutides.org/news/2003/12/medicare-modernization-act-excludes-weight-loss-drugs-part-2003/2026-09-15T04:23:38Zweekly https://semaglutides.org/news/2000/08/federal-appeals-court-strips-prozac-patent-protection-two-2000/2026-09-15T04:23:36Zweekly https://semaglutides.org/news/2000/01/novozymes-spun-novo-nordisk-2000/2026-09-15T05:34:17Zweekly https://semaglutides.org/news/1999/01/fda-approves-orlistat-xenical-lipase-inhibitor-weight-drug-1999/2026-09-15T05:14:28Zweekly https://semaglutides.org/news/1997/09/fenfluramine-dexfenfluramine-withdrawn-market-1997/2026-09-15T03:31:41Zweekly https://semaglutides.org/news/1997/07/public-valvular-heart-disease-fen-phen-users-1997/2026-09-15T03:31:36Zweekly https://semaglutides.org/news/1992/09/exendin-4-isolated-gila-monster-venom-1992/2026-09-15T04:23:45Zweekly https://semaglutides.org/news/1989/01/novo-nordisk-merge-form-novo-nordisk-s-1989/2026-09-15T05:14:36Zweekly https://semaglutides.org/news/1988/01/lilly-fluoxetine-prozac-1988/2026-09-15T04:23:42Zweekly https://semaglutides.org/news/1959/01/fda-approves-phentermine-short-term-weight-management-1959/2026-09-15T05:14:49Zweekly https://semaglutides.org/news/1923/12/novo-nordisks-founding-date-1923/2026-09-15T05:14:46Zweekly https://semaglutides.org/news/1923/01/lilly-sells-iletin-commercially-available-insulin-united-states-1923/2026-09-15T03:31:41Zweekly https://semaglutides.org/news/1876/05/colonel-eli-lilly-opens-laboratory-indianapolis-1876/2026-09-15T03:31:47Zweekly